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SUMMARY
Proteins, either specific to,or associated with, 
pregnancy, have been reported in the circulation of various 
mammalian species, especially man, where most of them reach 
peak concentrations at term. However the variety of
species studied is limited. Therefore the existence of
similar proteins was investigated in the horse, a species 
which exhibits many unusual features of pregnancy. The 
investigation used similar immunological methods to those 
which had been successful in other species. However they 
failed to reveal any pregnancy specific or pregnancy 
associated proteins in the maternal circulation in late 
pregnancy. The existence of pregnancy proteins in the 
mare was further investigated using antisera to placental 
extracts and two dimensional electrophoresis of pregnancy 
serum. The former identified unique proteins in the 
equine placenta at term but these were absent from the 
maternal circulation. The latter technique confirmed the 
results of the immunological investigation on pregnancy 
serum that pregnancy specific proteins were absent in late 
gestation. It did however identify pregnancy specific 
proteins in the early stages of gestation. Investigation 
( of two other parameters, serum alkaline phosphatase 
activity and sex hormone binding capacity, during pregnancy 
in the mare showed that although serum alkaline phosphatase 
activity varied it did not do so in a manner related to 
placental growth and that a protein similar to human sex
/
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sex hormone binding globulin was absent from equine serum.
On the basis of the results various theories could 
explain the lack of pregnancy proteins in the late PMS.
Of these the most probable explanation was that the 
comparative placentation of the horse and of humans could 
cause the difference in the presence of these plasma 
proteins.
CHAPTER 1
INTRODUCTION
1.1 General Introduction
Pregnancy has been one of the most studied phases of 
mammalian life cycles but the means whereby the maternal/ 
fetal inter-relationship is maintained are by no means 
elucidated. A feature of pregnancy in many species is the 
appearance of proteins in the maternal circulation which are 
not normally present. The first of these so called 
pregnancy proteins to be identified was in humans by Aschheim 
and Zondek (192 7). Since then other such proteins have been 
discovered in a variety of species. In humans many pregnancy 
proteins have been discovered in the maternal circulation 
throughout pregnancy and much is known about their chemistry, 
biology and clinical significance.
Pregnancy proteins in laboratory animals, such as 
primates and rodents, have also been well documented in the 
hope of providing models for the study of human pregnancy 
proteins.
Although pregnancy proteins have been identified in 
domestic animals, such as sheep, horses, cows and swine, 
only the early stages of gestation have been thoroughly 
investigated. In a review.of placental proteins Klopper 
(1980) states that these proteins are likely to "occur 
widely in mammals, which argues that they perform some 
essential function in pregnancy". That placental
placental pregnancy proteins similar to those in humans 
have not been identified in domestic animals possibly 
reflects the fact that they have not been investigated in 
these species. This research was therefore undertaken to 
investigate the proteins in late pregnancy serum from mares 
and to identify any pregnancy proteins present.
The following introduction has been divided into four 
sections. The first section deals with human pregnancy 
proteins and summarises the principal features of these 
proteins. The second section reviews the pregnancy 
proteins of primates and rodents and how they relate to 
the pregnancy proteins in humans. The third section 
demonstrates how research into pregnancy proteins in 
domestic animals has concentrated on the early stages of 
gestation and particularly on their involvement in one of 
the fundamental features of all pregnancies, the maternal 
recognition of the fertilised egg. Finally a summary of 
equine pregnancy is given, highlighting those features 
which are peculiar to the genus Equidae.
1.2 Human Pregnancy Proteins
The first pregnancy protein to be discovered in humans 
was chorionic gonadotrophin found by Aschheim and Zondek 
(19 2 7). After a gap of some 50 years, two other pregnancy 
proteins were discovered. These were Pregnancy Zone 
Protein (PZP) (Smithies, 1959) and Placental Lactogen (hPL) 
(Josimovich. and MacLaren, 1962) . Only in the last 14 years
years, with the advancement of immunological techniques, 
have numerous other pregnancy associated proteins been 
identified.
The history of-the new pregnancy proteins started with 
the publication by Tatarinov and Masyukevich (19 70) who 
identified, immunologically, a globulin with 
electrophoretic mobility unique to the serum of pregnant 
women. Using an antiserum to placental extract Bohn (19 71) 
identified the same protein which he named schwangershafts 
protein 1 (SP1). Four proteins were identified by Gall and 
Halbert (19 72) in late pregnancy serum which could not be 
detected in non-pregnant subjects. Subsequent examination 
revealed that only two of these proteins were previously 
unreported and designated Pregnancy Associated Plasma 
Proteins A and B (PAPP A and B) with the other two being 
SP1 and hPL (Lin et al, 19 74a). An immunological technique 
was used to identify these four proteins. An antiserum was 
raised in rabbits against late pregnancy serum and then 
adsorbed with non-pregnancy serum leaving only antibodies 
to those proteins peculiar to the pregnancy serum. These 
antibodies were then used to identify the proteins specific 
to pregnancy serum by immunological techniques such as 
crossed immunoelectrophoresis.
Continuing the work on human placental extract, Bohn 
(19 72a) identified another protein unique to pregnancy.
This protein, one of a host isolated from the placental 
extract and. designated Placental Protein 5 (PP5) , is a
/
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a soluble placental tissue protein (Sedlacek et al, 1976) 
which can be measured in the maternal circulation by 
radioimmunoassay (Klopper, 1980).
Other proteins exist which are pregnancy specific or 
have close associations with pregnancy and these include 
placental alkaline phosphatase, early pregnancy factor and 
sex hormone binding globulin. Recent work on immune 
complexes in pregnancy serum has revealed two new pregnancy 
associated proteins, namely pregnancy associated 81 and a2 
macroglobulins, (Stimson and Farquharson, 1982) and perhaps, 
as techniques become more sophisticated, other pregnancy 
proteins will be identified in humans.
On the basis of their origin human pregnancy proteins 
may be divided into two groups:- proteins synthesized by 
the fetal/placental unit and those proteins which are 
synthesized by the mother. The principal proteins in the 
former group are hCG, hPL, SP1, PAAP A, PAPP B, PP5, 
placental alkaline phosphatase and a-fetoprotein while in 
the latter group the major proteins are PZP and SHBG.
Placental Proteins SP1
(a) Purification.
Various procedures exist for the isolation of 
SP1. The protein was purified from placental 
extract by Bohn (19 76) using a combination of 
ammonium sulphate precipitation, immunoadsorption 
and hydroxyapatite chromatography. Although the
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the process yielded 99% purity the procedure 
required a high degree of technical skill 
(Tatarinov, 19 82). An alternative technique was 
employed by Sutcliffe (19 76) involving late 
pregnancy serum applied to an affinity 
chromatography column containing immobilised 
antibodies to non-pregnancy serum. A novel and 
original method, protected by patent, exists which 
relies on the fact that SP1 binds to concanavalin A 
to give soluble complexes. Prior treatment to 
remove other con. A binding glycoproteins from the 
serum followed by affinity chromatography using a 
con. A sepharose carrier results in purification 
of SP1 (Tatarinov, 1982).
The main physico-chemical properties are given in 
Table 1. Although the protein has an isoelectric 
point of pH 4.15 (Bohn, 1976), a minor component 
of isoelectric point pH 6.0 has been observed (Lin 
et al, 19 74b). This suggests some degree of 
microheterogeneity which may be due to carbohydrate 
content. In late pregnancy SP1 has been shown to 
be heterogeneous with a 8i glycoprotein (SP1 8) and 
a high molecular weight a2 glycoprotein (SP1 8) 
being identified (Teisner et al, 19 78 and 
Westergaard et al, 19 79). Immunoreactive SP1 can 
be detected in serum complexed with normal serum 
components (Hindersson et al, 19 81) and in 
pregnancy urine (Bohn, 19 79).
(b) Physiology.
The purification of SP1 has led to the production 
of high specificity antisera and their use in 
immunoassays to monitor the concentration of SP1 
throughout pregnancy. Originally SP1 levels were 
measured using either radial immunodiffusion or 
Laurel-type rocket immunoelectrophoresis (Bohn,
19 72b, Bruce and Klopper, 19 78). However these 
techniques only allow levels of SP1 to be measured 
after the tenth week of pregnancy. For studies 
on SP1 in early pregnancy a radioimmunoassay was 
developed (Grudzinskas et al, 19 77a). Using this 
assay SP1 can be detected in the circulation early 
in pregnancy, at 18 to 23 days after the L.H. 
surge which precedes ovulation (Grudzinskas et al, 
19 77b). This is slightly later than the 3 subunit 
of hCG used for pregnancy diagnosis. However it 
is possible that the proteins are produced 
together by the pre-implantation embryo, the 
difference being due to the greater sensitivity of 
the h C G 3 subunit assay (Klopper, 19 80).
The increase in concentration of SP1 in the first 
10 weeks is rapid which probably reflects the 
proliferation of the trophoblast (Grudzinskas et 
al, 19 77, Klopper, 19 80). During the second 
trimester the increase in serum concentration is 
much slower followed by a more rapid rise in the 
third trimester before reaching a plateau at the
/
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the 37th week. This pattern is similar to the 
growth curve of the placenta and it may be that 
SP1 concentrations are related to the mass of 
functioning trophoblast at any stage of gestation 
(Klopper, 19 80). The peak concentration at 37 
weeks is 200 yg/ml. and the half life, calculated 
from its rate of disappearance after delivery, is 
approximately 22 hours (Klopper, Buchan and 
Wilson, 1978).
Using radioimmunoassay SP1 has been demonstrated 
in males and non-pregnant females at concentrations 
up to 0.5 mg/100 ml. (Wurz, 19 79 and Rutanen and 
Seppala, 19 80). This extra placental SP1 is 
believed to originate from fibroblast cells (Rosen
et al, 19 79 and Engvall et al, 19 79).
The role of SP1 in pregnancy remains unknown. 
However several suggestions based on experimental 
observations have been made but these lack 
definitive proof. A possible role of SP1 in 
carbohydrate metabolism has been suggested based 
on the relationship between SP1 concentrations and 
maternal glucose levels (Tatra et al, 19 76). The
possibility that SP1 is an oestrogen binding
protein has also been considered (Bohn, 1973).
The prevention of' immunological rejection of the 
foetus by the mother is a phenomenon which has not
/
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not been elucidated and SP1 has been suggested as 
a possible immunosuppressive agent. Suppression 
of mitogen stimulated lymphocytes by physiological 
concentrations has been demonstrated (Tatarinov et 
al, 19 80, and Golovistikov et al, 19 80). However, 
Stimson (19 80) showed that removal of this protein 
did not significantly alter the immunosuppressive 
properties of pregnancy serum.
Pregnancy Associated Plasma Proteins A and B 
The studies on PAPP A and B have followed a similar 
pattern to those of SP1. The proteins have been 
isolated in a number of ways but most are based on a 
combination of protein separation techniques (Sutcliffe 
et al, 19 79, Bischof, 19 79, Lin et al, 19 82, Davey and 
Teisner, 19 82). PAPP A (Table 1) is believed to be a 
dimer with subunits of molecular weight 400,000 
(Bischof, 1979). Although some similarity between 
PAPP A and a 2 macroglobulin has been noted (Bischof,
19 79) on peptide mapping, the proteins proved to be 
very different (Sutcliffe et al, 19 80).
(a) Physiology of PAPP A and B.
PAPP A can be detected at 5 weeks post
fertilisation and reaches a concentration of
0.5-4 mg/100 ml. at term (Bischof et al, 19 81). 
During early pregnancy the concentration of 
PAPP A in the maternal circulation follows the 
placental weight curve. Typically the 
concentration increases steeply in early
/
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early pregnancy, slowly in the second trimester 
and more rapidly in the third. However at 37 
weeks when placental weight reaches a plateau 
concentrations of PAPP A continue to rise 
(Klopper, 19 82). It has been claimed that there 
is a further rise preceding the onset of labour 
(Smith et al, 19 81). The fact that PAPP A 
concentrations rise after placental growth has 
ceased suggests some extra-placental source of 
this protein and it is probable that the decidua 
produces PAPP A (Bischof et al, 1982).
PAPP B (Table 1) is a large glycoprotein which is 
eluted in the IgM fraction during gel filtration 
of pregnancy serum on Sepharose 4B (Halbert and 
Lin, 19 79). It can be separated from PAPP A by 
its insolubility in 30% ammonium sulphate, PAPP A 
being soluble (Halbert and Lin, 1979) .
Due to the insensitivity of the immunoelectrophoretic 
assay for PAPP B its presence in the maternal 
circulation cannot be detected until the second 
trimester. The concentration rises gradually in 
the second trimester, steeply in the third before 
reaching a plateau about the 37th week. The 
kinetics are similar to those of SP1 and correspond 
to the placental weight curve (Lin et al, 19 82) .
It has a post partum half life of less than one 
day.
/
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The functions of PAPP A and B are as yet unknown 
although various suggestions have been made.
In preliminary studies both PAPP A and B could 
bind steroid hormones but the binding was too 
weak to be specific (Lin et al, 1982). Both 
anti-plasmin and anti-urokinase activity have 
been reported for PAPP A as well as inhibition 
of complement mediated haemolysis using purified 
PAPP A (Bischof, 1981). Both PAPP A and B 
demonstrate some degree of in vitro 
immunosuppression (Kiefer, 19 77). However, 
although both proteins suppressed the stimulation 
of lymphocytes by phyto-haemagglutinin the degree 
of immunosuppression was unable to account for 
that exerted by term pregnancy serum.
Placental Protein 5
One further protein has been added to these pregnancy 
specific proteins, Placental Protein 5. Isolated 
immunologically from protein fractions of placental 
extract with a host of other tissue antigens, this 
protein was found to be unique to the placenta. The 
other placental proteins were found in other adult and 
fetal tissues (Bohn, 19 79). Although PP5 may be a 
tissue specific protein, it can be detected in the 
maternal circulation at 8-10 weeks of gestation by 
radioimmunoassay (Seppala et al, 19 79, and Obiekwe et 
al, 19 79). The concentration of PP5 increases with 
pregnancy reaching a plateau of 4.5 yg per 100 ml in
/
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in the last 4 weeks of pregnancy (Seppala et'al, 1979, 
and Obiekwe et al, 19 79). The physico-chemical 
properties of PP5 are given in Table 1.
The fact that PP5 levels are higher in pregnancy serum 
than in pregnancy plasma gives some insight into its 
possible function (Obiekwe et al, 19 79). The reason 
for this is that PP5 forms large molecular weight 
complexes with heparin which can be reversed by 
protamin (Salem et al, 1980). The fact that PP5 also 
has anti-plasmin and anti-trypsin activities (Bohn and 
Winckler, 19 77) and that it interacts with thrombin 
(Salem et al, 19 81) has led to the hypothesis that 
PP5 plays a part as a natural blood coagulation 
inhibitor at the placental site.
Placental Lactogen
Human placental lactogen (hPL) is a small protein of 
molecular weight 21,000 (Table 1) and no carbohydrate 
content (Niall et al, 19 73). The normal rate of 
synthesis of hPL in late pregnancy has been estimated 
at 1-2 g/day (Beck et al, 19 65, and Kaplan et al,
1968) and it has a biological half life of 10-20 mins. 
(Chard, 19 82a). The maternal concentration of hPL 
shows a similar pattern to SP1 and PAPP B and the 
levels correspond to the placental weight curve 
(Chard, 1982a).
A large number of biological activities have been
/
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been proposed for hPL including lactogenesis, growth 
promotion, stimulation of the corpus luteum, 
erythropoiesis, inhibition of fibrinolysis, an effect 
on carbohydrate and lipid metabolism and 
immunosuppression (Chard, 19 82a). Although these 
activities have been demonstrated in experimental 
systems the evidence that hPL has specific and 
essential functions in normal pregnancy is very 
limited (Letchworth, 1976, and Chard, 1982a).
Chorionic Gonadotrophin
Human chorionic gonadotrophin (hCG) is a trophoblastic 
glycoprotein hormone with a molecular weight of 38,000 
and a carbohydrate content 30%. The protein consists 
of two dissimilar subunits designated a and 3 (Tojo et 
al, 19 82). The use of hCG in pregnancy diagnosis 
stems from the fact that it can be detected in the 
maternal circulation 9 or 10 days post fertilisation. 
Thereafter the concentration rises rapidly reaching a 
peak at the 8th to 10th week of pregnancy before 
declining to 10% of its original value, at which it 
remains, until term. In contrast free hCG a levels 
rise continuously until term whereas the free 3 
subunit concentration remains low (Ashitaka et al, 
1974).
The strong luteotrophic function of hCG in the human 
female plays an important role in maintaining the 
function of the corpus luteum in early pregnancy 
(Ashitaka et al, 1973).
12.
Placental Alkaline Phosphatase
Another protein which can. be detected in the maternal 
circulation during pregnancy is the placental alkaline 
phosphatase. The placental form of this enzyme is 
readily distinguishable from other serum isoenzymes by 
its remarkable thermostability (Neale et al, 1965).
It can also be distinguished immunochemically from 
other serum isoenzymes (Boyer, 196 3, and Sussman et al, 
19 6 8). The placental isoenzyme appears to be a late 
evolutionary event since similar analogues have only 
been identified in chimpanzee and orangutan (Doellgast 
and Benirschke, 1979). The placental isoenzymes 
which have been identified in other mammalian species 
have properties similar to the liver isoenzyme 
(Goldstein and Harris, 19 79).
In the normal healthy adult basal levels of the 
placental alkaline phosphatase (2 ng/ml) have been 
detected by a highly sensitive radioimmunoassay (Wada 
et al, 19 79). During pregnancy the levels of placental 
alkaline phosphatase in the maternal circulation rise 
to reach a value of 150 to 400 ng/ml by the third 
trimester (Holmgren et al, 1978). The increased rate 
of production correlates with the growth of the 
placenta (Fishman et al, 1968).
Production of Placental Proteins
Direct evidence for the placental production of
the various pregnancy proteins has only been
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been produced for hPL. Using a radioactive gene 
probe, mRNA for hPL was identified exclusively in the 
syncytiotrophoblast (McWilliams and Boime, 19 80).
The evidence,that the other proteins mentioned are 
placental in origin, stems from immunofluorescent 
studies which have shown SP1 (Bohn, 19 72a, Horne et al,
19 76, Lin and Halbert, 19 76, and Tatarinov et al, 19 76), 
PAPP A (Lin and Halbert, 1976), PP5 (Bohn, 1976), hCG 
(Dreskin et al, 19 70) and placental alkaline phosphatase 
(Dempo et al, 19 80, and Kameya et al, 19 73) localised 
within the trophoblast mainly in the syncytiotrophoblast. 
The evidence for the placental production of PAPP B is 
circumstantial and relies upon the fact that, like SP1, 
hPL and PAPP A, it can be isolated from placenta in 
concentrations significantly higher than could be 
accounted for by its content in maternal serum (Halbert 
and Lin, 19 79).
There is now considerable evidence that the placental 
proteins are produced in normal non-pregnant adults.
SP1, hPL, hCG and PP5 can all be detected in seminal 
plasma by radioimmunoassay (Lee et al, 19 83). The 
reason for their presence in seminal fluid is unknown 
but they are not produced by testis or sperm since 
the level in vasectomised and non-vasectomised males 
are similar (Chard, 19 82b).
The factors which control the placental production of 
these proteins are unknown. However a novel idea,
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idea, proposed by Chard (19 82b) states that the levels 
of pregnancy proteins in the maternal circulation are 
a product of the mass of functioning trophoblast and 
the maternal blood flow at the placental/maternal 
interface, the syncytiotrophoblast. An increase in 
blood flow at the placental interface increases the 
rate of removal of the proteins and stimulates their 
rate of synthesis. However this hypothesis does not 
explain, in the case of SP1, why the concentration is 
higher in the maternal peripheral circulation than in 
the retroplacental blood (Klopper et al, 19 79). This 
observation could be explained by the fact that rather 
than direct secretion into the maternal blood by the 
chorionic villi the point of entry for SP1 is 
disintegrating migrating trophoblast (Klopper et al, 
1979) .
A further observation is that no definite function has 
been proven for any placental protein in vivo and it is 
possible that "they are by-products of a more 
fundamental process concerned with the basic 
functioning and maintenance of the placenta as an 
individual and independent organism" (Gordon and Chard, 
19 79). Combining these two ideas it is possible to 
arrive at the conclusion that placental proteins 
perform their function in the placenta and that their 
presence in the maternal circulation is unnecessary 
for pregnancy. The observations that an almost 
complete deficiency of hPL and SP1 may be associated
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associated with a normal pregnancy perhaps adds some 
weight to this hypothesis (Gaede et al, 1978, and 
Grudzinskas et al, 19 79).
Clinical Use of Placental Proteins
Despite the failure to elucidate any in vivo function 
for the placental proteins, their clinical implications 
as monitors of pathological pregnancies are numerous.
On clinical use and suggested function, the placental 
proteins can be divided into two groups (Chard, 1982b). 
Group 1 consists of proteins with possible hormonal/ 
enzymatic functions such as placental alkaline 
phosphatase, hCG, hPL and SP1. The circulating levels 
of these proteins are reduced in the presence of fetal 
pathologies such as growth retardation and acute fetal 
distress. Measurement of hPL and SP1 as obstetric 
parameters for identifying fetal risk has been well 
established (Gordon et al, 19 78 and Grudzinskas et al, 
19 81) and may be of real value in reducing perinatal 
mortality (Spellacy et al, 1975).
Group 2 proteins consists of placental proteins with 
a probable local function such as PP5 and PAPP A.
Their concentration in the maternal circulation is 
raised in the presence of placental pathologies such 
as placental abruption and pre-eclampsia. However 
more research is required into the relationship of 
these proteins with placental pathologies before they 
are accepted for routine obstetric practice.
/
16.
Placental Proteins as Tumour Markers
Pregnancy proteins have been used as tumour markers 
for both trophoblastic and non-trophoblastic cancers. 
Tatarinov et al (1974) were the first to show the 
presence of SP1 in 30% of patients with 
chorionepithelioma and other trophoblastic tumours 
using an immunodiffusion technique. Since then 
pregnancy proteins have been detected in patients 
suffering from a number of malignant tumours, 
including those of breast, lung, bowel, ovarian 
(epithelial), testis and melanoma (Sheth et al, 19 74, 
Vaitukaitis et al, 19 76, Rosen et al, 19 75, Stone et 
al, 19 77, Tatarinov and Sokolov, 19 77, Samaan et al, 
1976, and Grudzinskas et al, 1980).
Pregnancy Proteins of Non-Placental Origin 
(a) Pregnancy Zone Protein.
The pregnancy zone protein (PZP) was first 
identified in the sera from pregnant women by 
starch gel electrophoresis (Smithies, 1959).
Since then this protein has been identified 
independently by various groups and has therefore 
collected numerous synonyms, including pregnancy 
associated macroglobulin, pregnancy associated 
a 2 glycoprotein, pregnancy associated globulin, 
serum factor xh and a 2 pregnoglobulin. The 
physico-chemical properties of PZP are given in 
Table 1. Although PZP is found in both men and 
women, during pregnancy the concentration rises
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rises dramatically to exceed all other pregnancy 
protein concentrations (von Schoultz and 
Stigbrand, 19 82). During pregnancy, levels 
begin to rise probably around the time of 
implantation. In the first trimester the 
increase is exponetial with the rate of increase 
slowing down during the second and third trimester 
(von Schoultz, 1974). There is considerable 
variation between individuals in the concentrations 
of this protein at term, the range being 20-400 mg/ 
100 ml. with a mean value of 100-200 mg/100 ml.
(von Schoultz and Stigbrand, 19 82). The post 
partum concentration decreases slowly and reaches 
pre-pregnancy concentrations at about 6 weeks 
(von Schoultz, 1974).
The site of production of PZP is not the feto­
placental unit but the mother. In tissue culture 
PZP has been produced by leucocytes (Stimson and 
Blackstock, 19 75) and by macrophages from liver, 
spleen and reticulo-endothelial tissue (Lundgren 
et al, 19 79) . Immunofluorescent studies have 
provided strong evidence that hepatocytes produce 
PZP and it is most likely that the liver is the 
principal source of PZP (von Schoultz and 
Stigbrand, 1982).
The function of PZP remains unknown although it 
has been shown to be immunosuppressive (von Schoultz 
et al, 1973, Damber et al, 1975, and Stimson, 1976).
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Although PZP concentrations increase during 
oestrogen therapy it is unlikely that it acts as 
a transport protein for steroid hormones since it 
binds them with low affinity (von Schoultz and 
Stigbrand, 19 82). An interesting suggestion is 
that it may act as a feeder protein providing 
the fetus with amino acids by its degradation in 
the placenta (von Schoultz and Stigbrand, 19 82).
Sex Hormone Binding Globulin
Sex hormone binding globulin is a normal serum protein 
which binds reversibly and with high affinity the main 
biologically active androgen, testosterone and somewhat 
less well the active oestrogen, oestradiol (Anderson,
19 74) . The protein is a 3-globulin and from the
various molecular weight estimates, 52,000 (Mercier- 
Bodard et al, 1970) and 95,000-115,000 (Van Baelen et 
al, 1968, Rosner et al, 1969, Corvol et al, 1971, and 
Hansson et al, 19 72) it appears to exist as a dimer. 
Assays for SHBG are usually based on tritiated 5a 
dihydrotestosterone since it has higher affinity for 
this steroid than for testosterone and DHT does not 
bind to the corticosteroid binding globulins 
(Anderson, 19 74) . The production of SHBG by the 
liver is controlled by the hormones it binds, i.e. 
oestrogens stimulate its production and androgens 
inhibit (Pearlman et al, 1967, and Vermeulen et al, 
1969). Levels of SHBG rise markedly in pregnancy 
to some 5-10 times their original value and remain
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remain high until term and thereafter fall to their 
original value with a half life of 5 days (Anderson, 
1974).
1.3 Pregnancy Proteins in Laboratory Animals
Although the majority of research into pregnancy 
proteins has been performed in humans, researchers have 
investigated proteins of a similar nature in laboratory 
animals such as primates and rodents. The aim has been 
to provide models, based on laboratory animals, to assist 
in the study of pregnancy proteins in humans.
Primates
Proteins immunochemically related to SP1 have been 
identified in the placentae and plasma of non-human 
primates. The analogues identified in apes and 
monkeys show only partial immunological identity with 
human SP1. The proteins in apes and monkeys are 
however trophoblast - specific since they cannot be 
detected in the non-pregnant state (Bohn and 
Ronneberger, 19 73, Bohn et al, 19 76, Stevens et al, 
1976) .
Using an immunoadsorption technique the proteins 
antigenically related to SP1 have been extracted from 
the placentae of apes and monkeys. The proteins 
isolated from chimpanzee, rhesus and cynomolgus 
monkeys had faster electrophoretic mobilities than
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TABLE 1.2 COMPARISON OF HUMAN AND PRIMATE SP1
Physical Properties Rhesus SP1 Human SP1
Sed. Coeff 3.85 4.55
Mol. Wt. 80,000 90,000
Pi 3.8 4.1
IEP mobility 8 1 “ C*2 01
from Bohn, 1979
than human SP1 on polyacrylamide gels and were more 
acidic (Bohn et al, 19 76). A comparison of the 
properties of human SP1 and rhesus SP1 is given on 
Table 2.
Since SP1 is produced around the time of implantation 
there is the possibility that it could be an appropriate 
target for immunological destruction of an early 
pregnancy. Experiments using active or passive 
immunisation with human SP1 in cynomolgus monkeys have 
demonstrated an anti-fertility effect (Bohn and 
Weinmann, 19 74 and 19 76).
The cross reactivity of anti-human PAPP A and B antisera 
has also been tested in subhuman primates (Lin and 
Halbert, 19 78). Cross reactivity was detected in 
pregnant chimpanzee, orangutan and old World monkeys 
which was undetectable in non-pregnant animals. The 
cross reactivity obtained with pregnant chimpanzee and 
orangutan showed immunological identity with human 
PAPP A and B while that of old World monkeys was only 
partial. Similar reactions were observed with antisera 
to SP1 and placental lactogen. No cross reactivity was 
obtained using antisera to human PAPP A, B, SP1 and hPL 
in the sera of pregnant new World (squirrel) monkeys.
Using an antiserum to human pregnancy zone protein 
von Schoultz et al (19-76) demonstrated cross reactivity 
with serum from pregnant Rhesus monkeys. A PZP
/
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PZP analogue was also demonstrated in various other 
old World monkey species. However in some species 
there was a decrease in concentration during 
pregnancy (Lin et al, 19 76a).
Pregnancy Proteins in Rodents
Using a hyperimmune antiserum raised against late 
pregnant rat serum and adsorbed with non-pregnant rat 
serum, Lin et al (19 74c) were able to demonstrate four 
pregnancy associated plasma proteins. The antisera 
to human pregnancy associated plasma proteins did not 
cross react with pregnant rat serum and the antiserum 
to rat pregnancy proteins did not cross react with human 
pregnancy serum. An interesting point is that the 
pregnancy protein in the rat were undetectable in 
pseudopregnant rats (Lin et al, 19 74c).
By the same technique, four murine pregnancy associated 
proteins were identified (Lin et al, 19 74c). The 
antisera to the murine pregnancy proteins did not cross 
react with any proteins in rat serum.
Independently four murine pregnancy proteins have been 
identified and characterised (Hau et al, 19 78, Hau et 
al, 19 80, and Hau, 19 82) . The relationship between 
these four proteins and those identified by Lin et al 
(1974c) is unknown (Waites and Bell, 1984). Owing to 
the similarity in placentation between humans and mice 
(hemochorial) and because the fecundity of mice is high 
an attempt has been made to devise a model for the 
study of human pregnancy proteins based on mice (Hau,
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(Hau, 19 82). The proteins have been termed pregnancy 
associated murine proteins 1, 2, 3 and 4 (PAMP 1-4) and 
three of these appear to be analogues of human pregnancy 
proteins. Using antisera raised in rabbits, only 
PAMP-4 showed immunological cross reactivity with human 
AFP (Hau et al, 19 81a). However when antisera against 
murine and human pregnancy proteins raised in chickens 
was used, immunological cross reactivity was found 
between human PZP and PAMP-1 (Hau et al, 19 81b) and 
between human SP1 and PAMP-2 (Hau et al, 19 80). Some 
of the properties of PAMP 1-4 are given in Table 3.
Apart from the discrepancies between the molecular 
weight of PAMP-1 and that of hPZP and the concanavalin 
binding properties between AFP and PAMP-4 the physico­
chemical properties of the analogues are similar (Hau,
19 82). The levels of PAMP 1 and hPZP are similar 
during the first half of pregnancy but in the second 
half hPZP levels remain high while those of PAMP-1 fall 
(Hau et al, 19 81b). Both proteins show large 
variations between individuals and both are present in 
non-pregnancy serum at low levels (Hau, 19 82). The 
levels of SP1 and PAMP-2 are similar throughout 
pregnancy (Hau et al, 19 80). PAMP-4 and AFP levels in 
the maternal circulation both show a high degree of 
correlation with the fetal weight throughout pregnancy 
(Hau et al, 19 81a). At present, no human analogue to 
PAMP-3 has been identified although there is the 
possibility that it is similar to human sex hormone 
binding globulin (Hau, 1982).
1.4 Pregnancy Proteins in Domestic Animals
The majority of research into pregnancy proteins in 
domestic animals has tended to concentrate, for agricultural 
reasons, on the successful establishment of pregnancy. Only 
the early stages of gestation in the cow, sheep, horse and 
pig have been thoroughly investigated, there being little 
documentation on the later stages.
Studies on pregnancy associated proteins have revealed 
tissue antigens associated with pregnancy in a number of 
animals but apart from hormones of placental origin few 
proteins comparable to the human series have been found.
Sheep
Using an antiserum raised against day 14 sheep embryos 
Cerini et al (19 76) were able to demonstrate pregnancy 
associated antigens in the corpus luteum, uterus and 
embyronic membranes by immunofluorescence. The 
antigens were also detected in plasma and erythrocytes 
by haemagglutination at day 6. The antigens were 
undetectable in non-pregnant sheep. Continuing this 
work with calf antisera to day 16 sheep embryos, Staples 
et al (19 78) identified, an ovine pregnancy associated 
antigen (oPAA). The antigen was detected in all 
samples of trophoblast and uterine tissue and in 94% 
of uterine flushings from day 14-19 pregnant ewes but 
not in serum. Attempts to isolate the antigen revealed 
a high molecular weight fraction and a low molecular 
weight, fraction of 42,600 and 17,400 daltons respectively 
indicating that the molecule is probably dimeric (Staples,
/
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(Staples, 19 80). The antigen can be detected 
sufficiently early in pregnancy to be implicated in the 
prevention of luteal regression and could therefore be 
partly responsible for the maternal recognition of 
pregnancy. However the agent responsible for luteal 
maintenance has disappeared by day 2 4 (Rowson and Moor, 
19 6 7) whereas oPAA can be detected in late pregnancy 
(Staples et al, 1978).
In the sheep there is little evidence to suggest the 
presence of a chorionic gonadotrophin with similar 
properties to those of hCG (Heap et al, 19 79) although 
an hCG like substance has been detected in the early 
trophoblast tissue of sheep by radioreceptor assay 
(Wintenberger-Torres, 1978). A placental lactogen 
has been detected in plasma by day 60 (Kelly et al,
19 74) and rises to a concentration of 1000-2000 ng/ml. 
at term. However the assay used in this case was a 
mammary gland binding assay utilising 125I labelled 
ovine prolactin and ovine prolactin. A more recently 
developed homologous radioimmunoassay (Handwerger et 
al, 19 77) detected oPL at 41-50 days of gestation and 
the concentration increased progressively to 25 47 ng/ml. 
at 121-130 days gestation in sheep with singleton 
gestations. Levels in twin gestations were 
significantly higher. Concentrations of oPL decreased 
just before partuition (Kelly et al, 19 74, and 
Handwerger et al, 19 77). Compared with humans high 
levels, of oPL were detected in cord plasma suggesting
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suggesting that oPL may have a direct action in the 
fetus during pregnancy. The half life, calculated by 
surgical removal of the placenta, was 29 mins., 
similar to hPL (Handwerger et al, 19 77).
Work with day 14-16 sheep embryo homogenates and their 
ability to maintain corpus luteum function in sheep 
indicated the presence of an antiluteolytic component 
in the embryos. The fact that the factor is 
thermolabile and susceptible to protease activity 
suggests that it is protein in nature. The anti- 
luteolytic activity had disappeared by day 21-23 since 
homogenates of this age failed to prevent luteal 
regression (Martal et al, 1979). Working with in 
vitro culture products of day 16 sheep embryos, Godkin 
et al (19 84) identified a protein, ovine trophoblast 
protein (oTP-1), which was capable of maintaining 
corpus luteum activity. This protein was the major 
product of the cultured embryos between days 13 and 
21 of pregnancy, the period during which the maternal 
recognition of pregnancy in the sheep takes place.
The protein was undetectable in serum and whether or 
not it is the sole reagent responsible for maintaining 
corpus luteum activity in early pregnancy is unknown. 
However, the fact that a non-serum trophoblastic 
protein appears responsible for luteal maintenance in 
the sheep (Godkin et al, 19 84) is in contrast to 
primates where a serum chorionic gonadotrophin is 
implicated in luteal maintenance (Niswender et al, 1972)
Using cross reacting antisera, von Schoultz et al 
(19 76) reported the detection of an analogue to human 
PZP in sheep. Antisera to human PZP cross reacted 
with pregnant dog and monkey serum but not with sheep. 
However an antiserum to dog PZP showed strong cross 
reactivity with serum from pregnant sheep.
Apart from oPL and oPZP no other serum pregnancy 
proteins have been reported in the later stages of 
gestation in the sheep.
Cow
In the cow Roberts and Parker (19 76) detected three 
proteins which appeared in uterine flushings at day 7 
of gestation. At day 15 post fertilisation a 
pregnancy specific protein with a molecular weight 
between 50,000 and 60,000 can be detected in the 
bovine uterus (Laster, 19 77).
An antiserum to bovine placental membranes from day 
20-45 embryos revealed two pregnancy specific proteins. 
The proteins, designated A & B, were both located in the 
endometrium and placenta whereas only A could be 
detected in amniotic fluid. The proteins were 
undetectable in the uterine endometrium of non-pregnant 
cows. The proteins were detected in the placenta from 
day 25 to day 270 of pregnancy but not in placental 
membranes from 280 day conceptuses. Partial 
purification of the proteins revealed that protein
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protein A had a molecular weight of 65-70,000 and an 
isoelectric point of pH 4.6-4.8 and on Ouchterlony 
double diffusion'showed a reaction of identity with 
bovine ai fetoprotein. Protein B had a molecular 
weight of 47-53,000 and an isoelectric point of 
pH 4.0-4.4 but its identity remains unknown. Neither 
protein could be detected in plasma or on erythrocytes 
by haemagglutination (Butler et al, 19 82).
A bovine placental lactogen (bpL) has been identified 
and isolated by several research groups (Bolander and 
Fellows, 1976, and Hayden and Forsyth, 1979). Using 
a radioreceptor assay, Hayden and Forsyth (19 79) 
monitored placental and plasma levels of bPL throughout 
pregnancy in dairy cows. Levels in bovine placental 
cotyledons rose from day 60 to day 200 before falling 
by day 250. In contrast to this total lactogenic 
activity in bovine plasma remained below 150 ng/ml. 
throughout gestation confirming earlier results 
obtained using a bioassay (Buttle and Forsyth, 19 76) .
The bPL was partially purified and had a molecular 
weight of 45,000 by gel filtration and an isoelectric 
point of pH 5.3 (Hayden and Forsyth, 19 79). The bPL 
was found to be equipotent to ovine prolactin in 
stimulating secretory activity of mouse mammary gland. 
These findings are in agreement with those of Roy et 
al (19 77) who reported a preparation of bPL with a similar 
lactogenic potency and which circulated in late pregnancy 
with a concentration of less than 100 ng/ml. as measured
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measured by a specific radioimmunoassay.
In contrast to this the bPL isolated and purified by 
Bolander and Fellows (19 76) from bovine placenta had 
a molecular weight of 22,150 by gel filtration.
However in SDS gel electrophoresis bPL migrated as if 
it had a molecular weight of between 59,000 and 62,000. 
Two bands were obtained when the bPL was subjected to 
isoelectric focusing, a major band of pi 5.86 and a 
minor band of pi 6.1. Two peaks of bPL activity were 
obtained on DEAE cellulose chromatography, bPLl and 
bPL2, although no significant difference in amino 
acid composition was detected between the two forms.
The bPL had poor lactogenic potency as measured by 
radioreceptor assay. Levels of bPL as measured by 
radioimmunoassay were low for the first two trimesters 
and then rose sharply to a plateau of 1 yg/ml in the 
third trimester (Bolander et al, 1976). Higher levels 
of bPL were detected in animals bearing twins. Levels 
in dairy cows were greater than those in beef cows and 
high yielding dairy cows tended to have greater than 
average serum levels of bPL (Bolander et al, 19 76).
There is no explanation available as to the difference 
between the placental lactogen of Bolander and Fellows 
(19 76) and that of Hayden and Forsyth (19 79) .
Using an antiserum to dog PZP, von Schoultz et al (19 76)
were able to demonstrate the existence of a bovine
pregnancy zone protein in pregnant cow serum. As with
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with sheep PZP there was no cross reactivity with 
anti-human PZP.
There are no reports of any other pregnancy associated 
plasma proteins in late gestation in the cow.
Pig
An analogue to human pregnancy zone protein has been 
detected in pigs. Originally von Schoultz et al (1976) 
reported little or no cross reactivity between the 
antiserum to dog PZP, which cross reacted with pregnant 
cow and sheep serum, and pregnant sow serum. However 
in a later study immunoprecipitates obtained between 
anti-dog PZP and pregnant sow serum were used to raise 
an antiserum to swinePZP. The anti-swine PZP showed 
a reaction of identity between dog PZP and swine PZP. 
However, the levels of PZP were higher in both 
castrate males (80 Kg body weight) and non-pregnant 
sows than in pregnant sows 1-2 weeks before farrowing. 
The significance of this is unknown (Martinsson and 
Carlstrom, 1977).
Goats
Using an in vitro bioassay high levels of lactogenic 
activity, immunologically distinct from pituitary 
prolactin, were detected in pregnant goats. Co-culture 
of placental and mammary gland tissue indicated the 
placental origin of this activity which was referred to 
as caprine placental lactogen (cPL). Using a radio­
receptor assay for lactogenic and growth hormone
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hormone activity levels of cPL were measured throughout 
gestation. The concentration of cPL was low until 
day 50 (< 50 ng/ml) and thereafter rose to reach a 
peak in the last trimester of pregnancy (1000 ng/ml).
As in the sheep, levels decreased in the last 12 days 
of pregnancy. The approximate molecular weight of the 
cPL was 20,000 as measured by gel filtration (Currie et 
al, 19 77). This is the only pregnancy associated 
plasma protein which has been demonstrated in the goat.
1.5 The Early Pregnancy Factor
A subject which has attracted much interest, both in 
the human and domestic animal field, is the discovery by 
Morton et al (19 77) of an "early pregnancy factor" (EPF). 
Using a rosette inhibition assay, which measures the 
capacity of antilymphocyte serum to inhibit rosette 
formation between T cells and heterologous erythrocytes 
(Bach et al, 1969), Morton et al (1974) showed that the 
rosette inhibition titre (RIT) was dependent on the 
lymphocytes used. If lymphocytes from pregnant animals 
or lymphocytes incubated in the serum from pregnant animals 
were used, the RIT was greater. This observation led to 
the discovery of the early pregnancy factor. Using the 
rosette inhibition assay, EPF can be detected in the serum 
of mice, humans and sheep from 6 to 24 hours (Morton et al, 
1976, 197 7 and 19 79) and in cattle 4 days (Nancarrow et al, 
1981) after fertilisation. Partial characterisation of the 
EPF in sheep has led to the discovery of multiple forms at
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at different stages of gestation (Clarke et al, 19 80).
Soon after fertilisation a high molecular weight form 
(250,000) exists which slowly disappears as gestation 
proceeds to be replaced by a smaller 50,000 form which is 
prevalent in mid gestation. This situation is similar to 
that in mice (Clarke et al, 1978). In contrast, however, 
a transient 20,000 form can be detected in sheep in very 
early pregnancy. The 250,000 form consists of a carrier 
component present in normal serum and the 50,000 form.
All three forms can be made by two components A and B 
prepared from early pregnancy serum. Both A and B are 
required for an increase in RIT (Clarke et al, 19 80).
EPF levels are high in early pregnancy and steadily 
decline for the first two-thirds of pregnancy and may 
thereafter become undetectable (Morton et al, 19 77, 19 79 
and 19 82). Component A is synthesized by the oviduct and 
is dependent on oestrus and pregnancy whereas B is 
produced by the ovary and is pregnancy dependent.
Production of EPF B is the result of the combined action 
of signals from the pituitary and the zygote (Cavanagh et 
al, 1982).
A porcine EPF has recently been demonstrated which, 
although it displays the same characteristic components of 
other EPFs, its levels during gestation remain high 
(Morton et al, 1983).
Several reports have been published detailing failure 
to detect the EPF using lymphocytes from pregnant women or
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or lymphocytes incubated in pregnancy serum (Thomson et 
al, 1980, and Cooper and Aitken, 1981). However, this 
failure is possibly due to the inherent complexity of the 
assay rather than evidence against the existence of the 
EPF.
At present, the function of the EPF is unknown but it 
has been shown to be immunosuppressive (Noonan et al, 19 79) 
and may be involved in the acceptance of the fetus by the 
mother (Morton et al, 1976).
1.6 Equine Pregnancy
In the mare the fertilised egg enters the uterus 5 to 
6 days after ovulation. An unusual feature of equine 
pregnancy is the fact that only fertilised eggs enter the 
uterus while unfertilised eggs remain in the fallopian tube 
where they slowly degenerate (van Niekerk and Gerneke, 1966, 
Betteridge and Mitchell, 1975). Development of the 
allanto-chorionic placenta is not completed until day 40 
post ovulation and the conceptus does not become firmly 
implanted until day 45-50 with the formation of the allanto- 
chorionic villi which interdigitate with corresponding 
crypts in the endometrium. During this time the conceptus 
lies free in the uterine lumen and may even migrate from 
one uterine horn to the other (Amoroso, 1952, Bain and 
Howey, 1975, Ewart, 1897, and Hawkins et al, 1979). The 
free embryo relies upon the uterus for most, if not all, 
of its metabolic needs and uterine secretions have been
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been shown to contain proteins which may serve as enzymes 
and carrier molecules for hormones, vitamins and minerals 
(Bazer et al, 1978). A number of unique proteins which 
are not of serum origin are present in the uterus until 
day 20 of pregnancy (Zavy et al, 1982). One of these 
proteins has been identified as equine uteroferritin and 
may be involved in the transport of iron to the embryo 
(McDowell et al, 19 82).
It is during the time that the embryo lies free that 
one of the most unusual events in equine pregnancy 
commences. Around day 36 of pregnancy there appears, 
within the gravid horn of the uterus, densely packed 
decidual-like cells which form the endometrial cups 
(Schauder, 1912). The endometrial cups encircle the 
embryo and steadily enlarge for the next 20 to 30 days.
This growth causes them to become raised above the 
endometrium until day 70 when the cups begin to degenerate 
and are eventually sloughed off the surface of the 
endometrium. The mature cup consists of a well demarcated 
and densely packed mass of very large epithoid decidual- 
like cells. During their development the cups become 
surrounded by leucocytes which eventually assist in the 
degeneration and destruction of the cups by day 160 
(Allen, 1980).
Originally the progenitor cells of the endometrial cups 
were thought to be maternal in origin (Clegg et al, 1954, 
and Amoroso, 1955) and the conceptus provided the stimulus
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stimulus which transformed endometrial cells into cup cells 
(Clegg et al, 1954, and Allen, 19 70). However recent 
evidence indicates that the cells are fetal, originating 
from the chorionic girdle, which rapidly invade and 
phagocytose the endometrial epithelium and migrate into 
the endometrial glands and uterine stroma. Here they 
differentiate into large sessile endometrial cup cells 
(Moor et al, 19 75). The chorionic girdle is formed on 
the embryo at the interface of the developing allantois 
and the regressing yolk sac where the outer chorionic cells 
rapidly divide and become piled on top of one another 
forming a thickened and plainly visible chorionic girdle 
(Allen, 19 80).
The placenta of the mare is epitheliochorial with six 
layers of tissue separating the maternal and fetal blood 
(Grosser, 1909). This is the simplest form of 
placentation and consists of the apposition of the tissue 
of the placentas of each organism. The layers are 
endothelium of blood vessels, connective tissue, 
epithelium of uterus, trophoblast, connective tissue and 
endothelium of blood vessels.
The fetal origin of the endometrial cups and the 
presence of paternal histocompatibility antigens explains 
why the leucocytes surround the cup in a manner reminiscent 
of host rejection of a skin allograft (Allen, 1975).
/
35.
With the formation of the cups there appears, in the 
maternal circulation, a glycoprotein hormone, equine 
chorionic gonadotrophin (eCG), formerly pregnant mare serum 
gonadotrophin, which the cup cells produce during their 
lifespan (Allen and Moor, 1972). eCG is a high molecular 
weight glycoprotein, 5 3,000 daltons (Gospodarowicz, 1972), 
which expresses both FSH and LH like biological activities 
(Stewart et al, 1977). Dissociation of eCG into two 
subunits has been demonstrated (Papkoff, 1974).
Biological activity of the individual subunits was low but 
on recombination both FSH and LH like activities returned. 
The isoelectric point of eCG is pH 1.8 (Bourrillon and 
Got, 1957) and the carbohydrate content is nearly 50% 
(Bourrillon et al, 1959).
eCG was discovered by its ability to increase the 
weight of immature rat ovary (Cole and Hart, 19 30) and 
this has formed the basis of a bioassay to quantify eCG 
(Cole and Ewary, 1941). The sensitivity of the assay is 
approximately 2 i.u. of eCG. More recently immunological 
assays have been devised which are more sensitive, 
including haemagglutination inhibition assays and 
radioimmunoassay based on equine LH (Allen, 19 69, Nett et 
al, 1975). Levels of eCG are detectable about days 35-40 
and rise steeply to reach a peak between days 55-65 before 
declining to a minimum by day 120 (Allen, 1969). Peak 
values are variable, i.e. between 11 i.u./ml and 112 i.u./ml 
(Allen, 1969) and levels have been shown to vary with size, 
parity, number of fetuses present and fetal genotype (Cole,
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(Cole, 1938, Rowlands, 1963 and Clegg et al, 1962).
The detection of eCG in the maternal circulation 
corresponds with the appearance of a "crop" of secondary 
or accessory luteal structures. Plasma progesterone 
levels, which decline steadily from day 12-14 after 
ovulation, rise sharply with the appearance of these 
accessory luteal structures. The fact that the appearance 
of the accessory luteal structures and their secretion of 
progesterone coincides with the beginning of endometrial 
cup formation and their secretion of eCG led to the 
assumption that eCG was solely responsible for stimulating 
the luteal structures and maintaining their secretory 
activity (Amoroso et al, 1948). However isolated 
experiments and observations have cast some doubt as to 
whether eCG is solely responsible for maintaining luteal 
function during pregnancy. In some cases, despite 
surgical removal or abortion of the embryo, the endometrial 
cups remain and secrete eCG for up to 100 days. Despite 
this primary and secondary corpora lutea may regress 
within 20 days (Allen, 19 80). Another observation against
the direct luteotrophic action of eCG comes from 
progesterone levels in twin pregnancies and interspecific 
mule conceptuses. In the former case, the eCG levels may 
be very high compared with the norm and in the latter they 
may be very low due to increased immunological activity 
against the endometrial cups. In spite of these wide 
variations in eCG concentrations the plasma progesterone 
levels are-similar to normal intraspecific pregnancies
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pregnancies (Allen, 1975, Day and Rowlands, 1947).
Considerable follicular growth can be detected in the 
ovaries of 17-25 day pregnant mares, well before the 
appearance of eCG (Bain, 1967). The 10-12 day waves of 
FSH that occur during the oestrus cycle in the mare 
continue into early pregnancy (Evans and Irvine, 19 75) and 
this coincides with the observations of waves of follicular 
growth during early pregnancy (van Rensburg and van Niekerk, 
196 8). Despite this follicular growth secondary ovulations 
do not normally occur until the appearance of eCG (van 
Niekerk, Thesis). Therefore pituitary FSH must stimulate 
follicular growth and the LH activity of eCG is necessary 
to ovulate or luteinise the follicles to form the accessory 
corpora The action of eCG may help to maintain the secondary
corpora it helped to produce but some other unknown
fetal/pituitary factor is involved since loss of the
fetus leads to regression of the luteal structures 
(Allen, 1980).
Investigations by Gidley-Baird et al (1983) identified 
a new protein specific to pregnancy in the mare, Mare 
Pregnancy Protein I (MPP I). The protein was detected at 
day 30 of pregnancy and was also demonstrated at days 55 
and 6 8 of pregnancy. The protein was undetectable in 
non-pregnant mares and stallions. The function of MPP I 
and its origin are unknown although it cannot be produced 
by the endometrial cups which are unformed at day 30.
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pregnancy in the mare and these include steroid hormones, 
prolactin and lactogenic activity.
As mentioned previously, plasma progesterone levels 
decrease 12-14 days post ovulation before rising sharply 
at day 40 to reach a peak at day 60. Thereafter they 
decline to a low level by day 110 at which they remain 
until shortly before term. Prior to partuition there is 
an increase in progesterone levels (Terblanche and Maree, 
1981). Following the demise of the luteal structures, it 
is assumed that the placenta, which contains high levels 
of progesterone, supplies sufficient levels of this hormone 
to maintain the pregnancy (Short, 1958, and Allen, 1984).
At approximately 100 day of pregnancy the fetal gonads 
undergo tremendous enlargement so that by days 230-250 they 
are often larger than the maternal ovaries (Cole et al, 
1933, and Pashen and Allen, 1979). This growth is 
paralleled by a sharp rise in conjugated oestrogens in the 
maternal blood and urine. The principal oestrogens are 
oestrone and two unique to Equidae, equilin and equilenin 
(Cox, 1975) . Levels of these oestrogens rise rapidly 
between days 120 and 210. After this the levels fall 
slowly to partuition and take a precipitous post-partum 
fall (Nett et al, 1975). Fetal gonadectomy results in a 
fall in circulating oestrogens which supports the concept 
of a feto-placental unit for oestrogen synthesis in the 
mare. The oestrogens appear to play a major role in
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in fetal development since gonadectomy resulted in retarded 
fetal growth (Pashen and Allen, 1979). The retarded fetal 
growth may be the result of an alteration in utero­
placental blood flow, since studies in sheep indicate that 
oestrogens and their precursors affect both the distribution 
and rate of blood flow through uterine and placental blood 
vessels (Resnik et al, 19 74, and Rosenfeld and Worley,
1978).
Attempts to identify an equine placental lactogen have 
been unsuccessful. Using a co-culture of equine placenta 
and mouse or rabbit mammary gland, Forsyth et al (19 75) 
were unable to demonstrate the stimulation of the mammary 
gland by products of the equine placenta. Also using an 
in vitro bioassay, which had been successful in women 
(Forsyth and Edwards, 1972) and goats (Buttle et al, 1972), 
they failed to obtain positive results with equine plasma 
at any stage of gestation. Partially purified horse 
prolactin produced responses in the assay indicating that 
the negative results were not due to the lack of response 
from the mammary gland. Little variation in prolactin 
concentration throughout gestation in the mare has been 
shown by Nett et al (19 75).
Using the antiserum to swine PZP, Martinsson and 
Carlstrom (1977) demonstrated an equine PZP but no further 
reference has been made to this analogue. Apart from 
eCG, MPP I and ePZP, no other pregnancy associated serum
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serum proteins have been identified in the mare.
1.7 Aim of Work
The purpose of the following research was to 
investigate pregnant mare serum and identify any pregnancy 
associated proteins present. Initially late pregnant 
mare serum was investigated immunologically following 
preparation of antisera to whole and fractionated pregnant 
mare serum. Fractionation was performed using gel 
filtration and negative antibody affinity chromatography.
Since the source of most pregnancy proteins in humans 
is the placenta, an equine placental extract was prepared 
and antisera raised against the whole or fractionated 
extract. The antisera were used to investigate equine 
placental extract and late pregnant mare serum for proteins 
particularly associated with pregnancy.
Serum, from throughout gestation, was then subjected 
to two dimensional polyacrylamide gel electrophoresis as 
a further means of detecting the appearance of pregnancy 
associated proteins in equine serum. Finally two other 
proteins, (Alkaline phosphatase and sex hormone binding 
globulin) known to increase in concentration throughout 
gestation in humans, were investigated in pregnant mares 
by estimation of their activity in equine serum.
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CHAPTER 2
ANTISERA TO PREGNANT MARE SERUM
2.1 Introduction
The identification of the "new" pregnancy proteins in 
humans has relied upon immunological techniques requiring 
antisera which are specific to the proteins. The fact 
that the pregnancy proteins are either only found in, or 
present in, higher concentrations than normal in the 
maternal circulation has formed the basis for generating 
these specific antisera. Using third trimester pregnancy 
serum (or plasma), where the proteins are at their highest 
concentration, hyperimmune antisera are raised in a suitable 
host. These antisera can then be adsorbed exhaustively 
with normal male or non-pregnant female serum. This removes 
all the antibodies from the antisera which cross react with 
antigens common to both non-pregnant and pregnant serum.
The antibodies remaining are those directed against antigens 
which are present only in pregnancy serum. These antibodies 
can then be used to identify the proteins in the pregnancy 
serum using standard immunological techniques such as 
crossed immunoelectrophoresis or Ouchterlony double diffusion. 
This adsorption technique clearly identified pregnancy 
proteins in humans (Gall and Halbert, 19 72) and was therefore 
chosen as the principal technique for identifying pregnancy 
proteins in late gestation -in the mare.
Three /
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Three methods were chosen in order to obtain antisera 
for adsorption. The first method was based on that of Gall 
and Halbert (1972) and used a hyper-immune antiserum to late 
pregnant mare serum. The other two methods used prior 
fractionation of the pregnant mare serum before obtaining 
an antiserum. Fractionation was performed using gel 
filtration in the first case or negative antibody affinity 
chromatography. All methods had been successfully applied 
in humans (Gall and Halbert, 1972, Stimson, pers. com. and 
Sutcliffe, 1976).
2.2 Materials and Methods
2.2.1 Materials
Serum was obtained from four pregnant mares in the 
last month of gestation and used to prepare a pool of 
pregnant mare serum. Pools of stallion serum and non­
pregnant mare serum were also prepared from serum 
obtained from two stallions and two non-pregnant mares. 
All sera were stored at -20°C until required.
Gel Bond was obtained from FMC Corporation, Marine 
Colloids Division, Bio-Products, Rockland, Maine.
The immersible CX10 units for ultrafiltration were 
purchased from Millipore Corporation, Bedford, Mass. 
Sepharose 4B and Sephacryl S300 were obtained from 
Pharmacia Fine Chemicals, Uppsala, Sweden, as were 
the proteins thyroglobulin, catalase and aldolase for 
calibration of the gel filtration column. The other 
proteins used for calibration, bovine serum albumin,
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albumin, a chymotrypsinogen and myoglobin were 
purchased from Sigma Chemical Company Limited, Fancy 
Road, Poole, Dorset, England, as were the cyanogen 
bromide, high molecular weight polyethylene glycol 
and Freund's complete and incomplete adjuvant.
Agarose was obtained from Serva, Feinbiochemica, 
Heidelberg. The MIP-tests for the detection of eCG 
were provided by Carter-Wallace Inc., Cranbury, New 
Jersey. All other chemicals and reagents were of 
analar grade where possible.
2.2.2 General Methods
Ouchterlony double diffusion precipitation tests were 
performed using a modification of the method of 
Ouchterlonly (1958). Gels were formed by pouring 10 ml 
of molten agarose, 1%(w/v) in 0.9% (w/v) saline, onto 
the hydrophilic side of an 8 cm x 8 cm sheet of Gel 
Bond on a horizontal surface. Wells are cut in the 
solidified agarose to take 20 yl (maximum) of antiserum 
or sample and after addition of these the plates were 
incubated for 24 hrs at room temperature or 48-72 hrs 
at 4°C in a sealed humid box. Following incubation 
gels were pressed and washed three times in 0.9% (w/v) 
saline and three times in distilled water, air dried 
and stained. The staining solution consisted of 
250 mg Crocein scarlet and 15 mg Coomassie brilliant 
blue in 100 ml of 5% acetic acid and 3% 
trichloroacetic acid. Destaining was in 3% acetic 
acid (Crowle and Cline, 19 77).
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Immunoelectrophoresis
The method of Grabar and Williams (1953) was used 
for immunoelectrophoresis (IEP). Gels of 1% (w/v) 
agarose in electrophoresis buffer, 20 mM sodium 
barbitone, containing 4.3 mM diethyl barbituric acid 
at pH 8.6, were cast by pouring 10 ml of agarose on 
a 5 cm x 9 cm slide of Gel Bond, hydrophilic side up.
Serum (10 yl) was added to wells, 0.4 cm diameter,
along with lyl of 0.1% aqueous solution of bromo- 
phenol-blue dye (BPB). Electrophoresis was performed 
at 12V/cm until the dye front had moved 4 cm. 200 yl 
of antiserum was added to troughs cut alongside the 
wells. The gel was then incubated for 24 hrs at room 
temperature or 48 hrs at 4°C in a sealed humid box. 
Washing and staining were carried out as described for 
the double diffusion method.
Crossed Immunoelectrophoresis (XIE)
Crossed immunoelectrophoresis on agarose gels was 
performed using the method of Eckersall and Beeley 
(1980). Molten agarose (10 ml) was cast on 8 cm x 8 cm
plates of Gel Bond on the hydrophilic side. The
agarose was 1% (w/v) made up in electrophoresis buffer. 
Serum (10 yl) was applied to a 0.4 cm diameter well cut 
1 cm from the left hand edge and 0.5 cm from the base.
1 yl of 0.1% (w/v) aqueous solution of BPB was also 
added. Electrophoresis was carried out at 12V/cm at 
4°C until the dye front was 6 cm across the gel. After 
the first dimensional electrophoresis the upper 7 cm of 
the gel were removed and replaced with 8 ml of agarose
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agarose to which at 56°C, 500-1000 yl of antiserum 
were mixed. The gel was turned through 90° and 
electrophoresed for 18 hrs at 4V/cm. Gels were 
washed and stained as described previously.
Antiserum Adsorption
Two methods were employed to adsorb antisera. In the 
first method the adsorption was performed overnight at 
4°C in an end over end mixer. The second technique 
involved the antiserum having to stand at 4°C for 48 
hrs with occasional mixing. The antibody/antigen 
precipitates were removed by centrifugation at 13,000 g 
for 10 minutes. All antisera were adsorbed with 
either stallion or non-pregnant mare serum (i.e. normal 
equine serum). The adsorptions were performed in a 
sequential pattern starting at 5% and ending when the 
antiserum was fully adsorbed for normal equine serum,
i.e. the point at which no precipitin lines were 
detected between the adsorbed antiserum and normal 
equine serum by Ouchterlony double diffusion and 
immunoelectrophoresis. This fully adsorbed antiserum 
was then used to test pregnant mare serum.
Antibody Enrichment
Fully adsorbed antisera were enriched for immunoglobulins 
using a modification of the method described by Kekwick 
(1940) . To the antiserum 18% Na2 SOi, was added and 
the precipitate obtained by centrifugation. The 
precipitate was then suspended in as little volume of 
phosphate buffered saline (5mM potassium phosphate,
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phosphate, 0.16 NaCl at pH 7.4) as possible and 
dialysed against PBS overnight. This solution was 
designated antibody enriched and used in Ouchterlony 
double diffusion, immunoelectrophoresis and crossed 
immunoelectrophoresis in a similar fashion to the 
whole antiserum.
Radial Immunodiffusion
Radial immunodiffusion was performed according to the 
method of Mancini et al (1964). Agarose, 5 ml of 1% 
(w/v) in 0.9% saline (w/v), was melted and cooled to 
56°C. At this temperature 100 yl of antibody was 
added and the agarose poured onto the hydrophilic 
surface of a 5 cm square of Gel Bond. After cooling
wells, 0.4 cm diameter, were cut in the agarose a
minimum of 2 cm apart. Samples to be analysed were
applied to the wells (10 yl) and left overnight at
room temperature in a sealed humid box. Gels were 
washed and stained as described in Ouchterlony double 
diffusion.
SDS Polyacrylamide Gel Electrophoresis 
A modification of the method described by Laemmli 
(19 70) was used for SDS polyacrylamide gel 
electrophoresis (SDS PAGE). Gels were either 8 cm x 
8 cm with 1 mm spacers or 20 cm x 15 cm with 0.8 mm 
spacers. The stock solutions and solutions for gel
3
preparation are given in the appendix. The lower /4 
of the gel consists of the resolving gel. This was 
poured between the plates, overlayed with dist H 2O and
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and left to polymerise. Once polymerisation was 
complete the water was poured off and the surface of 
the gel rinsed once with a small volume of stacking 
gel buffer. Stacking gel was then poured to the top 
of the plates. Wells were formed in the stacking 
gel by means of a plastic comb.
Prior to electrophoresis samples were boiled for 2 
minutes in sealed containers in an equal volume of 
solubilizing buffer. Samples (5-15 yl) were then 
applied to the wells in the stacking gel. Upon 
dilution of the electrophoresis buffer SDS was added 
to a concentration of 0.1% w/v. Gels were run at 
either 15 mA constant current (8 cm x 8 cm gels) or 
25 mA constant current (20 cm x 15 cm gels). 
Electrophoresis was stopped when the BPB dye front 
was 1-3 cm from the end of the gel. Staining was 
performed in 0.1% (w/v) Coomassie Brilliant Blue R250 
dissolved in a methanol : acetic acid : H 2O ( 5 : 1 : 5 )  
solution and destained in 25% methanol, 10% acetic acid 
and 65% H20.
Protein Estimation
Protein estimations were performed using the method of 
Sedmak and Grossberg (19 77). The assay solution 
consisted of 0.06% (w/v) Coomassie G250 dissolved in 
2.2% (w/v) HC1. The absorbance of this solution was 
between 1.3 and 1.5 at' 465 nm. A standard curve was 
prepared using BSA in 0.9% saline over a concentration 
range of 1-100 yg/ml. 0.5mlof assay solution and
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and 0.5 ml of standard were added and the absorbance 
at 620 nm determined immediately. An identical 
procedure was used for samples and the protein 
concentration determined by intrapolation of the 
absorbance on the standard curve. If necessary the 
sample was diluted so that absorbance lay in the 
linear region of the curve, i.e. 1-60 yg/ml.
2.2.3 Antisera to Whole Pregnant Mare Serum (wPMS) 
Each of three rabbits was injected with a total volume 
of 1 ml of a 1:1 emulsion of serum in Freunds in 
complete adjuvant at four subcutaneous sites along the 
back. The serum was either from pregnant mares during 
the last month of gestation or from stallions. The 
injections were repeated at monthly intervals for one 
year. Blood was obtained from the rabbits 10-12 days 
after injection and serum separated and stored at 
-20°C until required.
The antiserum to stallion serum obtained after one 
year was adsorbed at various concentrations of stallion 
serum to determine the percentage of normal equine 
serum required to remove all antibodies to normal serum 
antigens from the antiserum. Once this was found the 
rabbit anti-wPMS was adsorbed at this percentage and 
tested against PMS and stallion serum by Ouchterlony 
double diffusion, immunoelectrophoresis and crossed 
immunoelectrophoresis.
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An antibody enrichment step was performed on the fully 
adsorbed antiserum to wPMS. The antibody enriched 
solution was then used to test for cross reactions 
against PMS and stallion serum using Ouchterlonly 
double diffusion and immunoelectrophoresis.
2.2.4 Antisera to Fractionated Pregnant Mare 
Serum (fPMS)
Antisera to subfractions of pregnant mare serum were 
prepared following gel filtration of whole PMS.
Gel filtration was performed using sephacryl S300 in 
a column 95 cm x 2.8 cm diameter. The eluting buffer 
was 5 mM potassium phosphate pH 7.4 with 0.5 M NaCl.
In total 100 ml of late pregnant mare serum was 
fractionated in 2.5 ml aliquots. The flow rate 
through the column was 40 ml/hr and 3.5 ml fractions 
were collected. Protein peaks were detected by their 
absorbance at 280 nm and concentrated using 
ultrafiltration with Millipore CX10 immersible units.
The column was calibrated using the following proteins, 
thyroglobulin, catalase, aldolase, bovine serum albumin, 
a chymotrypsinogen and equine myoglobin. Four protein 
peaks were obtained from each run of the PMS and each 
peak was pooled and concentrated to 15 mg/ml in the 
case of the first two peaks and 60 mg/ml in the case 
of the third and fourth peaks.
Two injection protocols (Stimson, W.H., personal
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personal communication) were used to raise antisera 
to the pooled fractions. The fractions from 50 ml 
of late pregnant mare serum were injected by each 
protocol.
(A) Rabbits were injected with the PMS fractions as 
follows:
Day 1 - 1 ml of 1:1 emulsion of the fraction
in Freund's complete adjuvant given 
intra muscularly.
Day 14 - A repeat of Day 1.
Day 24 - 1 ml of the fraction alone given
intra peritoneally.
Day 34 - Rabbits were bled, serum separated and 
stored at -20°C until required.
Two rabbits were injected per fraction.
(B) Alum adjuvant.
In this procedure fractions 1 and 2 were 
amalgamated in order to increase the protein 
content for injection and 2 rabbits were used 
per fraction. To 10 ml of each fraction, 32 ml 
of water and 36 nil of 10% (w/v) KA1 SOt* I2H 2O were 
added. The pH was adjusted to pH 6.5 using 
5N NaOH which gave a heavy precipitate. After
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After centrifugation the precipitate was washed 
twice in 0.9% (w/v) saline before being suspended 
in a final volume of 40 ml H20. This preparation 
was stable for 14 days.
Rabbits were injected as follows:
Day 1 - 5 ml of alum precipitate in each
hind leg muscle.
Day 14 - A repeat of Day 1.
Day 24 - 1 ml of untreated fraction given 
intra peritoneally.
The rabbits were bled on Day 34 and the serum 
separated and stored at -20°C.
Both sets of antisera were then adsorbed with stallion 
serum at a variety of concentrations between 5 and 50% 
and the resultant adsorbed antisera were then tested 
against PMS and stallion serum by Ouchterlony double 
diffusion and immunoelectrophoresis.
Partial purification of IgG was carried out as 
described in antibody enrichment (Section 2.2.2).
IgG concentrates were then used to test PMS and 
stallion serum by Ouchterlony double diffusion and 
immunoelectrophoresis.
52. /
2.2.5 Antiserum to fPMS - Negative Antibody Affinity
Chromatography
The method used for this chromatographic process was 
that of Sutcliffe (1976). Antiserum to stallion serum 
was raised in goats by intramuscular injections at 4 
weekly intervals of a 1:1 emulsion of stallion serum 
and Freund's incomplete adjuvant, 1 ml in each leg.
After the fifth and sixth injections 1 litre of blood 
was obtained and the serum separated.
Preparation of IgG
A two step procedure for the purification of IgG was 
employed and both steps were monitored using radial 
immunodiffusion and SDS PAGE.
IgG was initially partially purified using precipitation 
by 18% Na2SOi» (Kekwick, 1940) . The precipitated 
immunoglobulins were then suspended in 40% of their 
original serum volume. The precipitate was dissolved 
in a phosphate buffer pH 6.5 made by mixing 
0.2 M NaHzPO^ and 0.2 M Na2HP04 to the desired pH and 
making the volume up to 100 ml with distilled water.
QAE sephadex was then suspended in the same phosphate 
buffer and left to swell overnight before being packed 
into a column 45 cm x 2.8 cm diameter. The column 
was equilibrated at pH 6.5 using the phosphate buffer. 
The crude IgG solution was dialysed against the 
phosphate buffer pH 6.5 prior to chromatography.
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The crude IgG solution was divided into 50 ml aliquots 
and passed through the QAE sephadex column. The flow 
rate was 40 ml per hour and 10 ml fractions were 
collected. Protein peaks were determined by their 
absorbance at 280 nm. Bound protein was eluted from 
the column using the phosphate buffer pH 6.5 containing
0.5 M NaCl. The column was then re-equilibrated with 
phosphate buffer, pH 6.5, prior to another run. The 
first peaks were pooled and concentrated by dialysis 
against high molecular weight polyethylene glycol and 
tested for the presence of IgG using radial 
immunodiffusion. The purity of the first peak IgG 
was tested using SDS PAGE and its reactivity to 
stallion serum tested using immunoelectrophoresis and 
crossed immunoelectrophoresis.
CNBr activated sepharose was prepared and the protein 
coupled to it according to the method of Porath et al 
(1967). 1.5 litres of Sepharose 4B were washed
overnight in distilled water to remove preservatives 
before being suspended in 1042 ml distilled H 20.
All-procedures involving CNBr were performed in a fume 
cupboard. CNBr (125 g) was dissolved in 2084 ml of 
distilled H 20. The Sepharose 4B and the CNBr were 
then mixed and during the course of the reaction the 
pH was maintained at pH 11 by pumping 2 M NaOH via a 
variable speed peristaltic pump. The NaOH was 
required to maintain a high pH to prevent the release 
of cyanide gas during the reaction. The NaOH was
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was added rapidly to begin with but the rate of 
addition gradually decreased until the pH remained 
constant and the NaOH addition was stopped. The 
activated sepharose was washed for 1 hour in distilled 
H 20 and suspended in the coupling buffer 0.1 M NaHC0 3. 
The IgG, in coupling buffer, was added at a 
concentration of 5 mg/ml and gently agitated at room 
temperature for 2 hours. Binding to the activated 
sepharose was checked by comparing the IgG content of 
the supernatant before and after mixing using radial 
diffusion with a donkey anti-goat IgG. Any remaining 
active groups were blocked by washing with 1 M 
ethanolamine pH 8.0, for 1 hour. Non covalently bound 
protein was removed by three washing cycles of high and 
low pH buffers (0.1 M Acetate Buffer, pH4 and 0.1 M 
Borate Buffer pH 8) in 1 M NaC 1. The sepharose was 
then packed into a column and equilibrated with 
phosphate buffered saline.
5 ml aliquots of late pregnant mare serum were passed 
through the column. The column was maintained at 4°C. 
The flow rate was 25 ml/hr and 10 ml fractions were 
collected. The first peak, detected by its absorbance 
at 280 nm, was collected, concentrated by 
ultrafiltration and stored at -20°C. The second peak 
was eluted using 100 ml of 0.5 M acetic acid after 
which the column was re-equilibrated with phosphate 
buffered saline prior to more PMS being applied. 5 ml 
aliquots of stallion serum and non-pregnant mare serum
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serum were also applied and the first peaks retained 
and treated similarly. In total 200 ml of PMS and 
50 ml of stallion and non-pregnant mare sera were 
passed through the column.
The first peak concentrates from 100 ml of the PMS were 
used to raise an antiserum in two rabbits. The 
concentrate was emulsified 1:1 with Freund's incomplete 
adjuvant and 1 ml injected at four subcutaneous sites 
on the back. Rabbits were bled after four monthly 
injections and the serum stored at -20°C.
For immunological analysis the first peak PMS was 
divided into an early and late region on the basis of 
elution profile. The early and late regions were 
tested against the antiserum to the first peak PMS 
using Ouchterlony double diffusion and crossed 
immunoelectrophoresis and compared with the first 
peaks from stallion and non-pregnant mares. The 
antiserum was then adsorbed with 30% stallion serum 
and again tested against the first peak PMS and the 
first peak stallion and non-pregnant mare sera using 
Ouchterlony double diffusion and crossed 
immunoelectrophoresis.
The effectiveness of the affinity column was assessed 
by running serum known to contain eCG (taken from a 
day 55 days pregnant mare). 5 ml of this serum was
passed through the column and both the first peak and
/
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FIGURE 2.1
RESULTS OF ANTISERUM TO WHOLE PREGNANT MARE SERUM
Gel (a) 1. 10 yl whole pregnant mare serum.
2. 10 yl stallion serum.
As 200 yl rabbit anti-pregnant mare serum
in the trough.
Gel (b) 1. 10 yl whole pregnant mare serum.
2. 10 yl stallion serum.
As 200 yl rabbit anti-pregnant mare serum
adsorbed with 30% stallion serum in the 
trough.
For gels (a) and (b) immunoelectrophoresis was performed
at 12v/cm on gels of 1% (w/v) agarose in 20 mM sodium
barbitone and 4.3 mM diethyl barbituric acid at pH 8.6 as
described in Section 2.2.2.
Gel (c) p.s. 10 yl whole pregnant mare serum.
Antiserum in second dimensipn was 500 yl of 
rabbit anti-pregnant mare serum.
Gel (d) p.s. 10 yl of whole pregnant mare serum.
Antiserum in second dimension was 500 yl of 
rabbit anti-pregnant mare serum adsorbed with 
30% stallion serum.
For /
For gels (c) and (d) crossed immunoelectrophoresis was 
performed on 1% (w/v) agarose in 20 mM sodium barbitone 
and 4.3 mM diethyl barbituric acid, pH 8.6 as described 
in Section 2.2.2.
4. 10 yl of pregnant mare serum.
5. 10 yl of stallion serum.
6. 10 yl of non-pregnant mare serum, 
rabbit anti-pregnant mare serum in 
centre well.
4. 10 yl of pregnant mare serum.
5. 10 yl of stallion serum.
6. 10 yl of non-pregnant mare serum, 
rabbit anti-pregnant mare serum adsorbed 
with 30% stallion serum in centre well.
For gels (e) and (f) Ouchterlony double diffusion was 
performed on 1% (w/v) agarose in 0.9% (w/v) saline as 
described in Section 2.2.2.
Ge 1 (e) 1 &
2 & 
3 & 
As
Gel (f) 1 &
2 & 
3 & 
As
Fig. 2.1.a
Adsorption of rabbit antistallion serum
The wells contained 10 yl of stallion serum
The troughs contained 200 yl of rabbit antistallion 
serum adsorbed at the following percentages
nJ- 0% stallion serum
2 5% stallion serum
3 10% stallion serum
4 20% stallion serum
5 30% stallion serum
Immunoelectrophoresis was performed at 12V/cm on gels 
of 1% (W/V) agarose as described in Section 2.2.2 (p.45)
For antiserum production see p.49 and for results see p.57
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Fig. 2.1 Results of Antisera to Whole P.M.S.
For methods used see p.49, for results see p.57 and for 
discussion see pp.63-65.
and the second collected, concentrated by 
ultrafiltration and tested for eCG using a commercial 
haemagglutination test (MIP-test).
However the result obtained from this test is only
qualitative, i.e. whether eCG is present or not.
2.3 Results
2.3.1 Antiserum to Whole PMS
The antiserum to whole PMS produced cross reactions 
with pregnant mare and stallion sera on Ouchterlony 
double diffusion, immunoelectrophoresis and crossed 
immunoelectrophoresis. With the antiserum to 
stallion serum the minimum concentration required to 
totally adsorb cross reacting antibody from the 
antiserum was 30%. This concentration of stallion 
serum was then used to adsorb the antiserum to whole 
PMS from each of the rabbits immunised. The adsorbed 
antisera were then tested against PMS and stallion 
serum by Ouchertlony double diffusion, immuno­
electrophoresis and crossed immunoelectrophoresis 
(Fig. 2.1). No antibody/antigen precipitates were 
detected between the adsorbed antiserum from any 
rabbit and the pregnant mare serum.
The three antisera adsorbed with 30% stallion serum 
were pooled, subjected to antibody enrichment, and 
tested, using Ouchterlony double diffusion and 
immunoelectrophoresis, against stallion and pregnant 
mare sera. A precipitin line was detected between 
the enriched adsorbed antisera and PMS on Ouchterlony
/
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FIGURE 2.2
DIAGRAMMATIC REPRESENTATION OF AN OUCHTERLONY DOUBLE 
DIFFUSION GEL CONSISTING O F ;
1, 4. 10 yl of pregnant mare serum.
2, 5. 10 yl of stallion serum.
3, 6. 10 yl of non-pregnant mare serum.
As Pooled antisera against whole pregnant
mare serum, fully adsorbed with 30% 
stallion serum and antibody enriched 
as described in Section 2.2.2.
Ouchterlony double diffusion was performed on 1% (w/v) 
agarose in 0.9% (w/v) saline as described in Section 2.2.
Fig. 2.
© ©
® \ o  \  ©  
© ®
> Diagrammatic Representation of An Ouchterlony 
Double Diffusion Gel.
The results are given on pp.57-58 and discussed on p.64.
FIGURE 2.3
GEL FILTRATION CALIBRATION CURVE
The sephacryl S 300 column (95 cm x 2.8 cm diameter) was 
calibrated with the following proteins
Molecular Weight
1. thyroglobulin 669,000
2. catalase 232,000
3. aldolase 15 8,000
4. bovine serum albumin 6 7,000
5. a chymotrypsinogen 25,000
6. equine myoglobin 18,000
The void volume, as indicated by the arrow on the graph, 
was obtained using blue dextran 2000.
For calibration two duplicate runs were made with three 
proteins in each run. The first run consisted of thyro- 
globulin, aldolase and a chymotrypsinogen and the second 
consisted of catalase, bovine serum albumin and equine 
myoglobin. For each run 50 mg of the respective proteins 
were dissolved in 2.5 ml of 5 mM potassium phosphate, 
pH 7.4, with 0.5 M NaCl and 10% glycerol and applied to 
the column. Gel filtration was performed at 4°C as 
described in Section 2.2.4. The mean elution volume for 
each protein was calculated and graphed against the natural 
logarithm of the molecular weight.
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FIGURE 2.4
GEL FILTRATION OF PREGNANT MARE SERUM
Gel filtration of pregnant mare serum was performed at 4°C 
on a sephacryl S 300 column, 95 cm x 2.8 cm diameter, as 
described in Section 2.2.4.
A 2.5 ml aliquot of pregnant mare serum with 10% glycerol 
was applied per run. The four peaks which were obtained 
and pooled for antiserum production are indicated by the 
dotted lines on the graph. Protein peaks were detected 
by their absorbance at 280 nm.
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Ouchterlony double diffusion but this showed a reaction 
of identity with a line produced by stallion serum 
(Fig. 2.2). No reactions were detected by 
immunoelectrophoresis.
2.3.2 Antisera to PMS Fractionated by Gel Filtration 
The gel filtration column was calibrated using 
thyroglobulin, catalase, aldolase, bovine serum 
albumin, a chymotrysinogen and equine myoglobin and 
their elution volumes graphed against the In of their 
molecular weight (Fig. 2.3). Fractionation of 
pregnant mare serum gave four peaks of molecular weight 
ranges 1,800,000 - 1,300,000, 1,300,000 - 660,000f 660,000 - 
120,500 and 120,500 - 45,000 (Fig. 2.4).
Results for Injection Protocol 1
Antisera raised to fractions 1-4 produced very strong 
cross reactivity with pregnant mare serum and stallion
serum. The antisera were adsorbed by stallion serum
at a variety of concentrations. At 50% stallion 
serum there were no antibody/antigen precipitates 
detected between the adsorbed antisera and normal equine 
serum. These totally adsorbed antisera when tested 
against late PMS by Ouchterlony double diffusion and 
immunoelectrophoresis revealed no precipitin lines.
At the other concentrations of stallion serum, 5%,
10%, 20% and 30%, although precipitates were visible 
on Ouchterlony and immunoelectrophoretic gels between 
the adsorbed antisera and PMS similar precipitin
/
58.
FIGURE 2.5
ANTISERA RAISED TO FRACTIONATED PMS
Ge1 (1) 1. 10 yl of pregnant mare serum.
2. 10 yl of stallion serum.
From right to left the troughs contain the following:
Rabbit antiserum to first peak gel filtration PMS. 
Rabbit antiserum to second peak gel filtration PMS. 
Rabbit antiserum to third peak gel filtration PMS. 
Rabbit antiserum to fourth peak gel filtration PMS.
Gel (2) 1. 10 yl of pregnant mare serum.
2. 10 yl of stallion serum.
The trough contains rabbit antiserum to first 
peak gel filtration PMS adsorbed with 5% 
stallion serum.
Gel (3) 1. 10 yl of pregnant mare serum.
2. 10 yl of stallion serum.
The trough contains rabbit antiserum to first 
peak gel filtration PMS adsorbed with 10% 
stallion serum.
Gel /
Gel (4) 1.
2.
10 vi 1 of pregnant mare serum. 
10 yl of stallion serum.
The trough contains rabbit antiserum to first 
peak gel filtration PMS adsorbed with 20% 
stallion serum.
Gel (5) 1. 10 yl of pregnant mare serum.
2. 10 yl of stallion serum.
The trough contains rabbit antiserum to first 
peak gel filtration PMS adsorbed with 30% 
stallion serum.
For all gels, immunoelectrophoresis was performed at 
12v/cm on gels of 1% (w/v) agarose in 20 mM sodium 
barbitone and 4.3 mM diethyl barbituric acid at pH 8.6 
as described in Section 2.2.2.
2 5
Fig. 2.5 Antisera to Fractionated P.M.S.
The methods used for antisera production are given on 
pp.50-52, the results are given on pp.58-59 and discussed 
on pp.65-67.
TABLE 2.1 Estimated CROSS REACTIVITY REMAINING AFTER 
ADSORPTION OF ANTISERA TO GEL FILTRATION 
FRACTIONS (PROTOCOL 1) WITH VARIOUS CONCENTRATIONS 
OF STALLION SERUM
Antiserum Against
% adsorbing stallion serum
0 10 20 30 50
Fraction 1 + +  + +  '+ + +
Fraction 2 * +  + ~h — ■
Fraction 3 +  +  + ” + —
Fraction 4 +  ++ ' +  '+■ +  + +
The cross reactivity between the gel filtration fractions 
and the corresponding antiserum adsorbed with various 
percentages of stallion serum was estimated from the 
number of arcs remaining and the intensity of cross 
reactivity as observed on immunoelectrophoretic gels
+++ high cross reactivity 
++ medium 
+ low
no cross reactivity
FIGURE 2.6
IMMUNOELECTROPHORESIS USING ANTISERA RAISED TO FRACTIONATED 
PMS (ALUM ADJUVANT)
1. 10 yl of pregnant mare serum.
2. 10 yl of stallion serum.
From left to right the troughs contain the following 
Rabbit antiserum to peaks 1 and 2 from gel 
filtration of PMS.
Rabbit antiserum to third peak gel filtration PMS. 
Rabbit antiserum to fourth peak gel filtration PMS.
Immunoelectrophoresis was performed at 12v/cm on gel of 
1% (w/v) agarose in 20 mM sodium barbitone and 4.3 mM 
diethyl barbituric acid at pH 8.6 as described in 
Section 2.2.2.
Fig. 2.6.a Immunoelectrophoresis using Antisera Raised 
to Fractionated P.M.S. (Alum Adjuvant).
1. 10 yl of pregnant mare serum
2. 10 yl of stallion serum
c
In gels A and B the troughs contain, from left to right,
200 yl rabbit anti 1/2 fraction
200 yl rabbit anti 3rd fraction
200 yl rabbit anti 4th fraction
In gel A the antisera are adsorbed with 10% stallion
serum and in gel B the antisera were adsorbed with 
50% stallion serum.
Immunoelectrophoresis was performed at 12V/cm on 
1% (W/V) agarose as described in Section 2.2.2.
Antisera were raised as described in methods pp.50-52,
the.results obtained are given on pp.58-59 and discussed
on pp.65-67.

TABLE 2.2 Estimated: CROSS REACTIVITY REMAINING AFTER 
ADSORPTION OF ANTISERA TO GEL FILTRATION 
FRACTIONS (PROTOCOL 2) WITH VARIOUS CONCENTRATIONS 
OF STALLION SERUM
Antiserum Against
% of adsorbing stallion serum
0 10 20 30 50
Fraction 1/2 + t + + + *+* —
Fraction 3 ■H-+ +'+ 4“ —
Fraction 4 + + + 4~ —
The cross reactivity between the gel filtration fractions 
and the corresponding antiserum adsorbed with various 
percentages of stallion serum was estimated from the 
number of arcs remaining and the intensity of cross 
reactivity as observed on immunoelectrophoretic gels
+++ high cross reactivity 
++ medium 
+ low
no cross reactivity
precipitin lines were also detected in stallion serum 
(Fig. 2.5 and Table 2.1).
After several booster injections of 1 ml peak material 
given intraperitoneally a pool of antisera to each 
peak was obtained. After adsorption at 50% stallion 
serum the immunoglobulins were precipitated as 
described previously. The enriched preparation 
obtained was then used on Ouchterlony double diffusion 
and immunoelectrophoresis to test PMS and stallion 
serum. A precipitin line was observed on the 
Ouchterlony gels between the enriched antibody to the 
first and second peaks and the stallion serum. The 
gel filtration fractions were also tested but failed 
to reveal any unique reactions.
Protocol 2
Again the antisera raised by this injection protocol 
showed strong cross reactivity with stallion and late 
pregnant mare sera (Fig. 2.6). The antisera to 
fractions 1-4 were treated similarly to those from 
protocol 1. Complete adsorption of the antisera was 
obtained by 50% stallion serum with no cross reactivity 
between the adsorbed antisera and PMS. Cross 
reactivities were obtained at the intervening stallion 
serum concentrations but these were common to both 
PMS and stallion serum (Table 2.2).
With the enriched IgG preparations from the 50%
/
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FIGURE 2.7
PURIFICATION OF IgG FROM GOAT ANTISERUM TO STALLION SERUM
1. a. 5 pi supernatant from goat anti-stallion
serum after addition of 18% (w/v) Na2SOif. 
b. 5 pi precipitate from goat anti-stallion 
serum after addition of 18% (w/v) Na2S0lf.
The Mancini gels consisted of 100 pi of donkey antiserum to 
goat IgG added, at 56°C, to 5 ml of 1% (w/v) agarose in
0.9% (w/v). The gel was incubated at room temperature 
for 24 hours (Section 2.2.2).
2.a,b,c. 10 pi first peak from QAE sephadex
chromatography of precipitate from 18%
Na2S04 treatment of goat antiserum to 
stallion serum.
e,f,g. 10 pi second peak from QAE sephadex
chromatography of precipitate from 18%
Na2S0i* treatment of goat antiserum to 
stallion serum.
The purity of the IgG after these procedures was investigated 
using SDS polyacrylamide gel electrophoresis.
3. /
3. 1. supernatant from 18% N a 2S0lt treatment of
goat antiserum to stallion serum.
2. precipitation from 18% Na2SOlt treatment of 
goat antiserum to stallion serum.
3. first peak from QAE sephadex chromatography 
of precipitate from 18% N a 2SOlt treatment of 
goat antiserum to stallion serum.
4. pure swine IgG.
5. standards:- a chymotrypsinogen and equine 
myoglobin.
6. ovalbumin.
7. bovine serum albumin.
The polyacrylamide gel electrophoresis was performed under 
denaturing conditions as described in Section 2.2.2. All 
protein concentrations were approximately 2 mg/ml except 
the standards and swine IgG which were applied at 50 yg/ml.
10 yl was added per well.
4. s.s. stallion serum (10 yl)
The antiserum in the second dimension was 200 yl of the 
goat anti-stallion serum IgG. Crossed immunoelectrophoresis 
was performed on 1% (w/v) agarose in 20 mM sodium barbitone 
and 4.3 mM diethyl barbituric acid, pH 8.6, as described in 
Section 2.2.2.
a. 10 yl supernatant before 2 hours mixing 
with CNBr sepharose.
b. 10 yl supernatant after 2 hours mixing 
with CNBr sepharose.
Fig. 2.7 Purification of IgG From Goat Antiserum To 
Stallion Serum.
For methods see pp.53-55, results pp.60-61 and 
discussion p„68.
50% adsorbed antisera a precipitin line was detected 
between the antiserum to fractions 1 and 2 and stallion 
serum on Ouchterlony double diffusion. All other 
samples, including the gel filtration fraction 
concentrates, failed to show any precipitation 
reactions.
2.3.3 Antisera to PMS Fractionated by Negative 
Antibody Affinity Chromatography (NAAC)
The efficiency of the purification procedure for IgG 
is demonstrated by Figure 2.7. The radial 
immunodiffusion gel indicates that the 18% NaaSOi, . 
precipitated most of the immunoglobulins from the 
serum (Fig. 2.7.1). However the precipitate still 
contained some serum proteins as seen in the SDS PAGE 
gel (Fig. 2.7.3). The first peak from the QAE 
sephadex column contained all of the IgG (Fig. 2.7.2) 
and this was shown to have only two major bands 
corresponding to molecular weights 25,000 and 50,000 
as calculated from the standards on SDS PAGE (Fig.
2.7.3). The bands corresponded with the two bands 
obtained from pure swine IgG. The reactivity of this 
preparation of IgG was tested against stallion serum 
by immunoelectrophoresis and crossed immunoelectro- 
phoresis and was shown to be poly specific (Fig. 2.7.4). 
From the two litres of goats' blood, 25 g of pure IgG 
were isolated. Most .of this IgG was successfully 
coupled to the activated sepharose as very little
/
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FIGURE 2.8
NEGATIVE ANTIBODY AFFINITY CHROMATOGRAPHY OF PREGNANT 
MARE SERUM
The negative antibody affinity chromatography column 
consisted of 25 g of goat anti-stallion IgG coupled to 
1.5 litres of CNBr activated sepharose 4B. A 5 ml sample 
of pregnant mare serum was applied to the column, at 4°C, 
and the first peak eluted as described in Section 2.2.5. 
The second peak was eluted using 100 ml of 0.5 M acetic 
acid which was added to the column on elution of the first 
peak (point indicated by arrow on graph). The peaks were 
detected by their absorbance at 280 nm. The first peak 
was divided into an early and late region as indicated by 
the line on the graph.
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Fig. 2.8
For methods see pp.55-57, results pp.61-62 and 
discussion pp.68-70.
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The binding capacity was calculated from the
total protein eluted in 2nd peak -ioos- 
total protein applied
See results p.61 and discussion p.67-70
TABLE 2.3 PERCENTAGE BINDING TO NEGATIVE ANTIBODY AFFINITY 
CHROMATOGRAPHY COLUMN
Vol. of Serum 
Applied
% Binding to 
Column
3.0 ml 80%
5.0 ml 75%
7.5 ml 67%
Table 2.3a
Binding capacity for N.A.A.C. for every 10 runs of 5 ml 
equine serum.
Binding Capacity 
75%
74.8%
73%
73%
71%
62.5%
No. of Runs 
10 
20 ; 
30 
40 
50 
60
little IgG was present in the supernatant after 2 hours 
incubation as shown by radial immunodiffusion (Fig. 
2.7.5).
A 5 ml. aliquot of pregnant mare serum applied to the 
negative antibody affinity chromatography column gave 
a small breakthrough peak and a larger second peak 
eluted with 100 ml of 0.5 M acetic acid (Fig. 2.8).
The recovery of protein from the column was calculated 
from the total protein applied and the total protein 
eluted and this was found to be 95%. For a 5 ml 
aliquot the column bound 75% of the protein (Table
2.3). This figure was similar for stallion and 
non-pregnant mare sera. A 3 ml sample gave a 
binding of 80% whereas a 7.5 ml sample gave a binding 
of 67% (Table 2.3). The volume of 5 ml of serum was 
chosen by virtue of its binding capacity and the ease 
of detection of the first.peak. The binding capacity 
of the column was continuously monitored and after 6 
months the capacity began to decline and the column 
was discarded. By this time sufficient first peak 
material had been obtained. Of the 200 ml of PMS 
applied to the columnthe first peaks from 100 ml were 
pooled, concentrated and used for antiserum production 
in three rabbits. The peaks from the other 100 ml 
were divided into an early and late region on the 
basis of elution profile, pooled, concentrated and 
used for immunological analysis. 50 ml of normal 
equine serum was also applied to the column and the
/
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FIGURE 2.9
POLYACRYLAMIDE GEL ELECTROPHORESIS OF THE FIRST PEAK N.A.A.C 
OF PREGNANT MARE SERUM
Track No. 1 equine a and 3 globulins*
2 equine albumin (Cohn fraction V)/
3 standards:- ovalbumin, a chymo- 
trypsinogen and myoglobin.
4 stallion serum.
5 late pregnant mare serum.
6 first peak N.A.A.C. of pregnant 
mare serum, early region.
7 first peak N.A.A.C. of pregnant 
mare serum, late region.
Polyacrylamide gel electrophoresis was performed in a 10% 
acrylamide gel under denaturing conditions as described in 
Section 2.2.2. All protein concentrations were 
approximately 2 mg/ml except the standards which were at 
concentrations of 50 yg/ml.
* obtained from Pentex Incorporated, Kankakee, 
Illinois.
/ obtained from Koch-Light Laboratories Ltd., 
Colnbrook, Bucks, England.
iI
67K- 
43K-
I
25K- 
18K-
Fig. 2.9 PAGE of The First Peak N.A.A.C. of Pregnant 
Mare Serum.
The bands in lanes 6 and 1, marked with the arrow, are 
probably due to proteolytic degradation of albumin 
occurring during storage. The results are presented 
on p.62 and discussed on pp.68-69.
FIGURE 2.10
DIAGRAMMATIC REPRESENTATION OF CROSSED IMMUNOELECTROPHORETIC 
GEL
Using the antiserum to the first peak N.A.A.C. of pregnant 
mare serum -
s.s. 10 yl of stallion serum, 
p.s. 10 yl of pregnant mare serum-
500 yl of the rabbit anti first peak N.A.A.C. 
of pregnant mare serum was used in the second 
dimension.
Crossed immunoelectrophoresis was performed using 1% (w/v)
' agarose in 20 mM sodium barbitone and 4.3 mM diethyl 
barbituric acid, pH 8.6, as described in Section 2.2.2.
++
S.S.
Fig. 2.10 Crossed Immunoelectrophoresis using the 
Antiserum to the First Peak N.A.A.C. of 
P.M.S.
The antiserum was raised by the method given on p.56.
For results see p.62 and discussion on pp.68-69.
+However owing to the limitations of the MIP test 
quantitation was not attempted and the enhancement of 
the eCG concentration in the first peak could not be 
calculated.
the first peaks pooled and concentrated and used for 
comparison with the first peaks PMS in the immunological 
. analysis.
The first peak eluting when the eCG positive serum was 
applied to the column was concentrated to its original 
volume (5 ml) and was eCG positive. The second peak 
contained no eCG^ ~^~~
SDS PAGE of both the early and late regions of the first 
peak showed that they contained only proteins which were 
present in normal equine serum (Fig. 2.9). The major 
protein present was equine albumin. Attempts to 
reduce contamination of the first peak by albumin using 
a pre-chromatographic run on Affi-gel blue failed since 
the first peak from the NAAC was undetectable when 
dealbuminised serum was applied despite a large volume 
being used. A first peak was also undetectable upon 
rechromatography of the concentrated first peak 
material obtained from 20 ml PMS.
The antiserum obtained to the first peak reacted with 
two proteins in both pregnant mare and stallion 
sera on crossed immunoelectrophoresis (Fig. 2.10).
The pattern obtained on the gels with pregnant mare 
and stallion sera was similar. No peaks were 
detected after the antiserum was adsorbed with 30% 
stallion serum. Similar results were obtained on 
Ouchterlony double diffusion. Using the early and
/
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FIGURE 2.11
OUCHTERLONY DOUBLE DIFFUSION OF ANTISERUM TO FIRST PEAK 
N.A.A.C. OF PREGNANT MARE SERUM
1. 10 yl of first peak N.A.A.C. of pregnant
mare serum (early region).
2. 10 yl of stallion serum.
3. 10 yl of first peak N.A.A.C. of pregnant
mare serum (late region).
4. 10 yl of pregnant mare serum.
As 20 yl of rabbit anti first peak N.A.A.C.
of pregnant mare serum.
Ouchterlony double diffusion was performed on 1% (w/v) 
agarose in 0.9% (w/v) saline as described in Section 2.2.2.
Fig. 2.11.a
Ouchterlony Double Diffusion of Antiserum to First Peak 
N.A.A.C. of P.M.S.
1, 2, 3, 4 are as given in Fig. 2.11 
5 First peak from the normal equine serum
In gel A the antiserum in the centre well is to the 1st 
peak N.A.A.C. of P.M.S.
In gel B the antiserum in the centre well is to the 1st 
peak N.A.A.C. of P.M.S. adsorbed with 30% stallion serum.
Ouchterlony double diffusion was performed as described 
in Section 2.2.2.
For antiserum production and sample preparation see 
pp.55-56, for results see pp.61-63 and for discussion 
see pp.68-69.

and late regions of the PMS and the first peak from 
normal equine serum reactions were obtained but the 
precipitate lines were identical. All reactions 
were removed when the antiserum was adsorbed with 
30% stallion serum (Fig. 2.11).
2.4 Discussion
All the immunological methods described in this chapter 
have been successfully used in identifying pregnancy proteins 
in the late pregnancy serum of humans and laboratory animals 
However when applied to mares the methods consistently failed 
to reveal any proteins peculiar to the late stages of 
pregnancy.
The first method, the antiserum to whole pregnancy 
serum, has proved very successful in identifying pregnancy 
associated proteins in humans. In a review of placental 
proteins Klopper (1980) states that "we owe our awareness 
of the existence of these proteins" to the first method.
The pioneering work of Gall and Halbert (1972) in 
identifying four pregnancy associated plasma proteins in 
humans, relied upon raising an antiserum to whole pregnancy 
plasma (36 weeks gestation) and adsorbing it with normal 
human plasma (120 mg lyophilized plasma/ml antiserum) . The 
hyperimmune antisera were raised in rabbits by three weekly 
injections of pregnancy plasma emulsified in an equal 
volume of Freund's complete adjuvant. Using this method 
at least two of the antigens were readily detectable by
/
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by immunoelectrophoresis and were visible prior to staining. 
However the fact that only two of the antigens were readily 
visible, the other two required very potent antisera and 
longer staining, is perhaps indicative that concentration 
differences had to be considered. In subsequent 
publications (Lin et al, 1974a and 1974b) their antisera to 
pregnancy plasma were fully adsorbed then the immunoglobulins 
precipitated using 50% (NH1J 2SO4. The immunoglobulins 
were then re-suspended in as small a volume as possible 
and this preparation consistently revealed three antigens 
on immunoelectrophoresis and four on crossed immunoelectro­
phoresis. In fact, these pregnancy proteins were still 
detectable by immunoelectrophoresis even after the 
pregnancy plasma was diluted 8 fold. An identical 
procedure was used by Lin et al (1974c) to investigate 
pregnancy proteins in rats and mice and successfully 
identified four such proteins.
Antisera to pregnant mare serum were raised in three 
rabbits and a pooled antiserum was totally adsorbed with 
normal equine serum. Precipitation of the immunoglobulins 
and subsequent immunological investigation failed to reveal 
any proteins unique to the pregnant mare serum. The 
reactivity of the immunoglobulins after precipitation was 
preserved as indicated by the fact that a precipitin line, 
common to pregnant mare and stallion sera,was observed on 
Ouchterlony double diffusion. it is possible that
this protein was albumin although it was not specifically 
identified as such.
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Therefore this straightforward technique failed to 
reveal antigens peculiar to pregnancy in the later stages 
of gestation in the mare. As the technique has been 
successfully applied to identify pregnancy specific proteins 
in humans and other mammalian species, it was surprising 
that it failed to identify any pregnancy specific proteins 
in late pregnant mare serum. Indeed the technique has 
been used to identify pregnancy proteins in the mare during 
early pregnancy. An antiserum to day 55 pregnant mare 
serum, adsorbed with 100% stallion serum, revealed two 
proteins unique to pregnancy. One was eCG, the other was 
a new protein, MPP 1 (Gidley-Baird et al, 1983).
A possible explanation of the failure of the antiserum 
to whole PMS to reveal proteins unique to late pregnancy is 
that the antisera obtained did not contain antibodies to 
pregnancy proteins because these proteins were present in 
the late PMS at low concentrations. The response to these 
proteins could be masked by the much higher concentrations 
of other serum proteins. The subsequent methods employed 
attempted to reduce such masking by fractionating the late 
PMS prior to antisera production.
The method of fractionating the PMS by gel filtration 
and the two injection protocols have successfully been 
applied to identifying pregnancy proteins in humans 
(W.H. Stimson, personal communication). The combination 
of fractionation and concentration should have been 
sufficient to amplify the levels of all serum proteins to
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to such an extent that they would elicit a response from the 
rabbit immune system. Also the variation in the route of 
administration of the immunogen should have increased the 
likelihood of obtaining a suitable antiserum. The poly 
specific nature of the antisera obtained is evident from 
the immunoelectrophoretic gels. However when the antisera 
were fully adsorbed with normal equine serum no antigens 
unique to the late PMS were identified. Even the enriched 
immunoglobulins preparations from the antisera failed to 
reveal any antigens unique to the late pregnant mare serum.
Use of gel filtration prior to antiserum production 
has been successfully used in identifying and investigating 
murine pregnancy proteins (Hau, 1982). The method 
consisted of pooled pregnant mice sera fractionated by gel 
filtration and the three peaks collected, concentrated and 
injected into rabbits (Hau et al, 19,78). Two pregnancy 
associated murine proteins were initially identified by 
this technique (Hau et al, 1978) but further analysis has 
identified four murine pregnancy associated proteins (Hau, 
1982). The antisera obtained to the gel filtration 
fractions required adsorption with a 10-30% volume of a 
pool of male mice sera to identify two of the proteins 
(Hau et al, 1978). No immunoglobulin concentrates were 
required.
The use of gel filtration and an injection protocol 
similar to protocol A was used by Waites and Bell (1984) 
to identify two murine pregnancy proteins, one of which
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which was shown to be a female specific acute-phase 
reactant. The production of the antisera to murine 
pregnancy proteins by the gel filtration technique has 
made the mouse a reasonable candidate for a model for 
the study of pregnancy proteins in humans (Hau, 1982).
Failure to identify pregnancy proteins in different 
fractions of late PMS confirms the findings of the 
antiserum to whole PMS.
One final immunological method was employed to produce 
antisera against pregnant mare serum. An affinity column 
was prepared to remove all the normal serum proteins from 
PMS and allow any unique to pregnancy to pass straight 
through. The column consisted of antibodies to stallion 
serum proteins immobilised on Sepharose 4B. In a sample 
of PMS applied to the column the normal serum components 
would bind while any peculiar to the PMS would elute in a 
first peak. This strategy was applied by Sutcliffe (1976) 
and the subtractive or negative approach was termed 
negative antibody affinity chromatography (NAAC). Using 
immunoglobins from a sheep antisera against adult male 
human serum coupled to Sepharose 4B umbilical cord serum 
and second trimester fetal serum were applied to the 
column. Antisera were raised against the first peaks and 
from the cord serum three proteins were identified, AFP and 
two pregnancy associated proteins. Three proteins were 
identified in the fetal serum and a minimum of six in 
amniotic fluid. All antisera contained antibodies to
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to normal serum proteins but these were removed by 
adsorption with normal serum. The usefulness of the 
technique is perhaps indicated by the number of antigens 
identified in amniotic fluid since previous work had failed 
to show such a wide range of antigens (Sutcliffe, 1975, 
Sutcliffe and Brock, 1973). The technique was used to 
investigate further the proteins in human amniotic fluid 
(Sutcliffe et al, 1978).
This method was applied to pregnant mares using a 
poly specific antiserum to stallion serum raised in goats 
from which 25 g of IgG was isolated. All of these 
immunoglobulins were coupled to the activated sepharose 
giving the affinity column a high capacity for normal serum 
proteins. SDS PAGE of the first peak demonstrated that it 
contained only normal serum antigens, the major of which 
was albumin. The antiserum to the first peak cross 
reacted with several proteins in PMS and stallion serum but 
this cross reactivity was removed by adsorption of the 
antiserum with normal serum. Therefore it can be concluded 
that all the proteins eluting in the first peak are normal 
serum components and their elution is probably due to 
saturation of the binding sites on the column. These 
proteins are probably at high concentrations in the serum. 
Attempts to reduce contamination by albumin using an albumin 
affinity column failed since, when the dealbuminised sample 
was applied to the column, the first peak was undetectable. 
Re-chromatography of first peak material also failed to 
resolve a first peak. This is further evidence that the
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the proteins eluting in the first peak are common to pregnant 
mare and stallion sera.
This technique has several advantages over standard 
protein separation techniques in that the average degree of 
purification of minor proteins is proportional to the number 
of fractions obtained and each fraction has to be analysed 
by raising a corresponding antiserum (Sutcliffe, 1976).
The technique has been successfully used to remove adult 
contaminants from partially purified rabbit AFP (Pikho et 
al, 1971) and in the purification of crude tissue extracts.
(De Carvalho et al, 1964, and Anderson et al, 1974).
However the process does have some disadvantages, namely 
non-specific interactions between the column matrix and 
proteins and the fact that different proteins may share 
common antigenic determinants. This might have meant that 
unique proteins in the PMS could have been removed as the 
concentration of normal serum proteins was reduced to non­
competitive levels. The 5 ml sample of PMS applied to 
the column was a small volume compared with the column, . It 
could have been possible that these non-specific interactions 
were removing proteins unique to the PMS. This problem was 
overcome by Sutcliffe (1976) and Sutcliffe et al (1978) by 
passing a large volume of material through the column until 
only a small percentage of the starting material was 
eluting. In this method a small volume was chosen (5 ml) 
which gave a reasonably sized first peak indicating that 
the column was saturated for normal serum antigens and that 
non-specific interactions would be minimised. Thus although
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although the first peak contained normal serum protein 
contaminants it would hopefully be enriched with those 
proteins unique to PMS. Evidence that this was indeed the 
case is given in the experiment performed with eCG positive 
serum. At day 55 eCG may be regarded, in concentration 
terms, as a minor serum component. The fact that eCG 
eluted in the first peak indicates that non-specific 
interactions are minimal and it would be reasonable to 
assume that any pregnancy proteins in late PMS would behave 
likewise. Indeed it is possible that this technique could 
be used to purify eCG and MPP 1. The failure of this 
method to detect proteins specific to late pregnancy in 
the mare corroborates the immunological evidence obtained 
in the previous experiments.
On the basis of the evidence obtained from the 
immunochemical analyses described, there appears to be a 
major difference between the components of late pregnant 
mare serum and late pregnancy serum from humans, other 
primates and rodents. In the latter case, proteins 
specific to pregnancy are readily demonstrable by methods 
which have failed to yield results in mares. There are 
two possible explanations as to why these immunological 
methods have failed in the mare. It is possible that the 
proteins are present in the maternal circulation but are 
either at a low concentration or are poor immunogens in 
the rabbit. Therefore despite their presence in the 
maternal circulation during pregnancy, they are not 
recognised by the rabbit immune system and no antibodies
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antibodies are produced against them.
The alternative and perhaps more likely explanation is 
that there are no pregnancy specific proteins in late 
pregnant mare serum. The principal source of pregnancy 
proteins in most species during late gestation is the 
placenta. Therefore this lack of pregnancy proteins in 
the mare may result from inter-species differences in 
placentation. Possibly the equine placenta does not have 
any specific proteins or alternatively pregnancy proteins 
could be present within the placenta but are not secreted 
into the maternal circulation. Equine placenta was 
therefore investigated immunologically to identify any 
placental specific pregnancy proteins.
CHAPTER 3
ANTISERA TO PLACENTAL EXTRACT
3.1 Introduction
Pregnancy proteins in humans can be divided into two
types
(1) proteins which are specific to pregnancy, and
(2) proteins which are not specific to pregnancy 
but nevertheless have strong associations 
with it.
Proteins in the latter group are synthesized by the mother 
but increase in response to pregnancy. It is now generally 
assumed that the principal source of proteins peculiar to 
pregnancy in humans is the syncytiotrophoblast of the 
placenta (Klopper, 1980, and Chard, 1982b) which is the layer 
of placental tissue in contact with the maternal circulation. 
This assumption is mainly supported by immunohistochemical 
studies, but further evidence comes from the fact that these 
proteins are present in placental extracts in higher 
concentrations than could be accounted for by their content 
in the maternal serum. For instance, Lin et al (1976b) 
were able to demonstrate that the placental content of hPL, 
PAPP A and B and SPX was too high to be derived from the 
maternal circulation. In contrast, the levels of
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of pregnancy zone protein, which is most probably of 
maternal liver origin (von Schoultz and Stigbrand, 1982) , 
in the placental extract, could have been due to PZP in 
the maternal serum.
Owing to the levels of the pregnancy proteins in the 
placenta, this tissue has been used as a source of antisera 
to human pregnancy proteins. Four different proteins were 
originally identified in the sera of pregnant women using 
antisera to protein fractions from placentae (Bohn, 1971). 
Antisera obtained from rabbits, immunised with protein 
fractions from human placenta and adsorbed with normal 
adult serum, revealed four antigens on Ouchterlony double 
diffusion gels. One of the proteins was hPL and the 
others were designated SPx SP2 and SP3. Further studies 
revealed that SPX was a placental protein specific to 
pregnancy, whereas SP2 and SP3. were pregnancy associated, 
and not of placental origin, SP2 being sex hormone binding 
globulin and SP3 being pregnancy zone protein (Bohn, 1976). 
Since 1971 further work by Bohn has revealed a large number 
of placental proteins using antisera to placental extracts 
(Bohn, 1979 and Bohn et al, 1982).
Pregnancy proteins have also been identified in the 
placentae of various monkey species using antisera to 
protein fractions of placental extracts (Behrman et al, 1974).
In the sheep, day 14-19 embryo homogenates have been 
used to raise antisera to pregnancy associated antigens
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antigens (Cerini et al, 1976, Stapes et al, 1978) which 
could be detected in plasma. Similar work in the cow 
identified two pregnancy specific proteins using an 
antiserum to placental membranes from day 20-45 embryos.
There antigens were localized in the trophoblast and 
placenta but not in plasma (Butler et al, 1982).
Experiments performed with antisera to early equine and 
porcine embryos also failed to reveal any antigens in 
plasma, although they succeeded in identifying trophoblast 
specific antigens (Findlay et al, 1979). In late 
pregnancy, ovine and bovine placentae have been used as a 
source of placental lactogens (Fellows et al, 1976) and 
once purified they have been used in developing homologous 
radioimmunoassays (Robertson et al, 1980, Bolander et al, 
1976) which have been used to monitor this protein 
throughout gestation in these species.
Hence in both humans and domestic animals, the 
embryonic membranes have been used as a source of antisera 
to proteins specific to pregnancy. However in domestic 
animals the emphasis has again been placed on the early 
stages of gestation. Therefore in this study antisera 
were raised to extracts of delivered equine placenta. It 
was hoped that the antisera would identify pregnancy 
specific substances in the placental extract and the 
antisera could be used to investigate whether such antigens 
were present in late pregnant mare serum. If pregnancy 
specific proteins were present in late pregnant mare serum 
then the placenta would be the most probable source and 
they would be present in this tissue at higher concentration
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concentration than in the maternal circulation. 
Investigations were therefore performed using antisera to 
whole placental extract and also with placental extract 
which had been fractionated by gel filtration and ammonium 
sulphate precipitation.
3.2 Materials and Methods
3.2.1 Materials
The placentae were obtained from the following mares, 
one pony, one thoroughbred (2) and one Clydesdale, 
as soon after delivery as possible. Pools were 
prepared from pregnant mares (4) and stallions (2) 
sera. Liver and kidney were obtained fresh from a 
slaughtered colt.
Materials for immunological methods and gel filtration 
were identical to those given in Chapter 2.
All other reagents were of analar grade where possible.
3.2.2 Methods
The equine placentae, obtained after delivery, were 
extensively washed with 0.9% saline to remove blood. 
Small sections of placental tissue (approx. 1 cm2) 
were frozen and thawed several times prior to mixing 
with an equal volume of phosphate buffered saline and 
homogenised using a Sorvall blender.
i ■ •
^ - / Equal volumes from each extract were pooled and
' further
further homogenisation was performed using a ground 
glass homogeniser. Particulate material was removed 
by centrifugation at; 15,000g an(^  the supernatant retained and 
stored at -20°C until required. Samples of equine 
liver and kidney were treated likewise.
Gel filtration of placental extract was performed on 
the same column as described for equine serum 
(Section 2.2.3) 5 ml aliquots of placental extract
were passed through the column. The flow rate and 
eluting buffer were as described previously. The 
fraction size collected was 6.0 ml. Three pooled 
fractions were obtained and these were concentrated 
and stored at ~20°C until required.
Ammonium sulphate precipitation was performed at 4°C 
on 100 ml of placental extract as follows.
Saturated ammonium sulphate was added to a concentration 
of 50% and the solution allowed to stand for 30 minutes. 
The precipitate was obtained by centrifugation and 
washed with 50% (NH^) 2S0jj before being suspended in as 
small a volume of phosphate buffered saline as possible. 
The remaining supernatant was dialysed against two 
changes of phosphate buffered saline over a 24 hour 
period and concentrated by dialysis against high 
molecular weight polyethylene glycol. The solution 
obtained from the 50% (NH4) 2SO4. precipitate was also 
dialysed for 24 hours against PBS. Both solutions, 
termed ppt 50 and spt 50, were stored at -20°C until
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until required.
Antisera to the whole placental extract were raised in 
three rabbits. The rabbits were given an initial 
subcutaneous injection at four sites on the back of a 
1:1 emulsion of Freund*s complete adjuvant and whole 
placental extract. A total volume of 1 ml was 
administered. The injections of whole placental 
extract were repeated at monthly intervals for six 
months but emulsified with Freund's incomplete 
adjuvant. Blood was obtained 10 days after the final 
injection and serum separated and stored at -20°C.
These three rabbits were then used to raise antisera 
to the pooled gel filtration fractions. Each of the 
rabbits received an initial injection of fractions 1,
2 or 3 emulsified with Freund's complete adjuvant.
The injections were given subcutaneously with a total 
volume of 1 ml injected per rabbit. This was 
repeated with Freund's incomplete adjuvant twice, at 
monthly intervals, before the antisera were obtained 
10 days after the final injection.
Two new rabbits were injected with the 50% (NHif)2S0t 
supernatant and precipitate. The initial injection 
of 1 ml of a 1:1 emulsion with Freund's complete 
adjuvant wasfollowed by three injections at monthly interval 
given in Freund's incomplete adjuvant. Serum was 
obtained 10 days after the final injection and stored 
at -20°C until required. These rabbits were then
/
77.
Table 3.1
Protein concentration (mg/ml) injected for production of 
antisera to placental extracts.
Antigen Protein Cone, (mg/ml)
Whole placental extract 6
1st peak gel filtration 2
2nd peak gel filtration 2
3rd peak gel filtration , 2
(NHiJaSOi* precipitate 8
(NHi*) 2SOi* supernatant 16
then given a final injection of 1 ml whole placental 
extract in Freund's complete adjuvant, the antisera 
being obtained 10 days after injection.
Ouchterlony double diffusion,immunoelectrophoresis 
and crossed immunoelectrophoresis were performed as 
described in the general methods section (Section 2.2) 
as were SDS polyacrylamide gel electrophoresis and 
protein estimation.
Adsorption of all antisera was performed using stallion 
serum and liver and kidney homogenates at various 
concentrations until no cross reactivity was detected 
between the antisera and stallion serum or the tissue 
extract. The adsorbed antisera were then used to 
examine the whole or fractionated placental extract 
using Ouchterlony double diffusion, immunoelectrophoresis 
and crossed immunoelectrophoresis.
Immunoblotting was performed by Dr. J.G. Lindsay at 
the Department of Biochemistry, University of Glasgow.
The antiserum used was a pool obtained from the rabbits 
injected with the 50% (NHiJaSOt* ppt and spt after they 
received the final injection of whole placental extract. 
The method used for immunoblotting is given in the 
Appendix.
The protein conc. (mg/ml) for each placental extract 
preparation injected is given in table 3.1
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FIGURE 3.1
CROSSED IMMUNOELECTROPHORESIS USING ANTI-WHOLE PLACENTAL 
EXTRACT
1. 10 yl of stallion serum.
2. 10 yl of whole placental extract.
500 yl of rabbit anti-whole equine placental 
extract was used as the antiserum in the 
second dimension.
Crossed immunoelectrophoresis was performed on 1% (w/v) 
agarose in 20 mM sodium barbitone and 4.3 mM diethyl 
barbituric acid, pH 8.6 , as described in Section 2.2.2.
In immunoelectrophoresis the whole placental extract did 
not run very well. This was probably due to residual 
particulate material in the extract.
Fig. J.I urossea immunoeiecLrupnurebib usxny nnux 
Whole Placental Extract.
FIGURE 3.2
GEL FILTRATION OF EQUINE PLACENTAL EXTRACT
Gel filtration of the placental extract was performed at 
4°C on a sephacryl S300 column, 95 cm x 2.8 cm diameter. 
The eluting buffer and flow rate were as described in 
Section 2.2.4. 6.0 ml fractions were collected. A
5 ml aliquot of whole placental extract with 10% glycerol 
was applied per run. The three peaks which were obtained 
and pooled for antiserum production are indicated by the 
dotted lines on the graph. Proteins peaks were detected 
by their absorbance at 2 80 nm.
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FIGURE 3.3
OUCHTERLONY DOUBLE DIFFUSION USING ANTI-WHOLE PLACENTAL 
EXTRACT against gel filtration fractions of whole 
placental extract.
1, 4. 10 yl of pregnant mare serum.
2,5. 10 yl of stallion serum.
3, 6. 10 yl of third peak from gel filtration
c of whole placental extract.
Antiserum in well:- A 10 yl rabbit anti-whole placental
extract.
B 10 yl rabbit anti-whole placental 
extract adsorbed with 10% stallion 
serum.
C 10 yl rabbit anti-whole placental 
extract adsorbed with 10% stallion 
serum and 10% liver and kidney 
extract.
Ouchterlony double diffusion was performed on 1% (w/v)
agarose in 0.9% (w/v) saline as described in Section 2.2.2.
Fig. 3.3 Ouchterlony Double Diffusion using Anti 
Whole Placental Extract.
The antiserum was obtained as described on p.77. For 
results see p.79 and for discussion see p.82-83.
3.3 Results
The antiserum to whole placental extract, cross 
reacted with the placental extract on Ouchterlony double 
diffusion and crossed immunoelectrophoresis. It also 
cross reacted with pregnant mare and stallion serum. The 
reactions on Ouchterlony double diffusion between the 
placental extract, PMS and stallion serum, were of identity 
and the patterns obtained, with the placental extract and 
pregnant mare and stallion sera on crossed immunoelectro­
phoresis, were similar (Fig. 3.1). However all cross 
reactivity between the antiserum and placental extract was 
removed by 10% stallion serum. This percentage stallion 
serum also removed all cross reactivity from pregnant mare 
and stallion sera.
Fractionation of the placental extract by gel 
filtration gives three distinct peaks (Fig. 3.2).
Molecular weights were calculated using the calibration 
curve for the column (Fig. 2.3). The peaks corresponded to 
molecular weights 730,000, 80,000 and 18,000. Peaks 1 and 
2 were colourless, whereas peak 3 was a deep red colour.
The peaks were analysed, using the antiserum to whole 
placental extract, by Ouchterlony double diffusion and 
immunoelectrophoresis against pregnant mare and stallion 
sera. Peak 3 contained an antigen which appeared unique 
to the placental extract since the precipitin line remained 
even after the antiserum was adsorbed with stallion serum 
and liver and kidney extract (Fig. 3.3).
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FIGURE 3.4
OUCHTERLONY DOUBLE DIFFUSION USING ANTISERA TO FRACTIONATED 
PLACENTAL EXTRACT (GEL FILTRATION) to identify specific 
antigens in the peaks obtained by gel filtration of whole 
placental extract.
A 1,3. 10 yl third peak from gel filtration of
whole placental extract.
2. 10 yl equine myoglobin (50 yg/ml)
4. 10 yl equine haemoglobin (50 yg/ml)
Antiserum in well A was 10 yl of rabbit antiserum to third 
peak by gel filtration of placental extract.
B a, c. 10 yl of second peak from gel filtration
of whole placental extract, 
b, d. 10 yl of equine albumin (50 yg/ml)
Antiserum in well B was 10 yl of rabbit antiserum to
second peak from gel filtration of placental extract.
Ouchterlony double diffusion was performed on 1% (w/v)
agarose in 0.9% (w/v) saline as described in Section 2.2.2.
Fig. 3.4 Ouchterlony Double Diffusion using Antisera 
to Fractionated Placental Extract (Gel 
Filtration).
For results see p.80.
FIGURE 3.5
IMMUNOELECTROPHORESIS OF PLACENTAL EXTRACT FRACTIONS FROM 
GEL FILTRATION against the antisera to the placental 
extract gel filtration fractions.
1. 10 yl of first peak gel filtration of
whole placental extract.
2. 10 yl of second peak gel filtration of
whole placental extract.
3. 10 yl of third peak gel filtration of
whole placental extract.
4. 10 yl of stallion serum.
From right to left the antiserum in the trough is as 
follows
200 yl of rabbit anti first peak placental 
extract fractionated by gel filtration.
200 yl of rabbit anti second peak placental 
extract fractionated by gel filtration.
200 yl of rabbit anti third peak placental 
extract fractionated by gel filtration.
Immunoelectrophoresis was performed at 12v/cm on 1% (w/v) 
agarose in 20 mM sodium barbitone and 4.3 mM diethyl 
barbituric acid, pH 8.6, as described in Section 2.2.2.
+Fig. 3.5 Immunoelectrophoresis of Placental Extract 
Fractions from Gel Filtration.
For antisera production see p.77, for results see pp.80-81 
and for discussion see pp.83-84.
FIGURE 3.6
OUCHTERLONY DOUBLE DIFFUSION USING THE ANTISERUM TO THE 
THIRD PEAK FROM THE GEL FILTRATION OF WHOLE PLACENTAL 
EXTRACT
1, 4. 10 yl of pregnant mare serum.
2, 5. 10 yl of stallion serum.
3, 6. 10 yl of placental extract.
Antiserum A 10 yl of rabbit antiserum to the third
peak from the gel filtration of whole 
placental extract.
B 10 yl of rabbit antiserum to the third
peak from the gel filtration of whole 
placental extract adsorbed with 10% 
stallion serum.
C 10 yl of rabbit antiserum to the third
peak from the gel filtration of whole 
placental extract adsorbed with 15% 
stallion serum and 10% liver and kidney 
extract.
Ouchterlony double diffusion was performed using 1% (w/v) 
agarose in 0.9% (w/v) saline as described in Section 2.2.2.
Fig. 3.6 Ouchterlony Double Diffusion using the
Antiserum to the Third Peak from the Gel 
Filtration of Whole Placental Extract.
The results are given on p.80 and discussed on pp.83-84.
With the antisera raised against peak 3 from gel 
filtration, it was apparent that the red colour, in this 
peak, was due to haemoglobin. On Ouchterlony double 
diffusion a reaction of identity was obtained between peak 
3 and equine haemoglobin, using the antisera to peak 3.
Also, using the antiserum to peak 2, the presence of 
albumin was demonstrated in peak 2 as a line of identity 
was obtained between peak 2 and equine albumin on 
Ouchterlony double diffusion (Fig. 3.4).
On Ouchterlony double diffusion and immunoelectro­
phoresis, precipitates were obtained between the antisera 
to the gel filtration fractions 1-3 and the placental 
extract, pregnant mare and stallion sera (Fig. 3.5). All 
cross reactivity, between the pregnant mare and stallion 
sera, was removed by adsorbing the antisera with 10% 
stallion serum. However on Ouchterlony double diffusion, 
three precipitin lines were detected between the placental 
extract and the antiserum to the third fraction (Fig. 3.6). 
One of these lines gave a reaction of identity with equine 
haemoglobin as described above and was removed when the 
antiserum was adsorbed with liver and kidney extract.
The other two precipitin lines remained. Neither antigen 
was demonstrable on immunoelectrophoresis.
A precipitin line was also detected between the 
placental extract and the antiserum to the first peak 
which remained after adsorption with 10% stallion serum. 
However this precipitin line was removed when the antiserum
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FIGURE 3.7
IMMUNOELECTROPHORESIS USING ANTISERA TO THE spt AND ppt 
FROM THE TREATMENT OF PLACENTAL EXTRACT WITH 50% (NH^SOt*
1. 10 yl of stallion serum.
2 . 10 yl of placental extract.
Antiserum A 200 yl of rabbit anti-spt from the
treatment of placental extract with 
50% (NHif) 2S0i*.
B 200 yl of rabbit anti-ppt from the
treatment of placental extract with 
50% (NHif)2S0if.
Immunoelectrophoresis was performed at 12v/cm using 1% (w/v) 
agarose in 20 mM sodium barbitone and 4.3 mM diethyl 
barbituric acid, pH 8.6, as described in Section 2.2.2.
Fig. 3. Immunoelectrophoresis using Antisera to the 
spt. and ppt. from the Treatment of Placental 
Extract with 50% (NH^^SOi*.
The antisera were prepared as described on pp.7 7-78. 
The results are given on p.81 and discussed on p.84.
FIGURE 3.8
DIAGRAMMATIC REPRESENTATION OF OUCHTERLONY DOUBLE DIFFUSION 
GEL showing the two bands obtained between the antiserum 
to the 50% (NHit)2SOif supernatant and the placental extract.
1, 4. 10 yl of pregnant mare serum.
2, 5. 10 yl of stallion serum.
3, 6. 10 yl of placental extract.
The antiserum in the centre well was 10 yl of rabbit
anti-supernatant from the 50% (NHit)2S0if treatment of 
placental extract adsorbed with 15% stallion serum and 
10% liver and kidney extract.
Ouchterlony double diffusion was performed on 1% (w/v) 
agarose in 0.9% (w/v) saline as described in Section 2.2.2.
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Fig. 3.8 Diagrammatic Representation of Ouchterlony 
Double Diffusion.
The antiserum was prepared and adsorbed as described on 
pp.77-78. The results are given on p.81 and discussed 
on p.84
FIGURE 3.9
IMMUNOELECTROPHORESIS. USING ANTISERUM TO THE spt FROM 
50% (NH4)2SOlt TREATMENT OF WHOLE PLACENTAL EXTRACT.
1. 10 yl of placental extract.
2 . 10 yl of stallion serum.
The antiserum in the trough was 200 yl of rabbit antiserum 
to the supernatant obtained after the addition of 50% 
(NHi+JaSOi* to the placental extract adsorbed with 15% 
stallion serum and 10% liver and kidney extract. 
Immunoelectrophoresis was performed at 12v/cm in 1% (w/v) 
agarose in 20 mM sodium barbitone and 4.3 mM diethyl
barbituric acid, pH 8.6 , as described in Section 2.2.2.
Fig. 3.9 Immunoelectrophoresis using Antiserum to 
the spt. from 50% (NHit)2S0i+ Treatment of 
. Whole Placental Extract.
antiserum was adsorbed with liver and kidney extract.
No precipitin lines were detected between the antiserum 
to the second peak adsorbed with 10% stallion serum and 
the placental extract.
The antisera to the placental extract fractionated 
by (NH4)2SO4 cross reacted on Ouchterlony double diffusion 
and immunoelectrophoresis. The antisera to the 50%
(NHit) 2S0 i* precipitate and supernatant also cross reacted 
with pregnant mare and stallion sera (Fig. 3.7). The 
majority of the cross reactivity with the sera was obtained 
with the antiserum to the 50% (NHiJ 2S0i* supernatant. When 
the antisera were adsorbed with 10% stallion serum, there 
was no cross reactivity detectable with pregnant mare and 
stallion sera. When the adsorbed antisera were tested 
against the placental extract, three lines were detected 
between the antiserum to the 50% supernatant on 
Ouchterlony double diffusion. No lines were detected with 
the antiserum to the 50% (NHit)2SOtf precipitate and the 
placental extract. When the antiserum to the 50% (NHtJ 2S0t* 
supernatant was adsorbed with 10% liver and kidney extract, 
two lines remained detectable with the placental extract 
on Ouchterlony double diffusion (Fig. 3.8). One of these 
antigens was also detected using immunoelectrophoresis 
(Fig. 3.9).
SDS polyacrylamide gel electrophoresis revealed a 
large number of protein bands in the whole placental 
extract and the placental extract fractions from gel
/
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FIGURE 3.10
POLYACRYLAMIDE GEL ELECTROPHORESIS OF WHOLE AND FRACTIONATED 
PLACENTAL EXTRACTS AND LIVER AND KIDNEY EXTRACTS
Track No. 1. standards (see below).
2. whole placental extract
3. liver extract.
4. kidney extract.
5. placental extract, gel filtration peak 1.
6 . placental extract, gel filtration peak 2.
7. placental extract, gel filtration peak 3.
8. placental extract, 50% (NH,,) zSO^ ppt.
9. placental extract, 50% (NHJ 2S0„ spt.
Molecular weight standards (Pharmacia)
yg/ml Subunit M
1. phosphorylase B 64 94,000
2 . bovine serum albumin 83 67,000
3. ovalbumin 147 43,000
4. carbonic anhydrase 83 30,000
5. soybean trypsin inhibitor 80 20,100
6. a - lactalbumin 121 14,400
The polyacrylamide gel electrophoresis was performed in 
a 15% acrylamide gel under denaturing conditions as 
described in Section 2.2.2. 10 yl of a 2 mg/ml solution
of the extracts was added to the gels. 7.5 yl of the 
standards solution was added.
FIGURE 3.11
AN IMMUNOBLOT OF THE GEL SHOWN IN FIGURE 3.10
The tracks are identical to those given in Figure 3.10.
The antiserum was to whole placental extract adsorbed 
with 15% stallion serum and 10% liver and kidney extract.
Immunoblotting was performed as given in the Appendix.
Fig. 3.10 and 3.11 PAGE and Immunoblot of Whole and 
Fractionated Placental Extracts and 
Liver and Kidney Extracts.
For results see pp.81-82 and for discussion see pp.84-85
1 2 3 4 5 6  7 8 9
gel filtration and (NHlt)2SOi* precipitation. The patterns 
of protein bands obtained showed similarities with those of 
liver and kidney extract. However, owing to the large 
number of bands present in all samples, direct comparison 
in order to identify bands unique to the placental extract 
was not possible (Fig. 3.10).
When an identical gel was subjected to immunoblotting 
using an antiserum to whole placental extract and adsorbed 
with 15% stallion serum and 10% liver and kidney extract, 
two protein bands were specifically identified in the 
placental extract (Fig. 3.11). No bands were identified 
in either the liver or kidney extracts. Further, the 
bands were also demonstrable in the third fraction of the 
gel filtered placental extract and in the 50% (NH^)2S04 
supernatant. The bands were not detectable in the first 
n but were faintly visible in the second fraction from the geljfiltered
r-~- - i■ - ' "
cental extract.. Faint bands were observed in the 50% (NH^) 2S01* 
precipitate. The molecular weights of the two proteins,
as calculated from the distances moved by the molecular 
weight standards were within the range 22,000 - 25,000
3.4 Discussion
The immunological investigation into the proteins of 
the term equine placenta has successfully identified two 
proteins which appear to be specific to this tissue.
Initially an antiserum to the whole placental extract 
failed to reveal any proteins unique to the placenta.
/
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placenta. However from the cross reactivity with pregnant 
mare and stallion sera, it is probable that the majority of 
proteins in the crude extract stimulating a response in the 
rabbit were serum proteins. The tissue proteins present 
at lower concentrations would require longer to elicit a 
response.
Consequently the same rabbits were used to raise 
antisera to the three fractions obtained by gel filtration 
of the extract. It was assumed that these rabbits would 
be more responsive to the minor proteins present in the 
fractions. Using Ouchterlony double diffusion serum 
albumin was identified in the second peak and haemoglobin 
in the third. From the molecular weight of the third 
fraction, 18,000, the haemoglobin was assumed to be in 
subunit form. The contamination by haemoglobin is due 
to the fact that delivered rather than surgically removed 
placentae were used. However during the course of the 
study there were no placentae from Caeserian sectioned 
mares available. Excessive washing of the placentae 
prior to homogenisation did however substantially reduce 
contamination by haemoglobin subunits.
Adsorbing the antisera to the gel filtration 
fractions with 10% stallion serum revealed four antigens 
in the placental extract. Apart from haemoglobin the 
other three were not of serum origin, one antigen in the 
first peak and two in the third. Adsorption with a 
crude liver and kidney extract (10%) removed the
/
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the antibodies to the antigen from the first peak antiserum 
and the antibodies to the haemoglobin from the third peak 
antiserum. The line in the first peak was therefore 
assumed to be a tissue antigen common to adult tissues 
such as liver and kidney. The second peak revealed no 
precipitin lines after adsorption with 10% stallion serum. 
However the protein content of this fraction was low 
compared with the other two fractions and it is possible 
that tissue proteins present were at a too low 
concentration to stimulate the rabbit immune system. It 
is possible that if a more extended protocol of injections 
was used then antibodies would have been produced to some 
of the minor proteins present in this peak.
The placental extract was fractionated into a 
precipitate and supernatant using 50% (NH4)2S04. The 
supernatant contained the haemoglobin. Antisera were 
raised to the two fractions. Adsorption of the antiserum 
to the supernatant with 10% stallion serum and 10% liver 
and kidney extract again revealed two unique lines in the 
placental extract. Similar treatment of the antiserum 
to the precipitate revealed no unique placental precipitin 
lines. It was assumed that the lines identified in the 
supernatant were identical to those identified in the 
third peak of gel filtration and this was confirmed by 
immunoblotting. This method specifically identified the 
same antigens in the whole placental extract, the third 
fraction from gel filtration and the 50% (NHjJ 2SO4 
supernatant. The SDS PAGE gel of all samples of
/
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of placental extract revealed numerous staining bands, 
many of which corresponded to bands in the liver and 
kidney extracts. However when an antiserum to whole 
placental extract adsorbed with 15% stallion serum and 
10% liver and kidney extract was used in immunoblotting 
two antigens were identified which were only present in 
the placental extract. Therefore two equine placental 
specific antigens have been identified in the term 
placental extract. These antigens have been designated 
equine placental antigens 1 and 2 (EPA 1 & 2). Neither 
antigen was detected in late pregnant mare serum.
In humans pregnancy proteins have been identified 
using antisera to protein fractions from placental tissue 
extract. Using the antisera to the placental protein 
fractions Bohn (1971) identified hPL, SP1, SHBG and PZP 
in the maternal serum. Further investigations revealed 
another protein, PP5, specific to pregnancy.
The methods used with equine placenta are similar to 
those used in humans and have revealed two new proteins 
specific to the placental tissue. The proteins were not 
identified in late pregnant mare serum. There has been 
no previous investigation into the proteins of term equine 
placenta. However work performed using early equine 
embryos (Findlay et al, 1979) identified trophoblast 
specific antigens and it is possible that these antigens 
may be similar to those identified in this study and are 
produced throughout pregnancy. However, to confirm this
/
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this it would be necessary to investigate the placental 
tissues throughout gestation using the antiserum.
At partuition in the mare the three fetal layers 
separate leaving the uterine layers intact. Therefore 
the extract was derived from these fetal layers. However 
it would be impossible to speculate on the precise source 
of these antigens since they may be transferred between 
layers of the placenta. Indeed the antigens may be of 
fetal origin since contamination of the extract by fetal 
circulation was possible. Using immunohistochemical 
methods it would be possible to identify the proteins' 
location within the placenta.
Only liver and kidney tissue extracts were used to 
adsorb the antisera and it is possible that the antigens 
are present in other equine tissues such as those of the 
uterus or ovary. They may also be present in the 
endometrial cups which are of fetal origin (Allen, 1980).
The low molecular weights of the antigens is of 
interest. The molecular weights under denaturing 
condition from SDS gel electrophoresis (22,000 - 25,000) is 
in agreement with the approximate weight by gel filtration 
in non-denaturing conditions and it is probable that the 
antigens are single polypeptide chains rather than subunits 
of a larger protein. Since the placentae were obtained 
after delivery, it is possible that the low molecular 
weights are due to the degradation of a larger molecule.
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molecule. Apart from placental lactogen (Mol. Wt. 21,000) 
the EPA 1 & 2 are not comparable in size with the other 
main human pregnancy proteins which have much higher 
molecular weights (see Table 1, Chapter 1). However, on 
the basis of molecular weight, several comparisons with 
minor human pregnancy proteins are possible, notably 
placenta specific ai and ct2 microglobulins. These 
proteins have molecular weights 20,000 and 25,000 and are 
precipitated by 30-50% and 25-60% saturated (NH^)2S04 
respectively. Both proteins are produced by the 
trophoblast in largest amounts in the first trimester,
PAMG 1 being secreted predominantly into amniotic fluid. 
PAMG 2 has been identified by immunofluorescence, on 
premenstrual endometrium, menstral blood and sperm. The 
function of these proteins is unknown (Tatarinov, 1982). 
Another human placental protein with which comparison may 
be made on the basis of molecular weight is the human 
chorionic thyrotropin. This protein has a molecular 
weight of 28,000 and displays similarities with human 
thyroid stimulating hormone (Ashitaka and Tojo, 1982).
This investigation has successfully identified two 
antigens specific to the term equine placenta. However 
further investigations would be necessary before any 
definite conclusions can be made about these proteins.
The methods used in this study to successfully identify 
unique pregnancy specific equine placental proteins were 
similar to the methods which failed to identify pregnancy 
specific proteins in late pregnant mare serum. This
/
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This therefore provides evidence that the failure in the 
latter case is not due to the methods used.
88.
CHAPTER 4
TWO DIMENSIONAL ELECTROPHORESIS
4.1 Introduction
On the basis of the immunological evidence described 
in Chapter 2, there appears to be a major difference in the 
serum proteins of late pregnant mares and those of other 
species which have been investigated. Methods, successful 
in these other species, have been unable to identify 
pregnancy proteins in late PMS. There are two possible 
explanations for this. Either equine pregnancy proteins 
are weak immunogens in the rabbit or pregnancy proteins 
are absent from late pregnant mare serum. The more 
appropriate of these two hypotheses could be confirmed if 
the pregnancy proteins could be identified using a 
non-immunological technique. In the analysis of protein 
mixtures the highest resolution possible is obtained with 
two dimensional electrophoresis (O'Farrell, 19 75) and 
therefore this method was chosen to examine serum from 
mares throughout pregnancy to identify any proteins which 
appear but which are not present in non-pregnant mares.
The method optimizes protein separation by combining 
techniques which depend on independent parameters, 
isoelectric point and molecular weight. The proteins are 
separated under dissociating conditions in the first 
dimension by isoelectric-focusing with 9 M urea/2% Nonidet
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Nonidet P-40 followed by electrophoresis in the second 
dimension with sodium dodecyl sulphate (SDS). The 
potential resolution of the technique given by O'Farrell 
(19 75) is the product of the number of proteins resolved 
by each technique and has been estimated as 7,000 in the 
case of Escherichia coli components. A protein which 
constitutes 10 * - 10 5% of the total protein can be 
detected and quantified by autoradiography.
The process has been adapted to a clinical procedure 
capable of resolving individual gene products in biological 
fluids and cell homogenates from different tissues which 
can be used to detect the appearance of novel proteins 
associated with pathological conditions in humans 
(Anderson and Anderson, 1978a and 1978b). This method 
allows genetic screening and identification of significant 
increases in the mutation rate due to environmental or 
other factors to be performed.
The technique has been used to separate the proteins 
of human plasma and serum (Anderson and Anderson, 19 77, 
Thorsrud et al, 19 80) into several hundred gene products.
In the study of Thorsrud et 31/(19 80), the two dimensional 
gels allowed identification of the pathological 
immunoglobulin in patients suffering from multiple myelomas, 
various lymphoproliferative disorders and polyclonal 
hypergammaglobulinemia.
Although this technique has not been applied to human
/
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polyacrylamide gel would provide sufficient resolution to 
identify pregnancy specific proteins in humans and in 
horses if they are present. To assist in this a high 
sensitivity silver stain was used on the gels (Morrisey, 
1981). This technique has sensitivities of 0.42 ng/mm2 
for BSA, 0.083 ng/mm2 for ovalbumin and 0.17 ng/mm2 for 
cytochrome C. This sensitivity would allow the staining 
of minor serum components on the gel. With the 
combination of high resolution and sensitive staining it 
was hoped to distinguish between the two explanations of 
the results from the investigation of late pregnant mare 
serum.
4.2 Materials and Methods
4.2.1 Materials
The equipment for the two dimensional gels was 
obtained from Dr. D.I. Stott, Department of Immunology, 
Western Infirmary, Glasgow. The micro-dialyser was 
obtained from BRL Limited, Cambridge, U.K. Serum 
was obtained, with the assistance of Dr. D.H. Snow, 
Equine Research Station, Newmarket, U.K., from one 
thoroughbred and two pony mares at approximately every 
fifty days of gestation. Serum samples were also 
obtained from stallions and non-pregnant mares. All 
chemicals were of analar grade where possible.
/
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4.2.2 Sample Preparation
Prior to electrophoresis samples were treated to remove 
serum albumin, reduced and alkylated. To 0.5 ml of 
serum, 0.5 ml of saturated (NH^) was added slowly
with constant agitation and allowed to stand at 4°C 
for 30 minutes. The precipitate was obtained by 
centrifugation for 2 minutes at 10,000g, washed with 
1 ml of 50% saturated (NH4) 2S0 I* and respun. The 
pellet was then dissolved in 0.9 ml of 0.25 M Tris/HCl, 
pH 8.0 containing 8 M deionised urea and 0.01 M EDTA 
(UTE buffer) and 0.1 ml of UTE buffer containing 0.5 M 
dithiothreitol. This was incubated for 30 minutes at 
37°C after which time 90 yl of 1 M iodoacetamide in 
UTE buffer was added and incubated for a further 30 
minutes at room temperature. The solution was then 
dialysed, using a microdialyser, against 10 mM Tris/ 
HC1, pH 8, containing 9 M deionised urea. The 
supernatant from the (NH1+)2SOt precipitation was 
analysed by SDS PAGE as described in Chapter 2,
Section 2.2.2.
4.2.3 Two Dimensional Electrophoresis
The solutions used for the two dimensions, isoelectric 
focusing and SDS polyacrylamide gel electrophoresis, 
are given in the Appendix.
The first dimension consisted of isoelectric focusing 
in tube gels. Tubes were 130 mm x 2.5 mm internal
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internal diameter. Before use tubes were cleaned in 
chromic acid, washed thoroughly in tap water, rinsed 
three times with distilled water, dried, siliconised 
with "Repelcote" and washed as before. One end of 
the tube was sealed with several layers of parafilm.
10 ml of gel solution was prepared by dissolving
5.4 g of urea in 1.14 ml of acrylamide stock,
2 ml of 10% (w/v) Nonidet P40, 2.2 ml of H20, 0.5 ml 
Ampholine pH 3-10 and 0.1 ml of 0.1 M lysine. Once 
the urea was dissolved the solution was degassed and
2.5 yl of TEMED and 0.1 ml of solution D (riboflavin) 
added. Tubes were filled to the 10 cm mark with the 
above preparation by means of a tube attached to a 
syringe. The gels were overlayed with overlay 
Solution A and left to polymerise for 2 hours under
a fluorescent lamp.
To prepare a gel containing molecular weight standards 
1 ml was removed from the 10 ml of gel solution.
100 yg of BSA, ovalbumin, a chymotrypsinogen and 
myoglobin were added and the gel poured into the tube 
and allowed to polymerise under a fluorescent lamp. 
Once polymerised the gel was extruded and frozen 
using a solid C02/methanol mixture (approx. ratio 
1 vol:5 vols) and stored at -70°C until required.
A 5 mm length of the gel was removed and applied to 
the centre of the second dimension gel between the 
two IEF gels.
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Once polymerised the overlay solution and parafilm 
were removed and the tube gels placed in the 
electrophoresis tank. The anode chamber was filled 
with 1 litre of 0.01 M HaPOi*. Samples, 40-50 yl, were 
loaded in 50 yl of sample loading solution. Two 
blank gels were loaded with 50 yl of sample loading 
solution. The solution in all tubes was then 
overlayed with overlay Solution B and the tubes 
finally filled to the top by overlaying with the 
catholyte, 0.02 M NaOH, 1 litre of which was added to 
the cathode chamber. Electrophoresis was performed 
at lOOv for 15 minutes, 200v for 15 minutes, 300v for 
30 minutes and 400v overnight. The total number of 
volt hours per run was 7,200.
The gels were then extruded into 5 ml of equilibration 
buffer by means of a 10 ml syringe connected to the 
gel tube by plastic tubing. The gels were 
equilibrated in this solution for 2 hours, the solution 
being changed once. After this, gels were either used 
for the second dimension or frozen in a solid C02/ 
methanol mixture (1 vol:5 vols) and stored at -70°C 
until required. The blank gels were not equilibrated 
but cut into 5 mm lengths and placed, along with 0.1 ml 
degassed 0.01 M KC1 in an autoanalyser cup and left to 
equilibrate for 2 hours at room temperature. The pH 
of each section was then read using a flat membrane 
electrode.
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The second dimension was vertical SDS polyacrylamide 
gel electrophoresis. Gels were cast between two 
glass plates separated by a 1.6 mm spacer. One glass 
plate had a notch cut in it to accommodate the first 
dimensional gels. Plates measured 255 mm x 260 mm 
and two first dimension gels were applied per run.
The resolving gel was prepared by mixing 12.5 ml 
Solution A, 30 ml of Solution B, 50 ml of Solution E 
and 7.25 ml of H 20. This mixture was degassed and 
0.25 ml of 10% ammonium persulphate added. This 
solution was poured between the plates to 200 mm above 
the bottom spacer, overlayed with H 20 and left to 
polymerise.
During polymerisation the stacking gel solution was 
prepared by mixing 3.8 ml of Solution B, 4 ml of 
Solution C, 16 ml of Solution E and 4.2 ml of H20.
The mixture was degassed and 4 ml of Solution D added. 
The water was removed from the surface of the 
polymerised resolving gel and the surface rinsed with 
2 x 1 ml of stacking gel solution. Stacking gel 
solution was poured to the base of the notch and two 
first dimension gels, anodes towards the centre, were 
added. The stacking gel solution was then poured to 
the top of the plates and left for 30 minutes to 
polymerise under a fluorescent lamp.
Once the stacking gei had polymerised, the gel was 
inserted into the electrophoresis tank, which contained
/
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anode and cathode chambers, with the spacer removed 
from the base. Contact at the cathode was via a 
filter paper wick. Electrophoresis was performed 
at 20 mA for 16-18 hours until the bromophenol blue 
dye front reached the end of the gel. The gel was 
removed from between the glass plates and prepared 
for silver staining.
4.2.4 Silver Staining
Gels were prepared for silver staining by prefixing 
in 50% methanol, 10% acetic acid for 30 minutes 
followed by 5% methanol, 7% acetic acid for 30 minutes. 
Gels were then fixed for 30 minutes in 10% 
glutaraldehyde and then soaked overnight in a large 
volume of deionised H 20. After rinsing in deionised 
H 20 the gel was soaked in 5 yg/ml dithiothreitol for 
30 minutes. This solution was then poured off and, 
without rinsing, a 0 .1% (w/v) solution of silver 
nitrate was added and the gel soaked in this for 30 
minutes. The gels were handled at all times wearing 
gloves and both of the above solutions were filtered 
to remove dust. Staining was performed in a plastic 
container and, during soaking in the above solutions, 
the gels were gently agitated.
While the gels were agitated in the silver nitrate 
solution, the developer was prepared, consisting of
/
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FIGURES 4.1a AND 4.1b
pH GRADIENT IN FIRST DIMENSIONAL ISOELECTRIC FOCUSING GELS
4.1a gels A and B are blank gels taken from 
the same I.E.F. run.
4.1b gels A and C are blank gels taken from 
different I.E.F. runs.
The pH gradient was obtained by dividing the blank gel 
into 5 mm sections and equilibrating each section in
0.01 M KC1 for 2 hours at room temperature. The pH was 
measured using a flat membrane electrode.
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of 3% sodium carbonate containing 50 yl of 37% 
formaldehyde per 100 ml of developer. Before 
. developing gels were washed once with a small volume 
of distilled water and twice with small volumes of 
developer. Developer was then added and the gel 
continuously agitated until the desired level of 
staining was attained. The reaction was stopped by 
adding 5 ml of 2.3 M citric acid per 100 ml developer 
and the gel agitated for 10 minutes. After this gels 
were washed in distilled water and photographed.
4.3 Results
The 50% (NHjJ 2SO4 supernatants were tested on SDS 
polyacrylamide gel electrophoresis and were found to 
contain principally albumin. Several minor protein bands 
were visible but these were common to pregnant and non­
pregnant mare and stallion sera.
For each isolectric focusing run two blank gels were 
run to obtain the pH gradient. The gradients were used 
as a means of comparing the gels in one run with each 
other and with those from different runs. It was found 
that all gels conformed to a similar pattern whether they 
were from the same run (Fig. 4.1a) or from different runs 
(Fig. 4.1b). A linear gradient was obtained over the 
range pH 8 to pH 5, there being little variation between 
gels in this region. However some variation was found 
between gels in the anode and cathode regions. Despite
/
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FIGURE 4.2
SECOND DIMENSION POLYACRYLAMIDE GEL ELECTROPHORESIS: 
MOLECULAR WEIGHT CALIBRATION CURVE
The standards were:-
1. bovine serum albumin
2. ovalbumin
3. a chymotrypsinogen
4. equine myoglobin
The standards, 100 yg of each, were prepared in a 1 ml 
first dimensional gel as described in Section 4.2.3.
A 5 mm section of this gel was applied per second 
dimension run and the value given in the graph, distance 
moved from cathode, represents the mean from four runs in 
which the dye front moved 180 mm in the resolving gel.
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Despite this variation it was concluded that since the 
greater proportion of the gels was consistent then valid 
comparisons could be made between gels from the same or 
different runs. In the second dimension since the current 
and running time were constant then there would be little 
variation between gels in the distance moved by proteins 
and this was found to be the case.
Owing to the thinness of the gels and the agitation 
during silver staining, many of the gels were damaged by 
tearing (Figs. 4.5, 4.7 and 4.8). Also on some of the 
gels intensely staining irregular black spots are present. 
These are assumed to be due to dust contamination arising 
during the staining procedure. During silver staining 
it was found that the standards were overstained by the 
time that the proteins in the samples showed sufficient 
staining (Fig. 4.7). In the final gels the standards 
appeared as a dark line down the centre of the gel.
The distances moved by the standards was measured during 
staining and were used to construct a standard curve 
(Fig. 4.2).
For the purpose of analysis the proteins in the silver 
stained gels were referred to by their isoelectric point 
and approximate molecular weight. The isoelectric point 
was calculated by the distance moved from the IEF cathode 
and interpolating this distance on Fig. 4.1. For the 
molecular weight the distance moved from the top of the 
gel (SDS cathode) was measured and this was interpolated on
/
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FIGURE 4.3
A TWO DIMENSIONAL GEL OF PREGNANT MARE SERUM
40 yl of serum from a pony mare in the first 50 days of 
gestation was applied to the first dimensional gel and 
isoelectric focusing and polyacrylamide gel electrophores 
performed under denaturing conditions as'described in 
Section 4.2.3.
The gel was silver stained as described in Section 4.2.4.
The scale on the x-axis represents the pH gradient of the 
first dimension gel as given in Figure 4.1.
The scale on the y-axis represents the molecular weight 
as calculated from the standard curve (Figure 4.2).
The grided areas on the plate are the groups of spots 
(A1-A3, 331, and C1-C4) which were unique to early 
pregnancy (see Table 4.1).
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Fig. 4.3 Two Dimensional Gel of P.M.S. in First 50 Days 
of Gestation.
For results see pp.99-101 and for discussion see
pp.102-106.
FIGURE 4.4
TWO DIMENSIONAL GEL OF PREGNANT MARE SERUM
40 y1 of serum from a pony mare in the first 50 days of 
pregnancy applied to the first dimensional gel and 
isoelectric focusing and polyacrylamide gel electrophoresis 
performed under denaturing conditions as described in 
Section 4.2.3.
The gel was silver stained as described in Section 4.2.4.
Note the presence of the spots in the regions A, B and 
C (see Figure 4.3).
Fig. 4.4 Two Dimensional Gel of P.M.S. in First 50 Days 
of Gestation.
For results see pp.99-101 and for discussion see 
pp.102-105.
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FIGURE 4.5
TWO DIMENSIONAL GEL OF STALLION SERUM
40 yl of stallion serum subjected to isoelectric focusing 
and polyacrylamide gel electrophoresis under denaturing 
conditions as described in Section 4.2.3.
Silver staining was performed as described in Section 4.2.
On comparison with 2 D electrophoresis gels of human 
serum, it is probable that the spots SI, S2 and S3 are 
albumin, transferrin and IgG light chains respectively.
Note the large number of basic proteins in the grided 
region and the protein e, f, g and h within this region 
which were not observed in any sample from mares.
Fig. 4.5 Two Dimensional Gel of Stallion Serum. 
The results are given on pp.99-101 and discussed on
pp.102-106.
FIGURE 4.6
TWO DIMENSIONAL GEL OF PREGNANT MARE SERUM
40 yi of serum from a pony mare in the last 50 days of 
gestation was applied. The two dimensional 
electrophoresis was performed under denaturing conditions 
as described in Section 4.2.3.
The gel was silver stained as described in Section 4.2.4.
The spots observed in early pregnancy in regions A, B 
and C are absent from this gel.
Fig. 4.6 Two Dimensional Gel of P.M.S. in the Last 
50 Days of Gestation.
For results see pp.99-101 and for discussion see
pp.102-106.
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For further information see results pp.9 9-100 and 
discussion p.103.
TABLE 4.1 UNIQUE SPOTS ON PMS TWO DIMENSIONAL GEL
Protein Pi
Molecular
Weight
Appearance in 
Pregnancy
A1 4 50,000
First 2 
months onlyA2 4 47,000
A3 4 43,000
B1 5 24,000
c
First 6 
months
Cl 6.5 43,000
Concentration 
higher in 
early 
pregnancy
C2 6.2 43,000
C3 6.2 34,000
C4 6.2 30,000
Fig. 4.6.a
Two Dimensional Gels from the Thoroughbred Mare at 
Various Stages of Pregnancy
The section of the gels shown is the area which contained 
the proteins in Groups A, B and C, as marked on the 
photographs. 40 yl of pregnant mare serum obtained at ' 
days 20, 60, 100, 140, 180, 220, 260 and 300 post 
fertilisation were applied per gel. Two dimensional 
gel electrophoresis and silver staining were performed 
as described in Section 4.2. This information was used 
to obtain the value for "Appearance in pregnancy" in 
Table 4.1.
on Fig. 4.2 to give the molecular weight. Fig. 4.3 has 
the isoelectric point and molecular weight scales marked 
out on it.
The gels from the pregnant mares were compared with 
those from the stallions and non-pregnant mares.
Examination revealed that the gels from pregnant mares 
contained spots which were absent from the non-pregnant 
and stallion gels. In Figs. 4.3 and 4.4, spots are present 
which cannot be detected on the stallion gel (Fig. 4.5).
In Fig. 4.3, three groups of spots have been marked out 
A, B and C. Group A contains three spots Al, A2 and A3, 
Group B contains one spot Bl, and Group C contains four 
spots Cl, C2, C3 and C4. The corresponding isoelectric 
points and molecular weights for these spots are:
Al Pi 4 50,000 Cl Pi 6.5 43,000
A2 Pi 4 47,000 C2 Pi 6.2 43,000
A3 Pi 4 43,000 C3 Pi 6.2 34,000
Bl Pi 5 24,000 C4 Pi 6.2 30,000
(Table 4.1)
Figures 4.3 and 4.4 are from pony mares in the first 50 days 
of gestation. In subsequent gels from these mares, even at 
100 days gestation, the spots were undetectable. They were 
also undetectable in the gels from late pregnancy (Fig. 4.6). 
The gel from the thoroughbred mare in the first month of 
pregnancy revealed spots corresponding to A3, Bl, Cl and 
C2. It is possible that two of the other spots, C3 and
/
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FIGURE 4.7
TWO DIMENSIONAL GEL OF PREGNANT MARE SERUM
50 yl of serum from a thoroughbred mare 20 days after 
fertilisation was applied. Isoelectric focusing and 
polyacrylamide gel electrophoresis were performed under 
denaturing conditions as described in Section 4.2.3.
Silver staining was carried out as described in Section 
4.2.4.
Spots corresponding to A 3/ Bi, Ci and C2 are present.
The spot labelled TS on this gel was observed only in 
this thoroughbred mare.
pH
Fig. 4.7 Two Dimensional Gel of P.M.S. in the First 
50 Days of Gestation.
The results are given on pp.99-101 and discussed on
pp.102-106.
FIGURE 4.8
TWO DIMENSIONAL GEL OF NON-PREGNANT MARE SERUM
40 yl of non-pregnant mare serum was subjected to two 
dimensional gel electrophoresis under denaturing 
conditions as described in Section 4.2.3 and the gel 
silver stained as described in Section 4.2.4.
Fig. 4.8 Two Dimensional Gel of Non-Pregnant Mare 
Serum.
The results are given on pp.99-101 and discussed on
pp.102-106.
Mol. W
t. (x10,000)
and C4, are present but are not visible due to overstaining 
of an adjacent spot (Fig. 4.7). All these spots were 
present in a similar intensity in the gel of the sample 
taken from the second month of pregnancy. By the third 
month the spot in Group A had disappeared and the spots in 
Group C were only faintly visible. These proteins 
remained faintly visible until term in the thoroughbred 
mare but not in the pony mares. The protein in Group B 
was present until the sixth month of gestation, the spot 
becoming progressively fainter.
Comparison of the gels from late pregnancy (Fig. 4.6) 
with those from early pregnancy (Figs. 4.3, 4.4 and 4.7) 
and those from non-pregnant mares and stallions (Figs.
4.5 and 4.8) indicated that at this stage there were no 
unique spots.
Several other interesting points can be observed on 
the gels. On the thoroughbred mare a distinct spot was 
observed on all gels throughout pregnancy with a pi 5.2 
and a molecular weight of 79,000. This spot was not 
observed in any other of the serum samples from pregnant 
or non-pregnant pony mares or stallions (Figs.4.3, 4.4,
4.5, 4.6 and 4.8). Also in the gel of stallion serum 
(Fig. 4.5) a total of 14 proteins can be observed in the 
basic region of the gel between pH 8.5 and pH 9.0 and in 
the molecular weight range 180,900D to 45,OOOD. In any 
sample from a pregnant or non-pregnant mare, the maximum 
number of proteins recorded in this region was 6. In
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In the non-pregnant mare only 4 of these proteins can be 
observed (Fig. 4.8). Of particular interest are the four 
basic proteins, all of pi 9 and molecular weights 180, 900, 
88,000, 6 4,000 and 60/000 which were not observed in any 
samples from mares.
4.4 Discussion
The results show that this high resolution two 
dimensional system separating proteins on the basis of 
charge and molecular weight is capable of identifying 
unique substances in pregnant mare serum. However the 
unique proteins identified are restricted to the early 
stages of pregnancy in particular the first two months.
The silver stain with its high sensitivity makes 
visualization of these proteins possible. However in the 
case of serum it has one major drawback. Serum represents 
a heterogeneous mixture of proteins which show a wide range 
of concentrations. There may even be variations in the 
amount of a particular protein present in the serum between 
individuals. Therefore it is inevitable that on silver 
staining proteins in higher concentrations will appear 
sooner and stain quicker than those at lower concentrations. 
By the time some of the lower concentration proteins begin 
to stain the higher concentration proteins will be 
overstained and may obscure information from the gel. On 
silver staining it was necessary to obtain a balance which 
allowed for optimum staining of minor components but did 
not lead to excessive overstaining of higher concentration
/
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concentration proteins. The point chosen to stop the 
staining reaction was when the bands present in the region 
of pi 5.3 and mol. wt. of 45,000 began to merge due to 
overstaining. Some of the information was obtained as 
a result of observing the gels during the staining process. 
Since the photographs represent arbitrary points in the 
staining process ("the desired level of staining",
Morrisey, 19 81) then care must be taken in interpreting 
the results in view of the fact that the concentrations 
of proteins may vary considerably between individuals. 
Therefore results were only taken to be valid if they were 
observed in several individuals. Also the spots had to 
be stained in sufficient intensity in the individuals that 
their presence was not due to a concentration effect.
Weakly staining spots observed in single individuals were 
discarded.
On average the process was capable of resolving 
80-100 spots from a 40-50 yl sample of serum. Several of 
the spots were comparable with those present in humans 
(Thorsrud et al, 19 80). Fig. 4.5 has these proteins 
marked on it with Sj most probably being albumin, S 2 
transferrin and S 3 IgG light chains. Apart from these 
proteins there appears to be little similarity between 
the equine and human gels.
From the gels two types of unique proteins could be 
identified: (1) those proteins which were pregnancy
specific, and (2) those which appear to be specific to the
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the sex or breed of horses. Within the first group eight 
proteins were identified which were absent from non-pregnant 
and stallion sera. However these proteins were associated 
with the early stages of pregnancy. Further subdivision 
could be made based on the length of time that the proteins 
were present. Thus, although all proteins in all three 
groups A, B and C, stained strongly in the first two months 
of pregnancy, the three proteins in the first group Al, A2 
and A3 had disappeared by the third month and the one 
protein in the second group, Bl, had disappeared by the 
sixth month. The proteins in the third group stained 
strongly in the first two months of gestation and 
thereafter stained but only very weakly until term. It 
is probable that the proteins in Group C are normal serum 
components raised in concentration in early pregnancy but 
returning to normal levels after the third month. The 
failure to detect them in normal equine sera could be due 
to poor staining in this region of the gel and a lower 
concentration than in late pregnancy. However the other 
proteins Al, A2, A3 and Bl are early pregnancy specific 
since they can only be detected in early pregnancy serum 
and stain strongly in these gels.
The reduction and alkylation treatment of samples 
prior to electrophoresis would effectively dissociate 
subunits held together by disulphide bonds. The DTT would 
reduce these disulphide bridges and the alkylating reagent, 
iodoacetamide, would prevent them reforming. The 
dissociating conditions of the electrophoresis would also
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also reduce non-covalently bonded subunits to single 
polypeptide chains. Therefore each spot or band on the 
silver stained gels represents a single polypeptide chain.
It cannot be deduced from the gel whether these single 
polypeptide chains represent individual proteins or 
subunit chains of a larger protein.
The four polypeptide chains Al, A2, A3 and Bl are the 
earliest recorded proteins to be detected during pregnancy 
in the mare being present in the thoroughbred mare by day 
20 after fertilisation. Previous reports indicate that 
the earliest pregnancy proteins recorded in the mare are 
MPP1 by day 30 (Gidley-Baird et al, 19 83) and eCG by day 
40 (Allen, 1969). Although the pregnancy specific spots 
Al, A2, A3 and Bl cannot be identified some speculation is 
possible. Of particular interest for comparison in the 
mare are MPP1 and the early pregnancy factor. The low 
pi of eCG (pi 1.8) means that it would not focus within 
the gradient of the gels used and was lost. The molecular 
weight and isoelectric point of MPPl is unknown but this 
protein has been detected by day 30 and it is probable that 
one or several of the spots represents MPPl or its subunits. 
The early pregnancy factor has not been recorded in the 
horse but during pregnancy in sheep it exists in multiple 
forms notably a 250 K form, a 50 K form and a 20 K form 
(Clarke et al, 19 80). It is possible that two of the 
spots Al (M. Wt. 50 K) and Bl (25 K) represent forms of 
the early pregnancy factor in the mare. In early 
pregnancy in the sheep the 250 K and 20 K form only are
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are present but the 50 K form can be obtained by removal 
of a carrier component from the 250 K form (Clarke et al,
19 80). The 50 K form then predominates in mid pregnancy 
whereas in this study protein Al had disappeared by the 
third month of gestation.
Therefore although no specific comparisons can be 
made novel proteins have been detected within 20 days of 
fertilisation and have disappeared from the serum by the 
sixth month of gestation. It would be of great interest 
to fractionate early pregnancy serum from the mare to 
obtain sufficient protein for characterisation.
The other class of proteins identified in this study 
relate to the sex and breed of the horse. Thus in the 
stallion a large number of basic proteins were present,
14 in total. The maximum recorded in the mares was 6 but 
with longer staining times these proteins may have appeared. 
However the fact that they readily stain in the stallion 
indicates that if they are present in the mare then it is at 
a much lower concentration. Before any definite 
conclusions can be drawn that these spots represent sex 
specific proteins, a far larger sample of mares and 
stallions would have to be examined. The same applies 
to the single spot recorded exclusively in the 
thoroughbred mare.
From this investigation it can be concluded that 
pregnancy proteins are present.in the mare in the early
/
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early stages of pregnancy. These proteins were detected 
in high levels in early pregnancy and either disappeared 
with the advancement of pregnancy or, in the case of the 
thoroughbred mare, decreased to very low levels by term. 
Four proteins were identified in the former case (Groups 
A and B) differing in the time of their disappearance from 
pregnancy serum and four proteins were identified in the 
latter. This therefore supports the hypothesis that 
pregnancy proteins, similar to those identified in other 
species, are absent from late pregnant mare serum.
CHAPTER 5
ALKALINE PHOSPHATASE AND SEX HORMONE 
BINDING GLOBULIN
5.1 Introduction
During pregnancy in humans the circulating levels of 
a number of normal serum proteins increase significantly 
in response to the pregnant state. Some of these can be 
measured in assays depending on their biological activities 
and two of these, alkaline phosphatase and sex hormone 
binding globulin, were investigated in the pregnant mare.
Levels of alkaline phosphatase show a measurable 
increase in the third trimester of human pregnancy of 
approximately 100% (Young et al, 19 46). This increase 
in circulating alkaline phosphatase activity is due to 
the presence of a placental isoenzyme which is 
distinguishable from other serum isoenzymes by its 
remarkable thermostability (Fishman et al, 1972).
Originally assays for this placental specific enzyme relied 
upon this heat stability but recently a highly sensitive 
radioimmunoassay has been used to measure levels throughout 
pregnancy (Holmgren et al, 1978) . Levels are .low during 
the first trimester with a significant increase occurring 
around mid-pregnancy. Levels reach a peak of mean value 
252 - 70 ng/ml by the fortieth week of pregnancy, a 
twenty-five fold increase on first trimester values
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During pregnancy the placental isoenzyme is 
synthesized by the syncytiotrophoblast after the twelfth 
week and is secreted into the maternal circulation 
(Stigbrand et al, 1982). The levels of placental 
alkaline phosphatase coincide with the growth of the 
placental microvilli with peak levels occurring when 
microvilli growth ceases (Fishman et al, 19 72). Levels 
have also been correlated with the increased synthesis of 
oestrogens (Fishman et al, 1968). However the normal 
range of placental alkaline phosphatase is considered to 
be too large to be of any clinical significance in 
identifying pregnancy disorders (Sigbrand et al, 19 82). 
Little is known of the physiological function of this 
isoenzyme during normal pregnancy (Holmgren et al, 1978).
A previous study reported a 30% increase in alkaline 
phosphatase activity during pregnancy in the mare (Earle 
and Cabell, 1952), however only three samples were taken 
at random. Although the heat stability of the human 
placental alkaline phosphatase appears to be unique to 
man and closely related subhuman primates (Doellgast and 
Benirschke, 19 79) evidence suggests that placental 
alkaline phosphatases are present in most mammalian species 
(Goldstein and Harris, 19 79). Alkaline phosphatase was 
measured throughout pregnancy in the mare both for total 
activity and for a heat stable form.
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Sex hormone binding globulin is a pregnancy associated 
protein, synthesized by the maternal liver, the 
concentration of which rises during pregnancy in humans 
(Anderson, 1974). Levels rise steeply in the first 
trimester and gradually thereafter to reach a maximum by 
term. There is a rapid return to non-pregnancy levels 
after partuition. The increase in SHBG levels has been 
estimated from 50-70 nM in the non-pregnant female to 
300-400 nM in the pregnant one (Pearlman et al, 1967).
The production of SHBG is controlled by the steroids it 
binds with oestrogens stimulating its production in the 
liver (Anderson, 19 74). It is assumed that the rise 
during pregnancy is associated with the increase in 
unconjugated oestradiol seen in pregnancy (Svendson and 
Sorensen, 1964). However there is no change in 
circulating levels of SHBG during the menstral cycle 
despite the steroid hormone changes which take place.
This indicates that the changes in pregnancy are probably 
due to large increases in endogenous steroid production 
associated with advancing pregnancy and partuition 
(Pearlman et al, 1967).
SHBG has been identified in the rabbit (Mahoudeau and 
Corval, 19 73) and similar proteins probably exist in most 
primates (McCormack, 19 71, and Anderson, 19 74) but no 
investigation has been reported in the horse. Therefore, 
using a method which had successfully identified and 
measured SHBG in humans (Rosner, 1972), the serum of pregnant 
mares was investigated for a SHBG analogue.
/
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Also investigated was the possibility of cross 
reactivity between antisera to human pregnancy proteins 
and late pregnant mare serum using antisera to human 
pregnancy proteins. In previous reports cross reactivity 
between antisera to most human pregnancy proteins and 
pregnancy sera from other species has been limited to the 
closely related subhuman primates (Lin and Halbert, 19 78). 
However in the case of pregnancy zone protein a higher 
degree of inter-species cross reactivity has been recorded. 
Hence with an antiserum to human PZP von Schoultz et al 
(19 76) were able to demonstrate a PZP analogue in pregnant 
beagle dogs and Rhesus monkeys. Anti-dog PZP cross 
reacted strongly with pregnant cow and sheep sera.
Further work with an anti-swine PZP revealed this protein 
in the serum of pregnant horses (Martinsson and Carlstrom, 
19 77). Thus apart from PZP no previous work had tested 
the cross reactivity between antisera to human pregnancy 
proteins and pregnant mare serum. In view of this 
pregnant mare serum was tested using antisera to human 
PAPP A, PZP and two recently discovered pregnancy proteins, 
ct2 and (3 i pregnancy associated macroglobulins.
5.2 Materials and Methods
5.2.1 Materials
Serum samples for both the alkaline phosphatase and 
sex hormone binding globulin assays were obtained 
from one thoroughbred mare every week of gestation 
and from two pony mares at various stages of
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of gestation. Samples were also obtained from six 
non-pregnant mares, two stallions, a colt and a 
gelding. Alkaline phosphatase activity was assayed 
using a BCL Alkaline Phosphatase Kit (No. 415 286 and 
No. 415 29 4), Boehringer Mannheim GmbH, Mannheim,
West Germany and a LKB reaction rate analyser (LKB, 
Bromma, Sweden).
Tritiated dihydrotestosterone was obtained from the 
Steroids Laboratory, Glasgow Royal Infirmary. The 
radioinert dihydrotestosterone was obtained from 
Sigma Chemical Company, Fancy Road, Poole, Dorset, 
England.
Antiserum to human PAPP A was obtained from Dr. R.G. 
Sutcliffe, Department of Genetics, University of 
Glasgow, and the antisera to PZP (a2 PAG), a2 and 
PAM were obtained from Professor W.H. Stimson,
Division of Immunology f University of Strathclyde, 
as was the thirty-sixth week human pregnancy plasma.
5.2.2 Alkaline Phosphatase Activity 
Alkaline phosphatase activity in mares was measured 
throughout pregnancy using a 1 M diethanolamine 
buffer, pH 9.8, with 0.5 mM MgCl2 at 37°C with 10 mM 
p-nitrophenol phosphate as substrate. The samples 
from the six non-pregnant mares were used to establish 
a normal range. Pregnant mare serum was also
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also assayed for heat stable isoenzymes which involved 
heating the sample at 56°C for 20 minutes in a water 
bath prior to measuring the activity. All activities 
were calculated in IU/i.
5.2.3 Sex Hormone Binding Globulin
The method used for the measurement of sex hormone 
binding globulin was that of Rosner (19 72). Initially 
the validity of the assay to distinguish between 
specific globulin binding and non-specific binding to
serum albumin was investigated using 15,000 cpm of
3H dihydrotestosterone added to either 0.1 ml of late 
PMS or a solution of 50 mg/ml equine albumin. After 
incubation for 15 minutes at room temperature and 15 
minutes at 0°C, 0.9 ml of ice cold ammonium sulphate 
at 10%, 20%, 30%, 40%, 50%, 60%, 70% and 80% 
saturation were added to the tubes with constant 
mixing. Within 2 minutes the precipitate was spun 
down by centrifugation at 0°C. From the supernatant 
0.5 ml was removed, mixed with 10 ml of scintillation 
cocktail and counted. The amount of radioactivity in 
the supernatant was then compared with the 
concentration of (NHlf)2S04.
All equine samples were tested at the following 
specific activities of the 3H DHT:- 8,500 cpm/ng,
5,700 cpm/ng and 1,200 cpm/ng. They were prepared 
by adding radioinert DHT to the radioactive DHT in
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in specific amounts to give the desired specific 
activity. Human pregnancy serum from the thirty- 
sixth week was assayed at a specific activity of 
1,200 cpm/ng to monitor the success of the assay.
A sample of equine seminal plasma was also assayed 
at this specific activity.
The assay was performed in duplicate for samples and 
in triplicate for the control. 1,500 cpm of 3H DHT 
in methanol were added per assay tube. 120 ng of 
radioinert DHT in methanol were added to the control 
tubes and the solvent evaporated at 40°C. Serum was 
diluted in an assay buffer, pH 7.0, which consisted 
of 0.05 M sodium phosphate and 0.15 M NaCl. For 
human pregnancy serum and equine seminal plasma the 
dilution was 1:20 whereas dilutions of 1:5, 1:10,
1:15 and 1:20 were tried for all equine samples.
0.5 ml of dilute serum was used per assay tube.
Samples were incubated at room temperature for 15 
minutes then transferred to an ice bath for a further 
15 minutes. 0.5 ml of ice cold saturated ammonium 
sulphate was added with constant vortexing to give 
50% saturation and the precipitate spun down in a 
refrigerated centrifuge. From the supernatant 0.5 ml 
was removed and mixed with 10 ml of scintillation 
cocktail and counted. The amount of radioactivity 
added per tube was taken as the mean of the three 
controls. The results were expressed as follows:-
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% DHT specifically bound = — ^—  x 100%
and also using the formula given by Rosner (19 72)
TeBG = A ~ B (D)
where TeBG = capacity of serum to bind DHT in 
Ug/100 ml, A = cpm per assay tube (from controls),
B = cpm in supernatant of assay tube, C is the 
specific activity (cpm/ng) and D is a constant 
allowing for the serum dilution and the change in 
units (4 in the case of a 1:20 dilution and 3 in the 
case of a 1:15 dilution).
5.2.4 Antisera to Human Pregnancy Proteins 
The antisera obtained to human pregnancy proteins 
were tested for cross reactivity with pregnant mare 
serum from mid and late gestation by Ouchterlony 
double diffusion (Section 2.2.1). Stallion serum and 
plasma from a thirty-sixth week pregnant woman were 
used as controls.
5.3 Results Alkaline Phosphatase
A similar pattern was observed in all three pregnant 
mares throughout gestation although there was some individual
/
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FIGURE 5.1
ALKALINE PHOSPHATASE ACTIVITY THROUGHOUT PREGNANCY IN 
THE MARE
Serum alkaline phosphatase activity as measured throughout 
pregnancy in one thoroughbred and one pony mare. Samples 
were obtained from the thoroughbred mare every month and 
from the pony mare approximately every 50 days.
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The results are given on pp.114-115 and discussed on
pp.116-118.
FIGURE 5.2
COMPARISON OF THE DHT BINDING PROPERTIES OF EQUINE SERUM
AND ALBUMIN
To 0.1 ml of late pregnant mare serum or a solution of 
50 mg/ml equine albumin 15,000 cpm of 3H DHT were added. 
After 30 minutes incubation, 0.9 ml of ice cold ammonium 
sulphate at 10% - 80% saturation were added and the cpm 
remaining in the supernatant obtained.
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The results are given on pp.115-116 and discussed on
pp.118-121.
individual variation. Fig. 5.1 gives the results 
obtained from the thoroughbred mare and one of the pony 
mares. About day 100 there was a 25% increase in serum 
activity, this higher level being sustained until 
approximately day 2 30. At this point levels declined to
their original value until partuition. Post-partum levels 
were very high increasing sharply by approximately 100%.
All samples except the post-partum ones were within the 
normal range obtained with six different non-pregnant 
mares, i.e. 200-500 IU/1. Heating pregnancy serum at 56°C 
for 20 minutes reduced the alkaline phosphatase activity to 
undetectable levels in the system used.
Sex Hormone Binding Globulin
The initial investigation into the validity of the 
assay in horses indicated that the agent responsible 
for binding the 3H DHT in serum was soluble in 50% 
(NHJ+)2S0if. The pattern obtained with serum was 
identical to that obtained with equine albumin 
(Fig. 5.2), the radioactivity being precipitated in 
both at 60-70% (NHtt)2S0if. This result was further 
verified by the behaviour of the different equine sera 
in the assay. With all samples of equine sera at 
each dilution and specific activity the radioactivity 
remained in the supernatant. The % DHT bound 
specifically to SHBG in all equine serum samples was 
0%. The value obtained for thirty-sixth week human 
pregnancy serum was 96% and equine seminal plasma
/
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FIGURE 5.3
ANTISERUM TO HUMAN PZP TESTED AGAINST EQUINE PREGNANCY
SERUM
1. 10 yl of third trimester pregnant mare serum.
2. 10 yl of 36th week human pregnancy plasma.
3. 10 yl of second trimester pregnant mare serum.
4. 10 yl stallion serum.
5. 10 yl of third trimester pregnant mare serum.
6. 10 yl of non-pregnant mare serum.
As 10 yl of anti human PZP Ouchterlony double diffusion 
was performed on 1% (w/v) agarose in 0.9% (w/v) saline 
as described in Section 2.2.2.
Fig. 5.3 Antiserum to Human PZP Tested A.gainst Equine 
Pregnancy Serum.
The results are given on p.116 and discussed on pp.121-122.
plasma specifically bound 82% of the DHT. Values of 
TeBG were 0 yg/100 ml in all equine samples, 4.68 yg/
100 ml in human pregnancy serum and 3.28 yg/100 ml in 
the case of equine seminal plasma.
Antisera to Human Pregnancy Proteins
The antisera to human PZP cross reacted strongly with 
thirty-sixth week pregnant human plasma. No cross 
reactivity was observed with either mid or late PMS 
or stallion serum (Fig. 5.3). A similar result was 
obtained with antisera to PAPP A and a 2 PAM although 
the cross reactivity with thirty-sixth week human 
pregnancy plasma was not as strong. No cross 
reactivity was observed between the anti 0 1 PAM and 
human pregnancy plasma or equine sera.
5.4 Discussion
The alkaline phosphatase which accounts for the increase 
in serum activity during pregnancy in humans is a heat 
stable placental isoenzyme synthesized by the
syncytiotrophoblast (Stigband et al, 19 82). This isoenzyme 
significantly increases the total serum activity by the third 
trimester, the increase being approximately 100% by term 
(Young et al, 19 46). The levels of the placental alkaline 
phosphatase correlate with the growth of the placenta 
(Fishman et al, 1968).
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In the mare the changes in alkaline phosphatase serum 
activity in pregnancy did not resemble the human pattern.
In particular a decrease in activity was observed during 
the third trimester when levels returned to normal and it 
can therefore be concluded that if the changes in serum 
alkaline phosphatase in mares are caused by an isoenzyme 
of placental origin it is not secreted into the maternal 
circulation in a manner which reflects placental growth.
The placental isoenzyme in humans appears to be a 
late evolutionary event in that it has only been identified 
in man, chimpanzee and orangutan (Doellgast and Benirschke, 
19 79), the placental form of alkaline phosphatase in other 
eutherian mammals such as cat, dog, guinea pig, cow, sheep 
and pig being similar in its thermolability and chemical 
inhibitors to the liver form (Goldstein and Harris, 1979).
It is possible that the gene locus for placental alkaline
(
phosphatase in Hominidae represents a late evolutionary 
event, the placental locus in other species being identical 
to that of the liver (Goldstein and Harris, 1979). No heat 
stable alkaline phosphatase was identified in pregnant mare 
serum and the horse could therefore be included in the 
group of species examined by Goldstein and Harris (1979) 
which had placental isoenzymes identical to the liver 
isoenzyme.
In the mare levels of serum alkaline phosphatase were 
found to be unrelated to placental growth but significant 
changes did occur. Previous work has reported a 30%
/
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30% increase in serum alkaline phosphatase activity during 
pregnancy and a further rise on lactation (Earle and Cabell, 
1952), however samples were not taken consistently 
throughout pregnancy. In this study samples from three 
pregnant mares throughout gestation revealed a consistent 
pattern of a 25% increase by day 100 followed by a plateau 
until day 2 30 at which point a fall was detected to early 
pregnancy levels. A substantial increase was recorded 
at the time of partuition coinciding with the onset of 
lactation. The pattern of serum activity during 
pregnancy in the mare resembles that of the conjugated 
and unconjugated oestrogens in the maternal circulation.
The principal oestrogens in the pregnant mare at this time 
are oestrone, equilin and equilenin. Oestrone levels 
rise dramatically during the fourth month of pregnancy, 
this level being maintained for a further four or five 
months (Cox, 1975). Further investigation would be 
necessary to confirm this relationship; however it is 
interesting that a relationship has been noted in pregnant 
humans between oestrogen synthesis and alkaline phosphatase 
activity (Fishman et al, 1968). Whether the variation in 
serum activity was from placental or liver origin is 
difficult to determine since in the horse these isoenzymes 
are assumed to be identical in their low heat stability.
The method employed by Rosner (19 72) to measure sex 
hormone binding globulin in humans relies upon the fact 
that the dihydrotestosterone binds strongly to SHBG but 
has a low affinity for corticosteroid binding globulins.
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globulins. Also the assay allows the DHT bound 
specifically to SHBG to be separated from any which may be 
bound non-specifically to serum albumin. In humans this 
was readily demonstrated by comparing the 3H DHT binding 
properties of a solution of albumin and pregnancy serum. 
Comparison was made of the radioactivity precipitated at 
a variety of (NHit)2SCU concentrations. All the 3H DHT in 
the serum was removed from solution at 50% saturated 
(NHit) aSOit, bound to SHBG, whereas in the albumin solution 
the radioactivity remained in the supernatant until 60-70% 
(NHi*) 2S0i*. In order to validate the assay in equids 
this procedure was applied to a solution of equine albumin 
and late pregnant mare serum. However both samples 
behaved identically in that all the 3H DHT remained in the 
supernatant until 60-70% (NHtf)2S0it . Therefore it was 
concluded that an analogue to human sex hormone binding 
globulin was absent from pregnant mare serum. That an 
analogue to SHBG was absent from all equine sera is 
demonstrated by the assay performed on the selection of 
equine sera. No variation was found in any of the samples 
from stallions, pregnant and non-pregnant mares, a gelding 
and a colt with all the 3H DHT remaining in the supernatant 
at 50% (NHit) 2S04.
During pregnancy in humans levels of SHBG increase 
markedly. Using this technique Rosner (1972) described 
an increase in levels from a mean of 1.85 yg/DHT bound/
100 ml of serum to a mean of 12.4 yg DHT bound/100 ml of 
serum by the thirty-sixth week of pregnancy. As an assay
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assay control a sample of thirty-sixth week human pregnancy 
serum . was included along with the equine samples. A 
value of 4.68 yg DHT bound/100 ml serum was recorded for 
this sample which is low in comparison with the mean given 
by Rosner (1972) but is nevertheless high when compared 
with the non-pregnant woman value.
An androgen binding globulin has been identified in 
the testis of rats and boars which is secreted into the 
tubular fluid and is transported into the epididymis 
(Sanborn et al, 1976). It is believed to perform a local 
role in maintaining high levels of testosterone in the 
epididymis (Hansson et al, 19 74). A similar protein 
probably exists in the stallion testis which would account 
for the levels of 3H DHT binding detected in the sample of 
equine seminal plasma.
In humans the increase in SHBG levels during pregnancy 
is associated with the increase in unconjugated oestrogens 
seen in pregnancy (Svendson and Sorensen, 1964) which 
stimulates the synthesis of this protein in the liver 
(Anderson, 19 74). In mares there is a marked increase in 
conjugated and unconjugated oestrogens at day 120 (Nett et 
al, 1975). Assays performed on samples from throughout 
pregnancy in mares did not detect any appearance of SHBG 
at this stage. Therefore the results demonstrate that 
there is no sex hormone binding globulin in the serum of 
horses. A sex hormone binding globulin exists however in 
equine seminal plasma. It is possible that a sex steroid
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steroid binding protein exists in equine serum. However 
a more sophisticated assay such as Sephadex equilibration 
(Pearlman and Crepy, 1967) or competitive adsorption using 
a florisil adsorbent (Heyns et al, 1968) would be needed 
to distinguish it specifically from low affinity steroid 
binding with albumin.
The cross reactivity of four antisera to human 
pregnancy proteins and late pregnant mare serum was tested 
by Ouchterlony double diffusion. However no cross 
reactivities were found between the antisera to PAPP A, 
a2 PAG (PZP) and a2 and $! PAM. The failure to obtain 
cross reactivity between the anti 3i PAM and the thirty- 
sixth week pregnancy plasma was probably due to the fact 
that this protein shows very variable individual levels 
during pregnancy (Stimson and Farquharson, 19 82). Previous . 
work with an antiserum to hPAPP A indicated that cross 
reactivity was confined to closely related species (Lin and 
Halbert, 1978). The antiserum gave reactions of identity 
with pregnancy sera from chimpanzee and orangutan, partial 
identity with sera from pregnant Old World monkeys and no 
reaction with pregnancy sera from New World monkeys. Some 
cross reactivity might have been expected between the 
antiserum to a2 PAG (PZP) and equine serum since this 
protein has been identified in horses using a swine PZP 
antiserum (Martinsson and Carlstrom, 1977). However 
von Schoultz et al (19 76) reported little or no cross 
reactivity between their anti-dog PZP and pregnant mare 
serum. In view of this the failure to detect cross
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cross reactivity between antisera to human pregnancy 
proteins and pregnant mare serum was not unexpected.
CHAPTER 6
GENERAL DISCUSSION
The major conclusion to be drawn from the preceding
chapters is that, within the limits of the systems used
pregnancy proteins are undetectable in the circulation
during late gestation in mares.
However it would appear that the equine placenta does
produce pregnancy specific protein and that during early
pregnancy serum does contain a number of extra proteins.
In humans the major pregnancy specific proteins,
SP1 hPL, PAPP A and B, reach a maximum concentration in 
the last month of pregnancy and are readily demonstrable 
by immunochemical methods (Lin et al, 1974a). Indeed 
since 19 70 the identification of the numerous novel 
proteins associated with pregnancy in humans, subhuman 
primates and laboratory rodents has relied solely upon 
antisera to pregnancy serum or placental extracts. From 
the selection of successful methods, three were chosen to 
investigate whether similar proteins existed in pregnant 
mares. However, despite the fact that all three methods 
had produced highly poly-specific antisera to pregnant 
mare serum, all cross reactivity was removed by adsorbing 
with stallion serum. Two hypotheses were suggested to 
explain this. The first suggested that pregnancy proteins 
were present in late pregnant mare serum but were poor 
immunogens in the rabbit. Alternatively pregnancy
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pregnancy proteins were indeed absent from the maternal 
circulation in late gestation. In order to differentiate 
between these two possibilities high resolution two 
dimensional polyacrylamide gel electrophoresis was 
performed on PMS, the gels being stained with a highly 
sensitive silver stain. Although pregnancy serum in 
humans, subhuman primates and laboratory rodents has not 
been investigated by this technique it was assumed that 
the pregnancy proteins would be at sufficiently high 
concentrations to be identified by this system. Indeed 
electrophoresis has been used to identify a pregnancy 
specific protein in mink (Larsen et al, 19 70), the protein 
being readily visible on cellulose acetate gels. The 
dissociating conditions of the two dimensional system 
reduces proteins to single polypeptide chains. However 
only very faint spots were identified in the late pregnant 
mare gels and this in only one thoroughbred mare, and it 
was concluded that pregnancy proteins were virtually 
absent from the maternal circulation in late gestation.
A possible explanation for this lack of pregnancy 
specific proteins in the mare is based on the comparative 
placental morphology of mammals. Reasonable evidence 
exists that in humans both PAPP A and PP5 have local roles 
within the placental area (Bischof, 19 81, Siiteri et al,
19 82). The function of the other proteins is unknown 
but it has been suggested that the placental pregnancy 
proteins are merely by-products of a more fundamental 
process within the placenta, their presence in
/
in the mother being unimportant (Chard, 19 82b).
In Chapter 1 the outline of a recent theory on the 
factors which control the levels of placental proteins in 
the mother was given. The essential feature of this 
hypothesis is that an equilibrium exists between the site 
of synthesis of these proteins, the syncytiotrophoblast, 
and the rate of blood flow across this site. Any change 
in uteroplacental, blood flow would effectively change the 
concentration of the secreted proteins within this area 
and either increase or decrease the rate of synthesis 
accordingly. This could explain the changes in levels 
of pregnancy proteins associated with complicated 
pregnancies which affect the uteroplacental blood flow.
The levels of placental pregnancy proteins in the 
foetus are 10-1000 fold less than in the maternal 
circulation despite the fact that equal secretion rates 
into the maternal and fetal circulations would result in 
higher levels in the foetus (Chard, 1982b). This 
difference could be explained by assuming that secretion 
into the fetal circulation would be prevented by the 
basement membrane and fetal endothelium which would form 
a barrier between the circulation and the syncytiotrophoblast 
(Chard, 1982b). It therefore follows that disruption of 
the fetal barrier during pregnancy should result in an 
increase in levels of pregnancy proteins in the fetal 
circulation. This has been shown to be the case in 
pregnancies complicated by placental insufficiency where
/
125.
where levels of hPL were found to be raised in cord 
blood (Geiger et al, 1971).
The hypothesis may explain two other aspects of 
placental protein production. Firstly non-placental 
areas of the trophoblast, such as the chorion, produce 
only small amounts of placental proteins and this could 
be due to the fact that these areas are not in direct 
contact with the maternal blood. The other is the 
observation that some adult non-trophoblast tumours 
produce placental proteins such as hCG, hPL and SP1 
(Vaitukaitis, 19 77, Rosen et al, 19 75, and Grudzinskas 
et al, 19 80). It is possible that many normal adult 
cell types synthesize these proteins but because they 
are not in direct contact with the blood flow only small 
amounts are produced. However in the case of a tumour 
associated with the invasion of blood vessels contact 
with the cells and blood flow would be more intimate.
This cell/blood contact may be important in stimulating 
the production of placental proteins in cells containing 
the appropriate synthetic machinery (Chard, 19 82b).
Therefore, according to the hypothesis, the 
appearance of placental pregnancy proteins in the maternal 
circulation in humans is due to direct contact at the 
placental/maternal interface. Comparison of human and 
equine placental morphology may explain why no pregnancy 
specific proteins were detected in late PMS.
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The classification of placental morphology has proven 
problematical since it does not coincide with any 
taxonomic pattern. A useful classification, based on the 
number of layers of tissue between the maternal and fetal 
circulation is that of Grosser (1909). Although this 
classification was based on the misconception that the 
efficiency of the placenta is inversely proportional to 
the number of layers between maternal and fetal circulation 
it still provides a useful means of discerning placental 
morphology. Thus the placentae were classified 
epitheliochorial (three maternal and three fetal layers), 
syndesmochorial (two maternal and three fetal) 
endotheliochorial (one maternal and three fetal), 
haemochorial (no maternal layers and three fetal) and 
haemendothelial (no maternal and one fetal).
In humans the placenta is haemochorial with the 
trophoblast actively phagocytosing adjacent maternal tissues, 
maternal blood corpuscles and the secretions of the uterine 
glands. The trophoblast differentiates into an irregular 
cytotrophoblast surrounded at the point of invasion by an. 
extensive outer syncytium, the syncytiotrophoblast 
(Renfree, 1982). The maternal blood flows across the 
syncytiotrophoblast and, according to the hypothesis, 
stimulates the production of the placental proteins. It 
is interesting to note that in early pregnancy in the mare 
a similar invasion of the uterus by fetal cells in the 
formation of the endometrial cups leads to the appearance 
in the maternal circulation of a pregnancy specific
/
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specific protein, eCG.
In the mare the trophoblast tissue is separated by 
three layers of maternal tissue and there is no direct 
contact with the maternal circulation. Thus in the 
epitheliochorial placenta there is no intimate contact at 
the placental/maternal interface and hence no stimulation 
of synthesis and secretion of placental pregnancy proteins.
An example of this may be found in the comparison of 
levels of alkaline phosphatase in humans and mares.
Although the evidence indicates that a placental alkaline 
phosphatase exists in both species the pattern is entirely 
different during gestation. In humans the levels rise in 
a similar pattern to placental growth. In the mare levels 
do not show any such similarity. This difference could be 
explained using the hypothesis since in humans the maternal 
blood would remove the alkaline phosphatase, performing a 
local role, and stimulate its synthesis. In the mare 
although the alkaline phosphatase may perform a similar 
local role the lack of direct contact between the placenta 
and maternal circulation would prevent its secretion into 
the maternal circulation.
If it is assumed that the number of layers between 
fetal and maternal circulation affects the secretion of 
proteins into the mother then the reciprocal case, the 
flow of material from mother to foetus,might also be 
affected. . This can be seen when considering the
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the placental transfer of IgG (see Tizard, 19 82).
There is a direct relationship between the amount of IgG 
transferred from mother to foetus and the number of layers 
in the placenta. In humans the transfer of IgG is high.
It is even higher in species possessing haemoendothelial 
placentae with only one intervening layer between maternal 
and fetal circulations. In dogs and cats which have 
endotheliochorial placentae only 5-10% of maternal IgG is 
transferred. In the ruminants (syndesmochorial) and the 
horse with 5 and 6 layers respectively the transfer of
IgG from mother to foetus is non-existent, the offspring
of these species relying on protection from colostral 
transfer of IgG.
Thus the hypothesis proposed states that pregnancy 
proteins in the maternal circulation are a result of 
intimacy of contact between the maternal circulation and 
trophoblast tissue. In humans the proteins are present 
in the maternal circulation because the maternal blood 
flows across their site of synthesis. In the mare the
three layers of uterine tissue between the maternal
circulation and the trophoblast exclude the secretion of 
placental proteins.
In other species in which pregnancy proteins similar 
to the human ones have been identified the placental 
morphology is either haemochorial or haemendothelial.
Thus analogues to the human placental pregnancy specific 
proteins have been identified in subhuman primates (Lin
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(Lin and Halbert, 19 78) and rodents (Lin et al, 19 74c, 
Tatarinov, 19 82) all of which possess trophoblast tissue 
in direct contact with maternal blood. There are no 
reports of similar pregnancy specific proteins in late 
pregnancy in species like dogs, cats, horses or pigs and 
only placental lactogens have been identified in ruminants. 
However, this could be due to the situation in other 
species not being investigated, or at least not reported 
if negative results have been found.
Therefore a bias may exist in that species 
investigated for pregnancy specific proteins in late 
pregnancy have been restricted to those species possessing 
similar placental morphology to humans. If other species 
with either epitheliochorial or syndesmochorial placentae 
were investigated in a similar manner for pregnancy 
specific proteins in late gestation, then this may provide 
evidence to prove or disprove the hypothesis. Examination 
of pregnancy proteins, if present, in the dog and cat may 
provide further evidence since their placental morphology 
is intermediate between horse and human.
This hypothesis relating direct blood flow across the 
placenta with the appearance of proteins peculiar to 
pregnancy in the maternal circulation does not exclude 
the existence of such proteins in the mare. However it 
would be necessary for these proteins to be localised 
within the placenta. Here they would perform roles 
necessary for the maintenance of fetal and placental
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placental development. Two equine placental antigens were 
identified using antisera to placental extracts. These 
two antigens were not detected in serum or extracts of 
liver and kidney and were designated equine placental 
antigens 1 and 2. On the basis of their molecular weights 
comparisons were made with the human placental proteins 
and several possible analogues were identified. Their 
detection means that pregnancy proteins exist in the mare 
but they are restricted to the placenta. Perhaps if a 
more extensive study was performed on the equine placental 
extract using longer injection protocols then more equine 
placental proteins could be identified. Studies in humans 
have revealed at least twenty soluble and eleven solubilized, 
apparently membrane bound proteins (Bohn, 19 79 and Bohn et 
al, 1982).
Further investigations could be performed on the 
nature of EPA 1 and 2 using the antiserum obtained. Only 
liver and kidney extracts were used to adsorb the antisera 
and it would be of interest to investigate whether the 
antigens were present in other equine tissues such as 
uterus or ovary. This could be done using either 
homogenates of these tissues or by immunohistochemical 
techniques such as immunofluorescence. This technique 
could also be used to identify in which layer(s) of the 
equine placenta the antigens were localized. Their 
occurrence in the fetal circulation and amniotic fluid 
could also be tested for.
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Using embryo homogenates gathered from various 
stages of gestation the behaviour of the proteins could be 
investigated giving information on their time of appearance 
and peak placental production. Another consideration 
would be whether the antigens were present in the 
endometrial cups which are of fetal origin.
The antiserum could be used to monitor purification 
of the antigens. Various physical separation techniques 
such as gel filtration, chromatofocusing and ion exchange 
chromatography could be used and the presence of the 
antigens in the various fractions detected using the 
antiserum. Once purified the physico-chemical properties 
of the two antigens could be determined more accurately. 
Once all this information had been assimilated then more 
viable comparisons could be made with human placental 
proteins.
Although the two dimensional gel electrophoresis 
failed to resolve any proteins unique to late pregnant 
mare serum, it identified several in early pregnancy 
serum. Of particular interest were three proteins 
present only in the first two months of pregnancy and 
one present for the first six months only. All four 
spots stained strongly within 20 days of fertilisation, 
the earliest recorded detection of pregnancy proteins in 
the mare. The proteins they represent may therefore be 
involved in the maternal recognition of pregnancy. They 
may represent a previously reported early pregnancy
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pregnancy specific protein , MPP1, or the early pregnancy 
factor which has so far not been reported in the mare.
The fact that these proteins stained strongly on the 
gels would indicate that they are present in the serum at 
reasonable concentrations. An immunological investigation 
similar to that used on late PMS applied to early pregnant 
mare serum would therefore reveal more information about 
them. An antiserum to early pregnancy serum adsorbed 
with stallion serum would perhaps be sufficient to provide 
a specific antiserum. This antiserum could then detect 
the proteins throughout a purification procedure and the 
number of proteins involved could be determined since the 
spots on the two dimensional gels represent polypeptide 
chains which may be individual proteins or subunit parts 
of a larger protein. The physico-chemical properties 
of the pure proteins could be more accurately determined 
in both dissociating and non-dissociating conditions.
Using the antiserum the levels of the proteins throughout 
their appearance in the serum could be investigated as 
could their origin. From this information more valid 
comparisons could be made between these proteins and 
proteins known to be present at this stage of gestation.
The proposal that a lack of direct contact between 
maternal blood and placenta results in the absence of 
novel proteins in the serum adequately explains the 
failure to identify pregnancy specific protein in late 
pregnant mare serum. However it does not explain why
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why on adsorbance of the antisera to pregnant mare serum 
with stallion serum no pregnancy associated proteins, 
synthesized at for example the maternal liver, were 
identified. The major protein in this group is PZP which 
has been demonstrated in pregnant mare serum and is known 
to be a potent immunogen (Martinsson and Carlstrom, 19 77) 
and may have a possible role as a "feeder protein" within 
the placenta, providing amino acids by its degradation 
(von Schoultz and Stigbrand, 19 82). However it has been 
found that levels of PZP actually decrease during pregnancy 
in some monkey species (Lin et al, 19 76a) and in the pig 
(Martinsson and Carlstrom, 19 77). Since PZP was not 
demonstrated in late pregnant mare serum then the horse 
may be included within this group. In view of the feeder 
protein hypothesis and the fact that new born pigs and 
horses are highly mature when compared with humans then 
much higher levels might have been expected in these 
species.
Another pregnancy associated protein in humans, sex 
hormone binding globulin, was investigated in the mare 
throughout pregnancy. However no analogue of this 
protein was identified in equine serum. As the assay 
relied upon a relatively non-specific precipitation 
procedure it is possible that a sex steroid binding 
protein does exist in equine serum.
Therefore in the mare there appears to be very little 
change in the serum proteins in the later stages of
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of pregnancy. There is no detectable increase in levels 
of normal serum proteins and no appearance of proteins 
unique to pregnancy. A hypothesis has been proposed 
which may explain the lack of pregnancy specific proteins 
in the serum of mares in late gestation. However there 
may be other reasons which are worthwhile considering.
In early pregnancy there occurs an event which is unique 
to horses, the appearance of the endometrial cups and 
their secretion of eCG which coincides with the appearance 
of a "crop" of secondary luteal structures (Allen, 19 80). 
However, recent evidence indicates that these secondary 
luteal structures are a result of maternal pituitary 
hormones such as LH and FSH and a possible fetal factor 
and it may be that eCG represents "an irrelevant by-product 
of the endometrial cups which themselves have a more 
important and unrealised function" (Allen, 19 84). It is 
interesting to note the similarity between this and the 
human placental pregnancy specific proteins. A further 
observation is the crop of secondary luteal structures 
also appear unnecessary for the maintenance of pregnancy 
since normal pregnancies have been observed in their 
absence (Allen, 1982, Allen, 1984). Therefore during 
the course of equine evolution this sytem has arisen which 
appears to have little to do with the maintenance of 
pregnancy and any advantage to the mare gained from it 
remains unclear.
It is interesting to speculate on the possibility that 
the production of eCG by the endometrial cups in the mare 
and production of pregnancy specific proteins in humans
humans represent parallels in that both are by-products 
of more fundamental reproductive processes. Perhaps if 
such a process occurred once in early pregnancy in the 
mare this would considerably reduce the possibility of it 
occurring again in late pregnancy. A reason for this 
may be in the immunological aspects of pregnancy 
maintenance. The endometrial cups are rejected by the 
maternal immune system and it may be that if in later 
pregnancy numerous novel antigens appeared in the maternal 
circulation this could lead to a similar rejection of the 
foetus by the mother. This would therefore suggest an 
evolutionary mechanism to explain the absence of pregnancy 
specific proteins in late pregnant mare serum.
Prior to this investigation it had been stated that 
pregnancy specific proteins similar to human ones probably 
occur widely in mammals indicating that they perform some 
essential role (Klopper, 19 80). Now however this would 
appear not to be the case and the species difference in 
pregnancy associated proteins is another of the features 
of pregnancy which show the large variety of reproductive 
strategies adopted by mammals. Examples of this can be 
found when comparing the factors affecting luteal 
maintenance in early pregnancy in primates and ruminants.
In primates this process is performed by a chorionic 
gonadotrophin of trophoblast origin transported in the 
maternal circulation. In ruminants the process is 
carried out within the uterus (Heap et al, 19 79).
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It has been assumed that in all species progesterone 
is essential for the maintenance of pregnancy. However 
an exception to this rule has been found in the African 
elephant which is capable of maintaining its pregnancy 
in the absence of progesterone (Smith et al, 1969). 
Therefore the absence of pregnancy specific proteins in 
late pregnancy in the mare may be another unique feature 
in the reproductive strategy of the horse. During the 
course of evolution in eutherian mammals although the 
essential features of pregnancy such as fertilisation, 
the maternal recognition, growth and development of the 
foetus and partuition remain constant various unique 
features may develop within a certain genus. The lack 
of pregnancy specific proteins in the mare may be just 
such a unique feature. It is only by examination on a 
similar basis of a wide diversity of mammalian species 
that the hypotheses proposed in this thesis can be proven 
or disproven.
APPENDIX
S.D.S. Polyacrylamide Gel Electrophoresis 
Stock Solutions
1. Acrylamide
NN 1 methylenebisacrylamide
30.0 g
0.8 g
Dissolve and make up to 100 ml with dist. H 20.
Mix for 30 minutes with 2.5 g of Amberlite Monobed 
Resin MB1.
Filter and store at 4°C in a light proof bottle.
2. 1 M Tris/HCl buffer pH 8.8.
2 M Tris 
1 N HCL
dist. H2O to 100 ml
3. 0.5 M Tris/HCl buffer pH 6.8
1 M Tris 
1 N HC1
dist. H 20 to 100 ml
50 ml
16.2 ml 
(approx.)
50 ml
45 ml
(approx.)
4. /
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4. Tris/glycine electrophoresis buffer pH 8.3 (10 x conc.)
glycine
Tris
dist. H2O to 1 litre
Check pH after dilution 
Adjust with tris or glycine only
5. Ammonium persulphate 
make up fresh
6. S.D.S.
7. Bromophenol blue
8. Solubilizing buffer
Amount
0.5 M Tris/HCl pH 6.8 25 ml
SDS 20 ml
8 mercaptoethanol 10 ml
glycerol 20 ml
bromophenol blue 2 ml
dist. H2O 23 ml
Gel /
144 g 
30 g
0.8% w/v
20% w/v 
0.1% w/v
Final concn. 
in sample
0.0625 M
2%
5%
10%
0.001%
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Gel Preparation 
1. Resolving gel
Acrylamide 36.7 ml
1 M Tris/HCl 37.6 ml
20% SDS 0.5 ml
TEMED 50 yl
Ammonium persulphate 10 ml
H2O to 100 ml
Mix thoroughly.
2. Stacking gel
Acrylamide 16.7 ml
0.5 M Tris/HCl 25 ml
20% SDS 0.5 ml
TEMED 50 yl
Ammonium persulphate 10 ml
H 20 47.8 ml
Mix thoroughly.
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Immunoblotting
Solutions
1. Transfer buffer
Tris 9.1 g
SDS 0.6 g
glycine 43.25 g
Made up to 3000 ml with distilled H 20, no need to pH.
2. Blocking buffer
20 mM Tris. HC1
0.15 M NaCl
0.5% Tween 20
0.5 mg/ml Sodium Azide
The SDS gel is placed on top of a sheet of filter 
paper previously soaked in transfer buffer. Over 
this was placed a sheet of Nitrocellulose, large 
enough to cover the gel and presoaked in transfer 
buffer. A further piece of filter paper was placed 
on the Nitrocellulose and this assembly was sandwiched 
between two presoaked "Scotchbrite" pads. This was 
then placed in a plastic holder and placed in a 
Bio-rad Transblot cell with the gel at the negative 
and the nitrocellulose at the positive. A current
of 400. mA was then applied for 3 hours. After this
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this the nitrocellulose was removed, placed in 
blocking buffer overnight and then incubated for 
Ik hours in blocking buffer with 5% horse serum 
and 1:100 dilution of the antiserum. It was then 
washed five times over a thirty minute period with 
blocking buffer and incubated for a further Ik hours 
with approximately three million counts of 125i- 
protein A. The nitrocellulose was then washed with 
blocking buffer until the background was low and 
exposed to X-ray film.
Two Dimensional Electrophoresis 
Solutions for isoelectric focusing
1. Acrylamide stock
Acrylamide 33.3 g
Bis-acrylamide 1.9 g
Dissolve and make up to 100 ml with dist. H 20.
Mix with 2.5 g of Amberlite Monobed Resin MBl for 
30 minutes then filter.
2. 10% w/v Nonidet P40 in H 20
3. Overlay Solution A
8 M dionised urea 
1 mM Lysine
Store frozen.
4. Overlay Solution B 
Urea
Ampholine pH 3.5-10 
0.1 M Lysine 
H20
Store frozen in 200 yl aliquots.
/
4.8 g 
0.25 ml 
0.1 ml 
6.1 ml
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5. Sample Loading Buffer
9 M deionised urea 
0.01 M Tris /HC1 pH 8.0 
0.001 M PMSF 
0.7 yg/ml pepstatin 
0.001 M Na2 MO4 
0.001 M Lysine
Store frozen.
Solutions for second dimension SDS PAGE
A. 36.6 g Tris
48 ml of IN HC1 
0.23 ml OF TEMED 
H 20 to 100 ml 
Adjust to pH 8.8
B. 33.3 g of Acrylamide 
0.9 g of Bis-acrylamide 
H20 to 100 ml
Mix with 2.5 g of Amberlite Monobed Resin MB1 for 
30 minutes then filter.
C. 5.98 g of Tris 
0.46 ml of TEMED
+ IN HC1 to pH 6.8 
H20 to 100 ml
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D. 10 mg Riboflavin 
H 20 to 250 ml
E. 90 ml of 9 M deionised urea 
2 ml of 10% SDS
H 20 to 100 ml
Prepare fresh.
Equilibration Buffer 
54 g urea 
10 g glycerol 
1.0 ml 0.1 M Lysine 
20 ml 5 x Laemmli Sample Buffer 
31 ml H 20
5 x Laemmli Sample Buffer 
7.56 g Tris 
20 g SDS
0.01 g Bromophenol blue 
Adjust to pH 6.8 
H 20 to 200 ml
10 x Reservoir Buffer 
150 g Tris 
720 g Glycine 
50 g SDS 
H2O to 5 litres
Adjust to pH 8.3-8.5 on dilution.
N.B. Use tris or glycine to adjust pH
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